0001144204-16-131724.txt : 20161104 0001144204-16-131724.hdr.sgml : 20161104 20161104160233 ACCESSION NUMBER: 0001144204-16-131724 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161104 DATE AS OF CHANGE: 20161104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TAPIMMUNE INC CENTRAL INDEX KEY: 0001094038 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880277072 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37939 FILM NUMBER: 161975167 BUSINESS ADDRESS: STREET 1: 50 N LAURA STREET STREET 2: SUITE 2500 CITY: JACKSONVILLE STATE: FL ZIP: 98102 BUSINESS PHONE: (206) 504-7278 MAIL ADDRESS: STREET 1: 50 N LAURA STREET STREET 2: SUITE 2500 CITY: JACKSONVILLE STATE: FL ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: GENEMAX CORP DATE OF NAME CHANGE: 20020718 FORMER COMPANY: FORMER CONFORMED NAME: EDUVERSE COM DATE OF NAME CHANGE: 19990827 10-Q 1 v450946_10q.htm 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

x Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2016

¨ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____.

Commission File Number: 000-27239

TAPIMMUNE INC.

(Name of registrant in its charter)

NEVADA		45-4497941
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

50 N. Laura Street, Suite 2500 Jacksonville, FL		32202
(Address of principal executive offices)		(Zip Code)

904-516-5436
(Issuer's telephone number)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer or a smaller reporting company. See definition of “accelerated filer”, “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one):

¨ Large accelerated filer	¨ Accelerated filer
¨ Non-accelerated filer (Do not check	x Smaller reporting company
if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

As of November 2, 2016, the Company had 8,379,101 shares of common stock issued and outstanding.

		Page

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	1

	Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015	1

	Condensed Consolidated Statements of Operations for the Three and Nine months ended September 30, 2016 and 2015	2

	Condensed Consolidated Statement of Stockholders' Equity (Deficit) for the Nine months ended September 30, 2016	3

	Condensed Consolidated Statements of Cash Flows for the Nine months ended September 30, 2016 and 2015	4

	Notes to Condensed Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	24

Item 4.	Controls and Procedures.	24

PART II – OTHER INFORMATION		25

Item 1.	Legal Proceedings.	25

Item 1A.	Risk Factors.	25

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	25

Item 3.	Defaults Upon Senior Securities.	25

Item 4.	Mine Safety Disclosures.	25

Item 5.	Other Information.	25

Item 6.	Exhibits.	26

Signatures		27

NOTE REGARDING REVERSE STOCK SPLIT

On September 13, 2016, we filed a Certificate of Change pursuant to NRS 78.209 with the Secretary of State of the State of Nevada to effect a reverse split of our common stock at a ratio of one for twelve, effective on September 16, 2016. All historical share and per share amounts reflected in this report have been adjusted to reflect the reverse stock split.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

TAPIMMUNE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	September 30, 2016			December 31, 2015

ASSETS
Current Assets
Cash	$	9,586,773		$	6,576,564
Prepaid expenses and deposits		111,652			68,803

Total Assets	$	9,698,425		$	6,645,367

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued liabilities	$	1,678,079		$	967,358
Research agreement obligations		492,365			492,365
Derivative liability – warrants		29,000			26,493,000
Promissory note		5,000			30,000
Promissory note, related party		-			23,000
Total Liabilities		2,204,444			28,005,723

Commitments and Contingencies		-			-

Stockholders’ Equity (Deficit)
Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized:
Series A, $0.001 par value, 1,250,000 shares designated, -0- shares issued and outstanding		-			-
Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued and outstanding		-			-
Common stock, $0.001 par value, 41,666,667 shares authorized, 8,395,768 and 5,882,976 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively		8,396			5,884
Additional paid-in capital		151,724,573			112,142,187
Accumulated deficit		(144,238,988	)		(133,508,427	)
Total Stockholders’ Equity (Deficit)		7,493,981			(21,360,356	)

Total Liabilities and Stockholders’ Equity (Deficit)	$	9,698,425		$	6,645,367

See accompanying notes to these unaudited condensed consolidated financial statements.

- 1 -

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended September 30,						Nine months ended September 30,
	2016			2015			2016			2015

Operating Expenses:
Research and development	$	1,109,332		$	968,759		$	3,343,248		$	2,324,432
General and administrative		1,612,305			769,219			3,557,701			1,579,754

Loss from Operations		(2,721,637	)		(1,737,978	)		(6,900,949	)		(3,904,186	)

Other Income (Expense)
Changes in fair value of derivative liabilities		684,000			30,266,000			5,925,000			(28,485,585	)
Foreign exchange gain		-			-			-			775
Grant income		-			-			231,200			-
Loss on debt settlement agreements		(65,325	)		(24,697	)		(135,640	)		(24,697	)
Other income		-			-			1,828			-

Net Income (Loss)	$	(2,102,962	)	$	28,503,325		$	(878,561	)	$	(32,413,693	)

Basic Net Income (Loss) per Share	$	(0.29	)	$	7.04		$	(0.14	)	$	(10.61	)
Diluted Net Income (Loss) per Share	$	(0.29	)	$	4.23		$	(0.54	)	$	(10.61	)

Weighted Average Number of Common Shares Outstanding, Basic		7,281,000			4,048,750			6,370,000			3,054,297
Weighted Average Number of Common Shares Outstanding, diluted		7,281,000			6,745,416			6,935,000			3,054,297

See accompanying notes to these unaudited condensed consolidated financial statements.

- 2 -

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

(UNAUDITED)

	Common Stock				Additional
	Number of shares		Amount		Paid In Capital			Accumulated Deficit			Total
			$		$			$			$
Balance, December 31, 2015		5,882,976		5,884		112,142,187			(133,508,427	)		(21,360,356	)

Issuance of common stock in private placement		653,166		653		3,134,543			-			3,135,196

Finders’ fee and legal costs relating to private placements		-		-		(804,070	)		-			(804,070	)

Fair value of shares issued as inducement on August 10, 2016		750,000		750		4,499,250			(4,500,000	)		-

Fair value of series F and F-1 warrants issued as inducement in August 2016		-		-		5,352,000			(5,352,000	)		-

Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements		-		-		15,465,000			-			15,465,000

Exercise of warrants		1,000,000		1,000		5,999,000			-			6,000,000

Finders’ fee on exercise of warrants		-		-		(516,651	)		-			(516,651	)

Reclassification of fair value of derivative liabilities at exercise date		-		-		5,074,000			-			5,074,000

Shares issued in debt settlement agreements		10,191		10		70,305			-			70,315

Stock- based compensation		99,435		99		1,309,009			-			1,309,108

Net loss		-		-		-			(878,561	)		(878,561	)

Balance, September 30, 2016		8,395,768		8,396		151,724,573			(144,238,988	)		7,493,981

See accompanying notes to these unaudited condensed consolidated financial statements.

- 3 -

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine months ended September 30, 2016			Nine months ended September 30, 2015

Cash flow from operating activities
Net loss	$	(878,561	)	$	(32,413,693	)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities		(5,925,000	)		28,485,585
Loss on debt settlement agreements		70,315			24,697
Stock based compensation		1,309,109			261,805
Changes in operating assets and liabilities:
Prepaid expenses		(42,849	)		(55,782	)
Accounts payable and accrued liabilities		710,720			204,956
Net cash used in operating activities		(4,756,266	)		(3,492,432	)

Cash flow from financing activities
Private placements		3,135,196			2,464,000
Finders’ fee and legal costs on private placements		(804,070	)		(137,986	)
Repayment of promissory note		(25,000	)		-
Repayment of promissory note – related party		(23,000	)		-
Proceeds from exercise of warrants		6,000,000			7,427,998
Finders’ fee on exercise of warrants		(516,651	)		(316,508	)
Net cash provided by financing activities		7,766,475			9,437,504

Net increase in cash		3,010,209			5,945,072

Cash, beginning of period		6,576,564			141,944
Cash, end of period	$	9,586,773		$	6,087,016

Supplemental disclosure of cash flow information

Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

See accompanying notes to these unaudited condensed consolidated financial statements.

- 4 -

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine months ended September 30, 2016		Nine Months Ended September 30, 2015

Supplemental schedule of non-cash investing and financing activities:

Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson’s compensation	$	191,000	$	-

Accounts payable settled in common stock		-		24,000

Fair value of issuance of series F and F-1 warrants as inducement in August 2016		5,352,000		-

Fair value of shares issued as inducement on August 10, 2016		4,500,000		-

Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements		15,465,000		-

Fair value of issuance of warrants in January and March 2015 financing		-		9,313,000

Issuance of additional warrants in May 28, 2015 transaction		-		6,133,000

Reclassification of Derivative Warrant Liabilities to Equity at Exercise Date		5,074,000		11,745,000

See accompanying notes to these unaudited condensed consolidated financial statements.

- 5 -

TAPIMMUNE INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

(Unaudited)

Note 1:

Nature of Operations

TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

NOTE 2:

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results.

The results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2016 or for any future interim period. The condensed consolidated balance sheet at December 31, 2015 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2015, and notes thereto included in the Company’s annual report on Form 10-K.

NOTE 3:

LIQUIDITY AND FINANCIAL CONDITION

The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings.

The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.

As of September 30, 2016, the Company had cash and cash equivalents of approximately $9,587,000. Historically, the Company had net losses and negative cash flows from operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

- 6 -

Note 4:

SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 14, 2016 other than the one disclosed below relating to grant income:

Grant Income

The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company’s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable, and are not dependent on the Company’s ongoing future performance. The Company has adopted a policy of recognizing these payments as grant income when received.

Recent Accounting Pronouncement

Accounting Standards Update (“ASU”), No. 2016-09 - In March 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-09, Compensation-Stock Compensation. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the specific changes associated with the update include all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) being recognized as income tax expense or benefit in the income statement. The tax effects of exercised or vested awards should be treated as discrete items in the reporting period in which they occur. An entity also should recognize excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. An entity can make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years.

The Company has evaluated the impact of ASU No. 2016-09 and has determined that the adoption of the impact of forfeitures, net of income taxes, will not have a material impact on the Company’s future financial statements.

Note 5:

net income (loss) per share

Basic income (loss) per common share is computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted income per common share is computed similar to basic income per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

Income (loss) per-share amounts for all periods have been retroactively adjusted to reflect the Company’s 1-for-12 reverse stock split, which was effective September 16, 2016.

The following table sets forth the computation of income (loss) per share:

	For the Three Months Ended September 30,					For the Nine Months Ended September 30,
	2016			2015		2016			2015

Net income (loss)	$	(2,102,962	)	$	28,503,325	$	(878,561	)	$	(32,413,693	)
Less: Non cash income from changes in fair value of derivative liabilities		-			-		(2,856,000	)		-
Net income (loss) - diluted		(2,102,962	)		28,503,325		(3,734,561	)		(32,413,693	)

Weighted average shares outstanding - basic		7,281,000			4,048,750		6,370,000			3,054,297
Common stock warrants		-			2,663,333		565,000			-
Common stock options		-			33,333		-			-
Weighted average shares outstanding - diluted		7,281,000			6,745,416		6,935,000			3,054,297

Net income (loss) per share data:
Basic	$	(0.29	)	$	7.04	$	(0.14	)	$	(10.61	)
Diluted	$	(0.29	)	$	4.23	$	(0.54	)	$	(10.61	)

- 7 -

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	Nine Months Ended September 30,
	2016		2015
Common stock options		432,000		39,000
Common stock warrants - equity treatment		5,054,000		211,000
Common stock warrants - liability treatment		6,000		4,750,000
Potentially dilutive securities		5,492,000		5,000,000

Note 6:

DERIVATIVE LIABILITY - WARRANTs

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the nine months ended 2016 and 2015 is as follows:

Share Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Nine Months Ending September 30, 2016			For the Nine Months Ending September 30, 2015
Exercise price	$	1.20		$	7.56
Contractual term (years)		1.3			4.5
Volatility (annual)		105	%		159	%
Risk-free rate		1	%		1	%
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and

Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

- 8 -

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:

	As of September 30, 2016
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	29,000		-		-	$	29,000	$	29,000
Total	$	29,000		-		-	$	29,000	$	29,000

	As of December 31, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	26,493,000		-		-	$	26,493,000	$	26,493,000
Total	$	26,493,000		-		-	$	26,493,000	$	26,493,000

There were no transfers between Level 1, 2 or 3 during the nine months ended September 30, 2016.

The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2016:

	Derivative liability – warrants
Balance – December 31, 2015	$	26,493,000
Reclassification of derivative liabilities to equity at exercise date		(5,074,000	)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements		(15,465,000	)
Change in fair value of warrant liability		(5,925,000	)
Balance – September 30, 2016	$	29,000

Warrant Amendment Transaction

On August 10, 2016, the Company and holders of an aggregate of 3,096,665 outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements (the “Amended Warrants”) in which they agreed to amend the terms of the outstanding series warrants to remove provisions that had previously precluded equity classification treatment on the Company’s balance sheets.

In consideration for such amendment and the exercise of the Series C Warrants and Series C-1 Warrants, the Company issued an aggregate of 750,000 additional shares of common stock to such warrant holders and new five-year warrants to purchase 1,000,000 shares of Company common stock at an exercise price of $7.20 per share. The value of the shares and fair value of the warrants was treated as dividend on the statement of stockholders’ equity of $4.5 million.

The fair value of the Amended Warrants was re-measured immediately prior to the date of amendment with changes in fair value recorded as a gain of $556,000 in the statement of operations and $15.5 million was reclassified to equity.

- 9 -

Note 7:

STOCK-BASED COMPENSATION

The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015, respectively:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Research and development	$	-	$	-	$	-	$	-
General and administrative		573,137		13,244		1,309,109		261,805

Total stock-based compensation	$	573,137	$	13,244	$	1,309,109	$	261,805

Stock Options

A summary of the Company’s stock option activity is as follows:

	Stock Options			Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value

Outstanding as of December 31, 2015		298,679		$	9.25		9.75	$	177,000

Granted		135,000			6.00
Exercised		-			-
Forfeited/Cancelled		(1,667	)		228.00

Outstanding as of September 30, 2016		432,013		$	7.25		9.25	$	271,000

Exercisable as of September 30, 2016		262,395		$	8.00		9.00	$	174,000

Total stock-based compensation cost related to unvested awards not yet recognized and the weighted average periods over which the awards are expected to be recognized as of September 30, 2016 are as follows:

Unrecognized stock-based compensation cost:		$	1,081,000
Expected weighted average period compensation costs to be recognized (years):			1.75

Note 8:

Promissory note

At September 30, 2016, the Company had an outstanding promissory note in the amount of $5,000 as compared to two outstanding promissory notes totaling $30,000 at December 31, 2015. The promissory note outstanding at September 30, 2016 bears 10% annual interest.

During the nine months ended September 30, 2016, the Company paid a $25,000 promissory note and $6,524 of accrued interest in final settlement.

Note 9:

Promissory note, related party

At December 31, 2015, the Company had an outstanding promissory note in the amount of $23,000 owed to an officer of the Company. The promissory note bore no interest charges and had no fixed repayment terms. In September 2016, the note was paid in full.

- 10 -

Note 10:

Capital Stock

Reverse Stock Split

Effective September 16, 2016, the Company effected a one for twelve reverse stock-split of our issued and outstanding common stock and has retroactively adjusted our common shares outstanding, options and warrants amounts outstanding. The Company has presented its share data for and as of all periods presented on this basis. The par value was not adjusted as a result of the one for twelve reverse stock split. All prior period share transactions included in the Company’s stock transactions and balances have been retroactively restated.

2016 Common Stock Transactions

Private placements

On August 10, 2016 and August 25, 2016, the Company completed private placements of units with certain accredited investors. The units consisted of (i) one share of the Company’s common stock, par value $0.001 per share and (ii) one five-year warrant to purchase one share of Company common stock for $6.00. The Company issued and sold an aggregate of 653,166 units at a purchase price per unit of $4.80 for an aggregate of approximately $3.1 million. The Company incurred approximately $0.8 million in agency fees and legal costs.

In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to 65,317 shares of Company common stock for $4.80 per share.

Pursuant to the registration rights agreements entered into in connection with the private placements, the Company is required to file a registration statement with the Securities and Exchange Commission registering for resale (a) the common stock issued in the private placement offering; (b) the shares of common stock issuable upon the exercise of the five-year warrants; and (c) the shares of common stock issuable upon the exercise of the warrants issued to the placement agent. The Company is required to file the registration statement within 120 days of the August 10, 2016 closing or by December 8, 2016. The Company is also required to ensure that the registration statement is declared effective within 90 calendar days after filing with the Securities and Exchange Commission, or by March 8, 2017.

In accordance with the registration rights agreements, should the Company fail to meet the above criteria, the Company is subject to pay the investors liquidated damages. The liquidated damages shall be a cash sum payment calculated at a rate of ten percent (10%) per annum of the aggregate purchase price for the registrable securities or aggregate amount upon exercise of the placement agent warrants.

In accordance with applicable U.S. generally accepted accounting principles, a contingent obligation to make future payments must be recorded if the transfer of consideration under a registration payment arrangement is probable and can be reasonably estimated. The Company has determined that should it be required to pay liquidated damages to the investors of the private placements, the aggregate contingent liability it would be required to record would be approximately $29,000 per month for each month it fails or is estimated to fail to meet the above criteria.

At the August 10, 2016 and August 26,2016 private placement closings, and on September 30, 2016, the Company concluded that it is not probable that it will be required to remit any payments to the investors for failing to obtain an effective registration statement or failing to maintain its effectiveness.

Warrant Amendment Transaction

- 11 -

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of September 30, 2016 and changes during the period is presented below:

	Number of Warrants			Weighted Average Exercise Price
Balance, December 31, 2015		4,343,000		$	8.67
Exercised		(1,000,000	)		6.00
Issued		1,718,000			6.65
Expired		(2,000	)		300
Balance, September 30, 2016		5,059,000		$	8.51

Consulting Arrangements

During the nine months ended September 30, 2016, the Company issued 60,000 common shares as part of consulting agreements. The fair value of the common stock of approximately $414,000 was recognized as stock-based compensation in general and administrative expense.

Debt Settlement

In May 2016, the Company issued 10,191 common shares as part of debt conversion agreements from 2014. The fair value of the common stock of approximately $70,000 was recognized as loss on debt settlement agreements in other income (expense).

In September 2016, the Company paid $27,000 for a promissory note from 2008 and related $38,000 of accrued interest. The $65,000 payment was recognized as loss on debt settlement agreements in other income (expense).

Note 11:

grant income

During the nine months ended September 30, 2016, the Company received approximately $231,000 of grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV 200. The grant paid for the clinical supplies purchased by the Company.

Note 12:

COMMITMENTs

Employment Agreements

In November 2015, the Company entered into an employment agreement with Dr. Glynn Wilson, the Company’s Chief Executive Officer, President and Chairman of the Company. As part of the agreement, Dr. Wilson was awarded 19,018 fully vested common shares in March 2016. The fair value of the common stock of approximately $146,000 was recognized as stock-based compensation in general and administrative expense.

In July, 2016, the Company entered into an employment agreement with Dr. John Bonfiglio relating to his appointment as the Company’s President and Chief Operating Officer. As part of the agreement, Dr. Bonfiglio was awarded 20,833 common shares, which will vest upon the earlier of (i) the listing of the Company’s common stock on a national securities exchange in the United States or (ii) the first anniversary of the employment agreement, so long as Dr. Bonfiglio is employed with the Company. The fair value of the common stock of approximately $103,000 was recognized as stock-based compensation in general and administrative expense.

In August 2016, the Company appointed Michael Loiacono as the Company’s Chief Financial Officer, Chief Accounting Officer, Secretary and Treasurer. In connection with Mr. Loiacono’s appointment he entered into an employment agreement with the Company. The employment agreement provides that Mr. Loiacono’s base salary will be $200,000 per year and he is eligible for an annual performance bonus of up to 50% of his base salary. The term of the employment agreement is for two years and will be automatically extended for an additional 12 months unless terminated by Mr. Loiacono or the Company.

- 12 -

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, that involve risks and uncertainties. All statements other than statements relating to historical matters including statements to the effect that we “believe”, “expect”, “anticipate”, “plan”, “target”, “intend” and similar expressions should be considered forward-looking statements. Our actual results could differ materially from those discussed in the forward-looking statements as a result of a number of important factors, including factors discussed in this section and elsewhere in this quarterly report on Form 10-Q, and the risks discussed in our other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis, judgment, belief or expectation only as the date hereof. We assume no obligation to update these forward-looking statements to reflect events or circumstance that arise after the date hereof.

As used in this quarterly report: (i) the terms “we”, “us”, “our”, “TapImmune” and the “Company” mean TapImmune Inc. and its wholly owned subsidiary, GeneMax Pharmaceuticals Inc. which wholly owns GeneMax Pharmaceuticals Canada Inc., unless the context otherwise requires; (ii) “SEC” refers to the Securities and Exchange Commission; (iii) “Securities Act” refers to the Securities Act of 1933, as amended; (iv) “Exchange Act” refers to the Securities Exchange Act of 1934, as amended; and (v) all dollar amounts refer to United States dollars unless otherwise indicated.

The following should be read in conjunction with our unaudited consolidated interim financial statements and related notes for the three and nine months ended September 30, 2016 included in this quarterly report, as well as our Annual Report on Form 10-K for the year ended December 31, 2015.

Company Overview

Our Cancer Vaccines

We are a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease. We are also developing a proprietary technology to improve the ability of the cellular immune system to recognize and destroy diseased cells. This DNA expression technology named Polystart is in preclinical development.

To enhance shareholder value and taking into account development timelines, we plan to focus on advancing our clinical programs including our Folate Receptor Alpha program for breast and ovarian cancer and our HER2/neu peptide antigen program into Phase II clinical trials. In parallel, we plan to complete the preclinical development of our Polystart technology as an integral component of our prime-and-boost vaccine methodology.

The Immunotherapy Industry for Cancer

Immuno-oncology has become the most rapidly growing sector in the pharmaceutical and biotech industry. The approval and success of checkpoint inhibitors Yervoy and Opdivo (Bristol Myers Squibb) and Keytruda (Merck & Co.) together with the development of CAR T-cell therapies (Juno Therapeutics, Kite Pharma) has provided much momentum in this sector. In addition, new evidence points to the increasing use of combination immunotherapies for the treatment of cancer. This has provided greater opportunities for the successful development of T-cell vaccines in combination with other approaches.

Products and Technology in Development-Clinical

Phase I Human Clinical Trials – Folate Alpha Breast and Ovarian Cancer – Mayo Clinic

Folate Receptor Alpha is expressed in over 80% of triple negative breast cancers and in addition, over 90% of ovarian cancers, for which the only treatment options are surgery, radiation and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively short for these types of cancer and survival prognosis is extremely poor after recurrence. In the United States alone, there are approximately 30,000 ovarian cancer patients and 40,000 triple negative breast cancer patients newly diagnosed every year.

- 13 -

TPIV 200 Folate Receptor Alpha

A 24 patient Phase I clinical trial has been completed. The vaccine is well tolerated and safe and 20 out of 21 evaluable patients showed positive immune responses providing a strong rationale rational for progressing to phase II trials. GMP manufacturing for Phase II trials is progressing well towards a commercial formulation and final analyses of clinical plans are near completion. On July 27, 2015, TapImmune exercised its option agreement with Mayo Clinic with the signing of a worldwide exclusive license agreement to commercialize a proprietary folate receptor alpha vaccine technology for all cancer indications. As part of this Agreement, the IND for the folate receptor alpha Phase I trial was transferred from Mayo to TapImmune for amendment for the Company’s Phase II Clinical Trials on our lead product.

On September 15, 2015, we announced that our collaborators at the Mayo Clinic had been awarded a grant of $13.3 million from the U.S. Department of Defense. This grant, commencing September 15, 2015, will cover the costs for a 280 patient Phase II Clinical Trial of Folate Receptor Alpha Vaccine in patients with Triple Negative Breast Cancer. TapImmune will work closely with Mayo Clinic on this clinical trial by providing clinical and manufacturing expertise as well as providing GMP vaccine formulations. These vaccine formulations are being developed for multiple Phase II clinical programs in triple negative breast and ovarian cancer in combination with other immunotherapeutics.

On December 9, 2015, we announced that we received Orphan Drug Designation from the U.S. Food & Drug Administration’s Office of Orphan Products Development (OOPD) for our cancer vaccine TPIV 200 in the treatment of ovarian cancer. The TPIV 200 ovarian cancer clinical program will now receive benefits including tax credits on clinical research and 7-year market exclusivity upon receiving marketing approval. TPIV 200 is a multi-epitope peptide vaccine that targets Folate Receptor Alpha which is overexpressed in multiple cancers.

On February 3, 2016 we announced that the U.S. Food & Drug Administration (FDA) has designated the investigation of multiple-epitope Folate Receptor Alpha Peptide Vaccine (TPIV 200) with GM-CSF adjuvant for maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer who achieved stable disease or partial response following completion of standard of care chemotherapy, as a Fast Track Development Program. A Phase 2 study in this indication is being readied for initiation by the end of 2016.

We are currently enrolling a Company sponsored triple negative breast cancer study at 8 clinical sites nation-wide. The study will enroll 80 patients. It is open-label and designed to look at dosing regimens, immune responses and efficacy.

The Company also announced the start of an ovarian cancer study sponsored by Memorial Sloan Kettering Cancer Center in New York City in collaboration with Astra Zeneca Pharmaceuticals. This study is currently enrolling platinum resistant ovarian cancer patients and is designed to look at the effects of combination therapy with Astra Zeneca’s checkpoint inhibitor durvalamab. The study will enroll 40 patients and is open label. Although we have no business relationship with Astra Zeneca, we are paying for half of the clinical study plus providing our TPIV 200 for the study.

Phase I Human Clinical Trials – HER2/neu+ Breast Cancer – Mayo Clinic

Patient dosing has been completed. Final safety analysis on all the patients treated is complete and shown to be safe. In addition, 19 out of 20 evaluable patients showed robust T-cell immune responses to the antigens in the vaccine composition providing a solid case for advancement to Phase II in 2015. An additional secondary endpoint incorporated into this Phase I Trial will be a two year follow on recording time to disease recurrence in the participating breast cancer patients.

For Phase I(b)/II studies, we plan to add a Class I peptide, licensed from the Mayo Clinic (April 16, 2012), to the four Class II peptides. Management believes that the combination of Class I and Class II HER2/neu antigens, gives us the leading HER2/neu vaccine platform. As the folate receptor alpha vaccine is our lead product our plans are now initiating formulation studies to progress the HER2/neu vaccine towards a Phase II Clinical Trial in 2017.

Products and Technology-Preclinical

Polystart

We converted the previously filed U.S. Provisional Patent Application on Polystart into a full Patent Application, and in February 2016 we received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application entitled, “A chimeric nucleic acid molecule with non-AUG initiation sequences.” The term of this patent extends to March 17, 2034. Additional patent filings are in progress. We plan to develop PolyStart as both a stand-alone therapy and as a ‘boost strategy’ to be used synergistically with our peptide-based vaccines for breast and ovarian cancer.

- 14 -

Current State of the Company

We are a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. We now plan to conduct multiple Phase II clinical trials on our vaccines. The largest of these studies in triple-negative breast cancer is totally funded by a $13.3 million grant from the U.S. Department of Defense to our collaborators at the Mayo Clinic in Jacksonville, Florida. A Company-sponsored trial in triple negative breast cancer started during the second quarter of 2016 with recruitment at multiple sites and treatment of first patients. We believe that our development pipeline is strong and provides us the opportunity to continue to expand on collaborations with leading institutions and corporations.

We believe, the strength of our science and development approaches is becoming more widely appreciated, particularly as our clinical program has now generated positive interim data on both clinical programs in Breast and Ovarian Cancer.

We continue to be focused on our entry into Phase II Triple Negative Cancer Trials including application for Fast Track & Orphan Drug Status as well as planning for Phase II HER2/neu Breast Cancer Trials.

We expect to continue to prosecute our PolyStart patent filings and develop new constructs to facilitate collaborative efforts in our current clinical indications and those where others have already indicated interest in combination therapies.

We believe that these fundamental programs and corporate activities have positioned TapImmune to capitalize on the acceptance of immunotherapy as a leading therapeutic strategy in cancer and infectious disease.

TapImmune’s Pipeline

Clinical Program

We have a pipeline of potential immunotherapies under development. Phase I clinical programs on HER2/neu for breast and ovarian cancer have been completed and strong immune responses in over 90% of patients treated has provided the rationale and catalyst to advance these programs to Phase II clinical trials.

- 15 -

In addition to the exciting clinical developments, our peptide vaccine technology may be coupled with our recently developed in-house Polystart nucleic acid-based technology designed to make vaccines significantly more effective by producing four times the required peptides for the immune systems to recognize and act on. Our nucleic acid-based systems can also incorporate “TAP” which stands for Transporter associated with Antigen Presentation.

A key component to success is having a comprehensive patent strategy that continually updates and extends patent coverage for key products. It is highly unlikely that early patents will extend through ultimate product marketing, so extending patent life is an important strategy for ensuring product protection.

We have three active patent families that we are supporting:

1. Filed patents on PolyStart expression vector (owned by TapImmune and filed in 2014: this IP covers the use with TAP). The Company announced the allowance of this patent in February 2016.

2. Filed patents on HER2/neu Class II and Class I antigens: exclusive license from Mayo Foundation; and

3. Filed patents on Folate Receptor Alpha antigens: exclusive license from Mayo Foundation

While the pathway to successful product development takes time, we believe we have put in place significant for success. The strength of our product pipeline and access to leading scientists and institutions gives us a unique opportunity to make a major contribution to global health care.

With respect to the broader market, a major driver and positive influence on our activities has been the emergence and general acceptance of the potential of a new generation of immunotherapies that promise to change the standard of care for cancer. The immunotherapy sector has been greatly stimulated by the approval of Provenge® for prostate cancer and Yervoy™ for metastatic melanoma, progression of the areas of checkpoint inhibitors and adoptive T-cell therapy and multiple approaches reaching Phase II and Phase III status.

We believe that through our combination of technologies, we are well positioned to be a leading player in this emerging market. It is important to note that many of the late stage immunotherapies currently in development do not represent competition to our programs, but instead offer synergistic opportunities to partner our antigen based immunotherapeutics, and Polystart expression system. Thus, the use of naturally processed T-cell antigens discovered using samples derived from cancer patients plus our Polystart expression technology to improve antigen presentation to T-cells could not only produce an effective cancer vaccine in its own right but also to enhance the efficacy of other immunotherapy approaches such as CAR-T and PD1 inhibitors for example.

Recent Developments and Company Highlights

Research Programs

Her2neu License Agreement

On June 7, 2016 we announced that we exercised our option agreement with Mayo Clinic and signed a worldwide license agreement to a proprietary HER2neu vaccine technology. The license gives us the right to develop and commercialize the technology in any cancer indication in which the Her2neu antigen is overexpressed.

Phase II Trials Started

On April 26, 2016 we announced plans to participate in a Phase 2 trial of our cancer vaccine, TPIV 200, a multi-epitope anti-folate receptor vaccine (FRα), in combination with durvalumab (MEDI4736), an anti-PD-L1 antibody, in patients with platinum-resistant ovarian cancer. The study started with the enrollment and treatment of patients in the second quarter of 2016 at Memorial Sloan Kettering Cancer Center in New York and is being led by Jason Konner, M.D. as Principal Investigator. On June 21, 2016, we announced the treatment of the first patient in a company-sponsored Phase II trial in triple negative breast cancer as part of a multi-center study.

Manufacturing

On April 7, 2016, we announced that we have successfully completed formulation development, scale-up, GMP (Good Manufacturing Practice) manufacturing, and the release of TPIV 200, our multi-epitope folate receptor peptide vaccine for breast and ovarian cancer. The manufactured product contains five peptide antigens freeze dried in a single vial, ready for injection after reconstitution and addition of granulocyte-macrophage colony-stimulating factor (GM-CSF). TPIV 200 doses are now available for the upcoming Phase II clinical trials in both triple negative breast cancer and ovarian cancer.

- 16 -

Recent Developments

Enrolling Patients: Phase 2 TPIV 200 Trial in Triple Negative Breast Cancer

We have opened 8 clinical sites and begun treating patients in a Phase 2 trial of our Folate Receptor Alpha cancer vaccine, TPIV 200, in the treatment of triple negative breast cancer, one of the most difficult to treat cancers representing a clear unmet medical need. The open-label, 80 patient clinical trial is designed to evaluate dosing regimens, adjuvants, efficacy, and immune responses in women with triple negative breast cancer. Key data from the trial is expected to be included in a future New Drug Application submission to the FDA for marketing clearance. This trial is sponsored and conducted by TapImmune.

Enrolling Patients: Phase 2 Trial at Memorial Sloan Kettering of TPIV 200 in Ovarian Cancer

A Phase 2 study of TPIV 200 in ovarian cancer patients who are not responsive to platinum, a commonly used chemotherapy for ovarian cancer, sponsored by Memorial Sloan Kettering Cancer Center, and in collaboration with AstraZeneca and TapImmune, has begun enrollment for a 40 patient study. The open-label study is designed to evaluate a combination therapy which includes our TPIV 200 T-cell vaccine and AstraZeneca’s checkpoint inhibitor, durvalumab. Because they are unresponsive to platinum, these patients have no real options left. If the combination therapy proves effective, we believe it would address a critical unmet need. TPIV 200 has received Orphan Drug designation for use in the treatment of ovarian cancer.

Enrollment to Commence in Q4 2016: Phase 2 Mayo Clinic-U.S. DOD Trial of TPIV 200 in Triple Negative Breast Cancer We anticipate this Phase 2 study of TPIV 200 in the treatment of triple negative breast cancer, conducted by the Mayo Clinic and sponsored by the U.S. Department of Defense (DOD), will begin to enroll patients in the fourth quarter of this year. The anticipated 280 patient study will be led by Dr. Keith Knutson of the Mayo Clinic in Jacksonville, Florida. Dr. Knutson is the inventor of the technology and an advisor to TapImmune. While TapImmune is supplying doses of TPIV 200 for the trial, the remaining costs associated with conducting this study will be funded by a $13.3 million grant made by the DOD to the Mayo Clinic.

Clinical Sites to Open in Q4 2016: Phase 2 TPIV 200 Trial in Platinum-Sensitive Ovarian Cancer

By the end of 2016, we expect to have at least one clinical site open in a Phase 2 trial of TPIV 200 in 80 ovarian cancer patients who are responsive to platinum. We have received the FDA’s Fast Track designation to develop TPIV 200 as a maintenance therapy in combination with platinum, in platinum responsive ovarian cancer. This multi-center, double-blind efficacy study is sponsored and conducted by TapImmune.

Open IND with FDA for TPIV 110 in Q4 2016 or in Q1 2017: Phase 2 Protocol Now in Preparation

We have reformulated our second cancer vaccine product, TPIV 110, following very strong safety and immune responses from a Phase 1 Mayo Clinic study. TPIV 110 targets Her2/neu, which makes it applicable to breast, ovarian and colorectal cancer. The reformulated product adds a fifth antigen which should produce an even more robust immune response activating both CD4+ and CD8+ T-cells. We have requested a pre-Investigational New Drug (IND) meeting with the FDA and submitted questions to the FDA related to opening the IND. A response from the FDA is expected in September and we anticipate having an open IND by year-end pending comments from FDA. The protocol for a Phase 2 trial of TPIV 110 in the treatment of Her2/neu positive breast cancer patients has been designed and is now being reviewed by our Scientific Advisory Board and collaborators.

TPIV Products are Off-the-Shelf, Commercially Viable, with Excellent Potential Margins

We are continuously working on improving our product formulation and supply. We believe TPIV 200 and TPIV 110 are both very stable, off-the-shelf, lyophilized products that only require reconstitution at the clinical site before injection. We believe the investments we have made in the formulation work we have performed will result in a commercially viable product with excellent potential profit margins.

Robust Product Data & Independent Vetting Key to High-Value Collaborations

We believe the Phase 1 data produced for both TPIV 200 and TPIV 100 in collaboration with the Mayo Clinic are the driving force behind the high-value collaborations we have been able to maintain and establish with organizations including Mayo Clinic, AstraZeneca, Sloan Kettering, and the U.S. Department of Defense. As we move forward into advancing the Phase 2 studies, some of which are represent collaboration with prestigious third party organizations, we believe this represents further independent vetting of potential of our technology.

- 17 -

Company Highlights

Reverse Stock Split

On September 16, 2016, at the opening of trading, we effected a one-for-twelve reverse split of our common shares. The common shares began trading on a split-adjusted basis on September 16, 2016. The reverse stock split was effected in connection with the Company’s intent to apply to list the common stock on the NASDAQ Capital Market. On November 2, 2016, we received notification that we were approved for listing on The Nasdaq Capital Market. Our common stock is expected to begin trading on The Nasdaq Capital Market at the opening of trading on Tuesday, November 8, 2016 under the ticker symbol, TPIV.

Our historical financial results have been adjusted to reflect a reduction in the number of shares of our outstanding common stock from 62,890,763 shares to 5,240,897 shares at September 30, 2015 and from 70,550,763 shares to 5,879,230 shares at December 31, 2015. In addition, effective upon the reverse stock split, the number of authorized shares of our common stock was reduced from 500 million shares to 41,666,667 shares. All fractional shares resulting from the reverse stock split were rounded up to the nearest whole share. All share data herein has been retroactively adjusted for the reverse stock split. The par value was not adjusted as a result of the one for twelve reverse stock split.

August 2016 Private Placement Transaction

In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to 65,317 shares of Company common stock for $4.80 per share.

August 2016 Warrant Exercises

On August 11, 2016, holders of an aggregate of 583,333 outstanding Series C Warrants and 416,667 Series C-1 Warrants, each providing for the purchase of one share of our common stock for $6.00 per share, exercised their warrants for an aggregate exercise price of $6,000,000.

August 2016 Warrant Amendments

Simultaneous with the exercise of the warrants, we and holders of an aggregate of 3,096,665 outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants (the “Outstanding Series Warrants”) entered into Warrant Amendment Agreements (the “Amendment Agreement”), in which they agreed to amend the terms of the Outstanding Series Warrants to remove provisions from the Outstanding Series Warrants that had previously caused them to be classified as a derivative liability as opposed to equity on our balance sheet. In consideration for such amendment and the exercise of the Series C Warrants and Series C-1 Warrants, we issued an aggregate of 750,000 additional shares of common stock to such warrant holders and new five-year warrants to purchase 1 million shares of our common stock at an exercise price of $7.20 per share (the “Series F and F-1Warrants”).

- 18 -

The following table reflects the status of the outstanding warrants from the January 2015, March 2015, and August 2016 private placement financings (including placement agent warrants) following the Amendment Agreement and private placement:

Series	Outstanding Warrants		Exercise Price		Expiration
A		214,433	$	1.20	01/13/2020
C		424,433	$	6.00	01/13/2020
D		610,000	$	9.00	Between 07/16/2020 and 08/13/2020 and 08/19/2020 and 09/09/2020
E		616,100	$	15.00	Between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020
A-1		418,750	$	1.20	03/09/2020
C-1		2,083	$	6.00	01/13/2020
D-1		416,667	$	9.00	Between 08/19/2020 and 09/09/2020
E-1		418,750	$	15.00	06/16/2020
F		583,333	$	7.20	8/11/2021
F-1		416,667	$	7.20	8/11/2021
PIPE Warrants		653,166	$	6.00	8/11/2021
Broker Warrants		65,317	$	4.80	8/11/2021

Addition of Executive Officers

On July 18, 2016 we announced that Dr. John Bonfiglio, a consultant and a member of our Board of Directors, was appointed as our President and Chief Operating Officer and entered into an employment agreement with us. Concurrent with such appointment we amended the employment agreement of Dr. Wilson for Dr. Wilson to relinquish the office of President.

On August 25, 2016 we announced that Michael J. Loiacono, a consultant, was appointed as our Chief Financial Officer, Chief Accounting Officer, Secretary and Treasurer and entered into an employment agreement with us.

Critical Accounting Policies

The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the consolidated financial statements and the judgments and assumptions used are consistent with those described under Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2015.

- 19 -

Results of Operations

In this discussion of the Company’s results of operations and financial condition, amounts, other than per-share amounts, have been rounded to the nearest thousand dollars.

Three Months Ended September 30, 2016 Compared to Three Months Ended September 30, 2015

We recorded a net loss of $2,103,000 or ($0.29) basic and diluted per share during the three months ended September 30, 2016 compared to a net income of $28,503,000 or $7.04 basic and $4.23 diluted per share during the three months ended September 30, 2015.

Operating costs increased to $2,722,000 during the three months ended September 30, 2016 compared to $1,738,000 in the prior period. Significant changes in operating expenses are outlined as follows:

Research and development costs during the three months ended September 30, 2016 were $1,109,000 compared to $969,000 during the prior period. The increase was primarily due to the Company expensing the Mayo Foundation license fee payments in the current period and higher expenses relating to research.

General and administrative expenses increased to $1,612,000 during the three months ended September 30, 2016 from $769,000 during the prior period. This was due to generally increased expenses relating to consulting, general and administrative and professional fees during the three months ended September 30, 2016 due to increased activity in operations.

The changes in fair value of derivative liabilities for the three months ended September 30, 2016 was $684,000 as compared to $30,266,000 for the three months ended September 30, 2015. The variance is due to the revaluation of the Series A and A-1, Series C and C-1, Series D and D-1 and Series E and E-1 warrants issued by us in January and March 2015. We revalue the derivative liabilities at each balance sheet date to fair value. The fair value is determined using Black-Scholes valuation model using various assumptions. The most significant changes in the assumptions was the difference in the strike price used at September 30, 2016 of $6.69 compared to $7.40 at September 30, 2015, the exercise of warrants with derivative liabilities and the August 2016 amendments to certain of the warrants to remove the clause that caused the warrants to be classified as derivative liabilities. Due to these significant changes, the fair value of the derivative liabilities decreased by $684,000 with a corresponding gain in the condensed consolidated statement of operations.

During the three-month period ended September 30, 2016 the Company incurred $65,000 loss on debt settlement agreements relating to an outstanding agreement from a previous year. This compares to $25,000 loss on debt settlement agreements for the three months ended September 30, 2015.

Nine months ended September 30, 2016 Compared to Nine months ended September 30, 2015

We recorded a net loss of $879,000 or ($0.14) basic and ($0.54) diluted per share during the nine months ended September 30, 2016 compared to a net loss of $32,414,000 or ($10.61) basic and diluted per share for the nine months ended September 30, 2015.

Operating costs increased to $6,901,000 during the nine months ended September 30, 2016 compared to $3,904,000 in the prior period. Significant changes in operating expenses are outlined as follows:

Research and development costs during the nine months ended September 30, 2016 were $3,343,000 compared to $2,324,000 during the prior period. This was due to the Company exercising its option to acquire Mayo Clinic technology as part of an agreement entered into in March 2014 and increased in-house research activity in the current period.

General and administrative expenses increased to $3,558,000 during the nine months ended September 30, 2016 from $1,580,000 during the prior period. This was due to generally increased expenses relating to consulting, general and administrative and professional fees during the nine months ended September 30, 2016 as the Company’s operating activities increased substantially.

The changes in fair value of derivative liabilities for the nine months ended September 30, 2016 was $5,925,000 as compared to ($28,486,000) for the nine months ended September 30, 2015. The variance in the current period is due to the revaluation of the Series A and A-1, Series C and C-1, Series D and D-1 and Series E and E-1 warrants issued by us in January and March 2015. We revalue the derivative liabilities at each balance sheet date to fair value. The most significant changes in the assumptions was the difference in the strike price used at September 30, 2016 of $6.69 compared to $7.40 at September 30, 2015, the exercise of warrants with derivative liabilities and the August 2016 amendments to certain of the warrants to remove the clause that caused the warrants to be classified as derivative liabilities. Due to these significant changes, the fair value of the derivative liabilities decreased by $5,925,000 with a corresponding gain in the condensed consolidated statement of operations.

- 20 -

During the nine months ended September 30, 2016, the Company received $231,000 of a grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV 200. The grant paid for the clinical supplies purchased by the Company.

During the nine-month period ended September 30, 2016 the Company incurred $135,000 loss on debt settlement agreements relating to an outstanding debt agreement from previous years. This compares to $25,000 loss on debt settlement agreements for the nine months ended September 30, 2015.

Liquidity and Capital Resources

We have not generated any revenues since inception, we have financed our operations primarily through public and private offerings of our stock and debt including warrants and the exercise thereof. The following table sets forth our cash and working capital as of September 30, 2016 and December 31, 2015:

	September 30, 2016		December 31, 2015

Cash reserves	$	9,587,000	$	6,577,000
Working capital (deficit)	$	7,494,000	$	(21,360,000	)

Cash Flows

The following table summarizes our cash flows for the nine months ended September 30, 2016 and 2015:

	Nine Months Ended September 30,
	2016			2015
Net cash provided by (used in):
Operating activities	$	(4,756,000	)	$	(3,492,000	)
Financing activities		7,766,000			9,438,000

Net increase in cash	$	3,010,000		$	5,945,000

Net Cash Used in Operating Activities

Net cash used in operating activities during the nine months ended September 30, 2016 was $4,756,000 compared to $3,492,000 during the prior period. We had no revenues during the current or prior periods. Operating expenditures, excluding non-cash interest and stock-based charges during the current period primarily consisted of consulting and management fees, office and general expenditures, and professional fees.

Net Cash Provided by Financing Activities

Net cash provided by financing activities during the nine months ended September 30, 2016 was $7,766,000 compared to net cash provided by financing activities of $9,438,000 during the prior period. The financing consisted of proceeds from private placements and warrant exercises in the current period as was in the prior period.

Financings

Our current available funding has come from financings that we conducted in January and March of 2015 and from the exercise of warrants issued in connection with our January and March, 2015 financings as well as our recent August 2016 private placement.

January 2015 Financing

In January, 2015, we entered into a Securities Purchase Agreement with certain investors for the sale of 610,000 units at a purchase price of $2.40 per unit, for a total purchase price of approximately $1,250,000, net of finders’ fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “January 2015 Warrants”). Series A warrants were exercisable at $18.00 per share, with a five-year term. Series B warrants were exercisable at $4.80 per share, with a six-month term. Series C warrants were exercisable at $12.00 per share, with a five-year term. Series D warrants were exercisable at $9.00 per share only if and to the extent that the Series B warrants are exercised, with a five-year term from the date that the Series B warrants are exercised. Series E warrants were exercisable at $15.00 per share, only if and to the extent that the Series C warrants are exercised, with a five-year term from the date that the Series C warrants are exercised. Pursuant to a placement agent agreement, we agreed to issue warrants to purchase 30,500 common shares with substantially the same terms as the January 2015 Warrants.

- 21 -

March 2015 Financing

In March, 2015, we entered into a Securities Purchase Agreement with certain accredited investors for the sale of 416,667 units at a purchase price of $2.40 per unit, for a total purchase price of approximately $950,000, net of finders’ fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A-1 warrant to purchase one share of common stock, (iii) one Series B-1 warrant to purchase one share of common stock (iv) one Series C-1 warrant to purchase one share of common stock, (v) one Series D-1 warrant to purchase one share of common stock, and (vi) one Series E-1 warrant to purchase one share of common stock (the Series A-1, B-1, C-1, D-1 and E-1 warrants are hereby collectively referred to as the “March 2015 Warrants”). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants. Pursuant to a placement agent agreement, we agreed to issue warrants to purchase 10,417 common shares with substantially the same terms as the March 2015 Warrants.

Restructuring of January and March 2015 Financings

In May 2015, we entered into a restructuring agreement with the investors of the January 2015 and March 2015 financings, where:

The exercise price of the Series A and Series A-1 warrants was changed from $18.00 per share to $1.20 per share,

The exercise price of Series B and Series B-1 warrants was changed from $4.80 per share to $2.40 per share,

Each warrant of Series B and Series B-1 existing prior to the restructuring agreement was replaced with two warrants of such series,

The exercise price of the Series C and Series C-1 warrants was changed from $12.00 per share to $6.00 per share, and

Each warrant of Series C and Series C-1 existing prior to the restructuring agreement was replaced with two warrants of such series.

As a result of the restructuring agreement, we issued an additional 1,026,667 Series B and B-1 warrants and 1,026,667 Series C and C-1 Warrants.

2016 Financing

August 2016 Private Placement Transaction

In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to 65,317 shares of Company common stock for $4.80 per share.

- 22 -

Warrant Exercises

Between June 16, 2015 and December 9, 2015, 3,090,000 shares were issued upon exercise of certain warrants we issued in connection with our 2015 financings, providing $9.22 million in proceeds. In August 2016, holders of an aggregate of 583,333 outstanding Series C Warrants and 416,667 Series C-1 Warrants, each providing for the purchase of one share of our common stock for $6.00 per share, exercised their warrants for an aggregate exercise price of $6,000,000.

Future Capital Requirements

Our capital requirements through 2017 will depend on numerous factors, including the success of our research and development, the resources we devote to develop and support our technologies and our success in pursuing strategic licensing and funded product development relationships with external partners. Subject to our ability to raise additional capital including through possible joint ventures and/or partnerships, we expect to incur substantial expenditures to further develop our technologies including continued increases in costs related to research, nonclinical testing and clinical studies, as well as costs associated with our capital raising efforts and being a public company. We intend to spend approximately $7,500,000 over the next twelve months in carrying out our plan of operations. We will require substantial funds to conduct research and development and nonclinical and Phase II clinical testing of our licensed, patented technologies and to develop sublicensing relationships for the Phase II and III clinical testing. Our plans include seeking both equity and debt financing, alliances or other partnership agreements with entities interested in our technologies, or other business transactions that would generate sufficient resources to ensure continuation of our operations and research and development programs.

We expect to continue to seek additional funding for our operations. Any such required additional capital may not be available on reasonable terms, if at all. If we were unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned clinical testing and research and development activities, which could harm our business. The sale of additional equity or debt securities may result in additional dilution to our shareholders. If we raise additional funds through the issuance of debt securities or preferred stock, these securities could have rights senior to those of our common stock and could contain covenants that would restrict our operations. We also will require additional capital beyond our currently forecasted amounts.

Because of the numerous risks and uncertainties associated with research, development and commercialization of our product candidates, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:

the number and characteristics of the product candidates we pursue;

the scope, progress, results and costs of researching and developing our product candidates, and conducting nonclinical and clinical trials including the research and development expenditures we expect to make in connection with our license agreements with Mayo Foundation;

the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;

our ability to maintain current research and development licensing agreements and to establish new strategic partnerships, licensing or other arrangements and the financial terms of such agreements;

our ability to achieve our milestones under our licensing arrangements and the payment obligations we may have;

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and

the timing, receipt and amount of sales of, or royalties on, our future products, if any.

- 23 -

We have based our estimates on assumptions that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate. Potential sources of financing include strategic relationships, public or private sales of our shares or debt and other sources. We may seek to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when we need it on terms that will be acceptable to us, or at all. If we raise funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of our existing stockholders will be diluted. If we are not able to obtain financing when needed, we may be unable to carry out our business plan. As a result, we may have to significantly limit our operations and our business, financial condition and results of operations would be materially harmed.

Various conditions outside of our control may detract from our ability to raise additional capital needed to execute our plan of operations, including overall market conditions in the international and local economies. We recognize that the United States economy has suffered through a period of uncertainty during which the capital markets have been impacted, and that there is no certainty that these levels will stabilize or reverse despite the optics of an improving economy. Any of these factors could have a material impact upon our ability to raise financing and, as a result, upon our short-term or long-term liquidity.

Going Concern

We have no sources of revenue to provide incoming cash flows to sustain our future operations. As outlined above, our ability to pursue our planned business activities is dependent upon our successful efforts to raise additional capital.

While these factors raise substantial doubt regarding our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared on a going concern basis, which implies that we will continue to realize our assets and discharge our liabilities in the normal course of business. Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes of financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4.

Controls and Procedures

(a)

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on such evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are not effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act.

It should be noted that any system of controls is based in part upon certain assumptions designed to obtain reasonable (and not absolute) assurance as to its effectiveness, and there can be no assurance that any design will succeed in achieving its stated goals.

(b)

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the nine months ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

- 24 -

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

Management is not aware of any material legal proceedings and there are no pending material procedures that would affect the property of the Company. Management is not aware of any legal proceedings contemplated by any government authority or any other party involving the Company. As of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceeding.

Item 1A.

Risk Factors

For risk factors, see Item 1.A.-“Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

(a)	We issued the following unrestricted securities during the period covered by this report to the named individual pursuant to exemptions under the Securities Act of 1933 including Section 4(2):

On July 18, 2016 the Company issued 20,833 shares to Dr. John Bonfiglio pursuant to the employment agreement.

On August 10, 2016, the Company issued and sold 653,166 shares of stock as part of a private placement with certain accredited investors.

On August 11, 2016, the Company issued 1,000,000 shares of stock in relation to the exercising of 583,333 outstanding Series C Warrants and 416,667 Series C-1 Warrants.

On August 11, 2016, the Company issued 750,000 shares of stock to warrant holders as an inducement to amend certain warrant agreements.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosure

Not Applicable.

Item 5.

Other Information

Not applicable.

- 25 -

Item 6.

Exhibits

The following exhibits are included with this Quarterly Report on Form 10-Q:

Incorporated by Reference

Exhibit
number

Exhibit description

Form

File no.

Exhibit

Filing

date

Filed

herewith

3.1

Articles of Incorporation

31.1

Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended.

31.2

Certification of Chief Financial Officer and Chief Accounting Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended

32.1

Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended.

32.2

Certification of Chief Financial Officer and Chief Principal Accounting Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 101

101.INS

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Label Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

- 26 -

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TAPIMMUNE INC.

/s/ Glynn Wilson
Glynn Wilson
Chairman, Chief Executive Officer
Date: November 4, 2016

- 27 -

EX-3.1 2 v450946_ex3-1.htm EXHIBIT 3.1

Exhibit 3.1

Filed in the office of the
Secretary of State of the
STATE OF NEVADA

October 22, 1991

ARTICLES OF INCORPORATION

WARD’S FUTURA ATOMOTIVE, LTD

KNOW ALL MEN BY THESE PRESENTS:

We, the undersigned, natural persons of the age of 21 year, or more, acting as incorporators of a corporation under the Nevada Business Corporation Act, adopt the following Articles of Incorporation for such corporation:

ARTICLE I - NAME

The name of the Corporation shall be WARD'S FUTURA ATOMOTIVE, LTD.

ARTICLE II - DURATION

The period of its duration shall be perpetual unless dissolved or terminated according to law.

ARTICLE III – CORPORATE PURPOSES

The general purposes and objects for which the corporation is organized are to engage primarily in any type of manufacturing of automobiles, and/or marketing of automobiles or, automotive related products both retail and wholesale. Realstate unimproved or improved, land development, and/or investment in real property or real estate related endeavors. To engage in any business, investment or other pursuit or activity, whether retail or wholesale, whether commercial or industrial; and to perform any and all other lawful acts or purposes as are or may be granted to corporate entitles under the laws of the State of Nevada and by any other state or foreign country. The corporation may conduct its business anywhere within the States of the United States of America or in any foreign country, without in any way limiting the foregoing powers. It is hereby provided that the corporation shall have the power to do any and all acts and things that may be reasonably necessary or appropriate to accomplish any of the foregoing purposes for which the corporation is formed.

ARTICLE IV - SHARES OF STOCK

The aggregate number of shares which the corporation shall have authority to issue is 50,000,000 shares of common stock at par value of $0.001 per share, or a total capitalization of $50,000.00.

There shall be no cumulative voting, and all pre-emptive rights are denied. Each share shall entitle the holder thereof to one vote at all meetings of the stockholders.

Stockholders shall not be liable to the corporation or its creditors for any debts or obligations of the corporation.

ARTICLE V - STOCK RESTRICTIONS

All shares of stock in the company are assignable and any stockholder may sell, assign and transfer his shares, and certificates of stock at pleasure except that no such transfer, sale or assignment shall be valid unless and until it shall have been entered upon the books of the company and the old certificate or certificates shall have been surrendered for cancellation to the Secretary and a new certificate or certificates issued in lieu of the same.

ARTICLE VI COMMENCING BUSINESS

The corporation will not commence business until consideration of the value of at least One Thousand Dollars (1,000.00) has been received for the issuance of shares.

ARTICLE VII - REGISTERED AGENT AND OFFICE

The name and post office address of its initial registered agent is Donald C. Bradley. 5312 Ithaca, Las Vegas, NV, 89122

ARTICLE VIII - DIRECTORS

That the number of directors of this corporation, their qualifications, terms of office and the time and manner of their election, removal and resignation shall be as follows:

The number of directors shall not be less than two (2) nor more than seven (9), the exact number within such limits to be determined in the manner prescribed by the by-laws.

Directors shall be elected at the annual meeting of the stockholders of this corporation and shall serve for one (1) year and until their successors shall have been duly elected and qualified.

A majority of the entire number of directors, but not less than (2), shall be necessary to form a quorum of the board of directors, authorized to transact the business and exercise the corporate powers of the corporation.

Such officers shall consist of:

(a) President;

(b) One or more Vice Presidents as shall be provided by the by-laws or the board of directors;

(d) A Treasurer - may be held by officers who concurrently hold another office.

Such officers shall be elected annually by the board of directors and shall serve for one (1) year and until their successors shall have been duly elected and qualified.

Any officer may be removed by vote of a majority of the board of directors or in such other manner as may be prescribed in the by-laws.

ARTICLE IX

That the following named person, parties hereto, the directors and officers of this corporation from the date hereof and until their successors shall have been elected and qualified:

PRESIDENT & DIRECTOR:	DONALD C. BRADLEY
	5312 ITHACA
	LAS VEGAS, NV 09122

VICE PRESIDENT & DIRECTOR:

SECRETARY/TREASURER & DIRECTOR:	SHIRLENE BRADLEY
	5312 ITHACA
	LAS VEGAS, NV 89122

ARTICLE X - SHAREHOLDER LIABILITY

That the private property of the stockholders of this corporation shall not be liable for the debts or obligations of the corporation.

ARTICLE XI - INCORPORATORS

The name and address of each incorporator is:

DONALD C. BRADLEY

5312 ITHACA

LAS VEGAS, NV 89122

SHIRLENE BRADLEY

5312 ITHACA

LAS VEGAS, NV 89122

ARTICLE XII - 1244 STOCK

Shares of stock of this corporation authorized and issued pursuant to these Articles of Incorporation within two (2) years from the date of incorporation are, for the purpose of the Internal Revenue Code, authorized and issued in. compliance with and as prescribed by Section 1244 of the Internal Revenue Code of 1954, as amended shall be known as "Section 1244 Stock".

ARTICLE XIII – DIRECTORS’ OF OFFICERS’ CONTRACTS

No contract or other transaction between this corporation and one or more of its directors or any other corporation. firm, association or entity in which one or more of its directors are directors or officers are financially interested shall be either void or voidable because of such relationship or interest, or because such director or directors are present at the meeting of the board of directors or a committee thereof, which authorizes, approves or ratifies such contracts or transaction, or, because his or their votes are counted for such purpose, if: (a) the fact of such relationship or interest is disclosed or known to the board of directors or committee which authorizes, approves or ratifies the contract or transaction by vote or consent sufficient for the purpose without counting the votes or consents of such interested director: or (b) the fact of such relationship or interest is disclosed or known to the shareholders entitled to vote and they authorize, approve or ratify such contract or transaction by vote or written consent: or, (c) the contract or transaction is fair and reasonable to the corporation. Common or interested directors may be counted in determining the presence of a quorum at a meeting of the board of directors or committee thereof which authorizes, approves or ratifies such contract or transaction.

INCORPORATORS

STATE OF NEVADA	)
	)
COUNTY OF CLARK	)

On October 21, 1991, personally appeared before me, Donald C. Bradley and Shirlene Bradley, who being duly sworn by me first, declared that he had read the foregoing Articles of Incorporation, that he had signed the foregoing document as an incorporator and that the statements contained therein are true.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this day of October, 1991

	/s/ Donald C. Bradley
	Donald C. Bradley

	/s/ Shirlene Bradley
	Shirlene Bradley

	/s/ O Chase
	NOTARY PUBLIC

My Commission Expires:

2-4-95

I, Donald C. Bradley acting as registered Agent, in the State of Nevada and living in Clark County, Nevada, do hereby accept the full legal responsibility as Agent for the corporation registered under the name of Ward’s Futura Atomotive, LTD. who’s address is, 5312 Ithaca, Las Vegas, NV 89122.

	/s/ Donald C. Bradley
	Donald C. Bradley

STATE OF NEVADA	)
	)
COUNTY OF CLARK	)

SUBSCRIBED AND SWORN to before me This 21^st day of October, 1991.

	/s/ O Chase
	NOTARY PUBLIC
	Residing in Las Vegas, Nevada

My Commission Expires: 2-4-95

Filed in the office of the
Secretary of State of the
STATE OF NEVADA

December 20, 1995

ARTICLES OF AMENDMENT

PERFECT FUTURE, LTD.

The Articles of Amendment to the original Articles of Incorporation of WARD'S FUTURA AUTOMOTIVE, LTD. a Nevada corporation are set up as follows:

A. ARTICLE I -

The name of the corporation (hereinafter called the corporation) is PERFECT FUTURE, LTD.

AMENDMENT - ARTICLE I -

The name of the corporation is amended to: PERFECT FUTURE, LTD.

B. Article IV

The total amount of authorized shares is 50,000,000 having par value of .001.

AMENDMENT - ARTICLE IV

The total amount of authorized shares is 50,000,000 of common shares at a par of .001.

As of the date of the Special Meeting of Shareholders the Company had issued and outstanding TWO MILLION (2,000,000) shares of COMMON .001 par value stock, held by 30 shareholders all of which were entitled to vote on the proposed amendment.

AMENDMENT

ARTICLE VI PERFECT FUTURE, LTD.

At the Special Stockholders Meeting held December 5, 1995, TWO MILLION SHARES voted in favor of the amendment and none (0) voted against the amendment.

Dated this 5th day of December 1995

	/s/ Donald C. Bradley	President
	Donald C. Bradley

	/s/ Shaun Hadley	Secretary
	Shaun Hadley

STATE OF NEVADA

COUNTY OF CLARK

On December 5th, 1995 Donald C. Bradley, personally appeared before me a notary

public, acknowledges that Donald C Bradley executed the above instrument.

Signature of Notary

/s/ Kristina A. Heffner

STATE OF NEVADA

SECRETARY OF STATE

CERTIFICATE OF REINSTATEMENT

I, DEAN HELLER, the duly elected Secretary of State of the State of Nevada, do hereby certify that WARD’S FUTURA AUTOMOTIVE, LTD. a corporation formed under the laws of the State of NEVADA having paid all filing fees, licenses, penalties and costs, in accordance with the provisions of Title 7 of the Nevada Revised Statutes, as amended, for the years and in the amounts as follows:

1992-93 LIST OF OFFICERS AND PENALTY	$	100.00

1993-94 LIST OF OFFICER AND PENALTY	$	100.00

1994-95 LIST OF OFFICER AND PENALTY	$	100.00

1995-96 LIST OF OFFICER AND PENALTY	$	100.00

REINSTATEMENT FEE	$	50.00

And otherwise complied with the provisions of said section, the said corporation has been reinstated, and that by virtue of such reinstatement it is authorized to transact its business in the same manner as if the aforesaid filing fees, licenses, penalties and costs had been paid when due.

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the Great Seal of State, at my office in Carson City, Nevada, this 20^th day of December, A.D., 1995.

	/s/ Dean Heller
	Secretary of State


	Deputy

Filed in the office of the

Secretary of State of the

STATE OF NEVADA

May 20, 1997

CERTIFICATE OF AMENDMENT OF ARTICLE OF INCORPORATION

(AFTER ISSUANCE OF STOCK)

Perfect Future, Ltd.

Name of Corporation

We the undersigned Donald Bradley and

President or Vice President

Shaun Hadley	of	Perfect Future, Ltd.
Secretary or Assistant Secretary		Name of Corporation

do hereby certify:

That the Board of Directors of said corporation at a meeting duly convened and held on the 22nd day of April 1997, adopted a resolution to amend the original articles as follows:

Article IV is hereby amended to read as follows:

The corporation is authorized to have two classes of stock:(1) Common ; (2) non-voting preferred. The total amount of authorized shares is 50,000,000 common and 5,000,000 preferred, each class of which shall have a par value of $0.001.

The number of shares of the corporation outstanding and entitled to vote on an amendment to the Articles of Incorporation are 900,000, that the said change(s) and amendment has been consented to and approved by a majority vote of the stockholders holding at least a majority of each class of stock outstanding and entitled to vote thereon.

	/s/ Donald Bradley
	President or Vice President

	/s/ Shaun Hadley
	Secretary or Assistant Secretary

State of Nevada

ss.

County of Clark

On April 29, 1997 , personally appeared before me, a Notary Public, /s/ Donald C. Bradley & Shaun Hadley

(Names of persons appearing and signing document)

Who acknowledged that they executed the above instrument.

	/s/ Claudia Hill
	Signature of Notary

Filed in the office of the

Secretary of State of the

STATE OF NEVADA

December 22, 1997

CERTIFICATE OF AMENDMENT OF ARTICLES OF INCORPORATION

(AFTER ISSUANCE OF STOCK)

	Perfect Future, LTD.
	Name of Corporation

We the undersigned	Spencer Bradley Vice President	and
	Name of Corporation

Shaun Hadley	of	Perfect Future, Ltd.
Secretary or Assistant Secretary		Name of Corporation

do hereby certify:

That the Board of Directors of said corporation at a meeting duly convened and held on the 15th day of December, 1997, adopted a resolution to amend the original articles as follows:

Article IV is hereby amended to read as follows:

The corporation is authorized to do a FORWARD SPLIT of the issued and outstanding shares of two and one half for one. Making the total issued and outstanding 2,250,000 two million two hundred and fifty thousand.

The number of shares of the corporation outstanding and entitled to vote on an amendment to the Articles of Incorporation are 2,250,000; that the said change(s) and amendment has been consented to and approved by a majority vote of the stockholders holding at least a majority of each class of stock outstanding and entitled to vote thereon.

	/s/ Spencer Bradley
	President or Vice President

	/s/ Shaun Hadley
	Secretary or Assistant Secretary

State of Nevada

ss.

County of Clark

On 12/22/97 , personally appeared before me, a Notary Public, /s/ Spencer Bradley & Shaun Hadley

(Names of persons appearing and signing document)

who acknowledged that they executed the above instrument.

	/s/ Todd Fredlund
	Signature of Notary

Filed in the office of the
Secretary of State of the
STATE OF NEVADA

June 16, 1998

CERTIFICATE OF AMENDMENT OF ARTICLES OF INCORPORATION

(After Issuance of Stock)

PERFECT FUTURE LTD.

(Name of Corporation)

We the undersigned Mark E. Bruk, President and Robert Harris, Secretary of Perfect Future Ltd.

do hereby certify:

That the Board of Directors of said Corporation at a meeting duly convened, held on the 11th day of June, 1998, adopted a resolution to amend the original articles as follows:

Article I

The name of the corporation (hereinafter called the Corporation) is PERFECT FUTURE, LTD.

Article I is hereby amended to read as follows:

The name of the corporation (hereinafter called the Corporation) is amended to: EDUVERSE Accelerated Learning Systems, Inc.

The number of shares of the Corporation issued and outstanding and entitled to vote on an amendment to the Articles of Incorporation is ELEVEN MILLION TWO HUNDRED AND FIFTY THOUSAND (11,250,000) common $0.001 par value stock, that the said change(s) and amendment have been consented to and approved by a majority vote of the stockholders holding at least a majority of each class of stock outstanding and entitled to vote thereon.

	/s/ Mark Bruk
	President

	/s/ Robert Harris
	Secretary

Province of British Columbia
County of Vancouver

On June 15, 1998, personally appeared before me, a Notary Public, Mark E. Bruk, who acknowledged that he executed the above instrument.

	/s/ Kesho Ram Ditta
	Signature of Notary

Filed in the office of the
Secretary of State of the
STATE OF NEVADA

May 19, 1999

Certificate of Amendment to Articles of Incorporation

For Profit Nevada Corporations

(Pursuant to NRS 78.385 and 78.390 – After Issuance of Stock)

- Remit in Duplicate –

Name of corporation: EDUVERSE Accelerated Learning Systems, Inc.

The articles have been amended as follows (provide article numbers, if available):

Article I

The name of the corporation (hereinafter called the Corporation) is: EDUVERSE ACCELERATED LEARNING SYSTEMS, INC.

Article I is hereby amended to read as follows:

The name of the corporation (hereinafter called the Corporation) is amended to: EDUVERSE.COM

3. The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation have voted in favor of the amendment is 7,571,134 (59.9%) of the 12,647,452 entitled to vote^*:

4. Signatures:

/s/ Mark Bruk		/s/ Robert Harris
President or Vice President		Secretary or Asst. Secretary
(acknowledgement required)		(acknowledgement not required)

State of British Columbia
County of Vancouver

This instrument was acknowledged before me on
May 18 , 1999, by
/s/ Mark Bruk (Name of Person)
as President
as designated to sign this certificate
of Amendment to Articles
(name on behalf of whom instrument was executed)

/s/ Anthony K. Wooster
Notary-Public Signature

^* If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless of limitations or restrictions on the voting power thereof.

IMPORTANT: Failure to include any of the above information and remit the proper fees may cause this filing to be rejected.

Filed in the office of

Dean Heller,

SECRETARY OF STATE

June 10, 2001

Certificate of Amendment to Articles of Incorporation

For Profit Nevada Corporations

(Pursuant to NRS 78.385 and 78.390 – After Issuance of Stock)

Remit in duplicate

1.	Name of corporation:	Eduverse.com.

2.	The articles have been amended as follows (provide article numbers, if available):

See attached “Attachment A” Amendment to Articles of Incorporation of Eduverse.com” for Amendment of Article V.

Against 13,404.

4. Signatures (required):

/s/ Grant Atkins		and		/s/ Grant Atkins
President or Vice President				Secretary or Asst. Secretary

^* If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote. In addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless of limitations or restrictions on the voting power thereof.

IMPORTANT: Failure to include any of the above information and remit the proper fees may cause this filing to be rejected.

ATTACHMENT A

AMENDMENT TO

ARTICLES OF INCORPORATION

EDUVERSE.COM

Pursuant to the provisions of sections 78.385 and 78.390 of the Nevada Revised Statutes, the undersigned corporation adopts the following articles of amendment to Article V of its Articles of Incorporation.

“The aggregate number of shares which the corporation shall have authority to issue is 50,000,000 shares of common stock at par value of $0.001 per share and 5,000,000 shares of preferred stock at par value of $0.001 per share.

Common Stock. There shall be no cumulative voting, and all pre-emptive rights are denied. Each share of common stock shall entitle the holder thereof to one vote at all meetings of the stockholders. Stockholders shall not be liable to the corporation or its creditors for any debts or obligation of the corporation.

Simultaneously with the effective date of this amendment (the “Effective Date”), each share of the Company’s Common Stock, $0.001 par value, issued and outstanding immediately prior to the Effective Date (the “Old Common Stock”) shall automatically and without any action on the part of the holder thereof be reclassified as and changed, pursuant to a reverse stock split, into any fraction thereof, into 1/50 of a share of the Company’s outstanding Common Stock, $0.001 par value (the “New Common Stock”), depending upon a determination by the Board that a Reverse Stock Split is in the best interests of the Company and the Shareholders, subject to the treatment of fractional share interests as described below. Each holder of a certificate or certificates which immediately prior to the Effective Date represented outstanding shares of Old Common Stock (the “Old Certificates” whether one or more) shall be entitled to receive upon surrender of such Old Certificates to the Company’s Transfer Agent for cancellation, a certificate or certificates (the “New Certificates”, whether one or more) representing the number of whole shares of the New Common Stock into which and for which the shares of the Old Common Stock formerly represented by such Old Certificates so surrendered, are reclassified under the terms hereof.

From and after the Effective Date. Old Certificates shall represent only the right to receive New Certificates pursuant to the provisions hereof. No certificates or scrip representing fractional share interests in New Common Stock will be issued, and no such fractional share interest will entitle the holder thereof to votes, or to any rights of a shareholder of the Company. Any fraction of a share of new Common Stock to which the holder would otherwise be entitled will be adjusted upward to the amount whole share. If more than one Old Certificate shall be surrendered at one time for the amount of the same Shareholder, the number of full shares of New Common Stock for which New Certificates shall be issued shall be computed on the basis of the aggregate number of shares represented by the Old Certificates so surrendered. In the event that the Company’s Transfer Agent determines that a holder of Old Certificates has not rendered all his certificates for exchange, the Transfer Agent shall carry forward any fractional share until all certificates of that holder have been presented for exchange such that payment for fractional shares to any one person shall not exceed the value of one share. If any New Certificate is to be issued in a name other than that in which the Old Certificates surrendered for exchange are issued, the Old Certificates so surrendered shall be properly endorsed and otherwise in proper form for transfer. From and after the Effective Date the amount of capital represented by the shares of the New Common Stock into which and for which the shares of the Old Common Stock are reclassified under the terms hereof shall be the same as the amount of capital represented by the shares of Old Common Stock so reclassified, until thereafter reduced or increased in accordance with applicable law.

Preferred Stock. The board of directors of the corporation is authorized to divide the preferred stock into as many series as the board of directors from time to time may determine, and to issue the preferred stock in such series. The board of directors shall determine the number of shares comprising each series, which number may, unless otherwise provided by the board of directors in creating such series, be increased or decreased from time to time by action of the board of directors. Each series shall be so designated, as to distinguish the shares thereof, from the shares of all other series. The board of directors shall have the authority to fix and determine the following relative rights and preferences as of the shares of any such series of preferred stock (i) the rate of dividend, if any, (ii) whether shares can be redeemed, and if so, the redemption price and the terms and conditions of the redemption, (iii) the amount payable upon shares in the event of voluntary or involuntary liquidation, (iv) sinking fund provision, if any, for redemption or purchase of shares, (v) the terms and conditions, if any, under which shares may be converted to common stock, and (vi) the voting powers, if any.”

IN WITNESS WHEREOF, Eduverse.com has caused these presents to be signed in its name on its behalf by Grant Atkins, its President, and its corporate seal to be hereunder affixed and attested by Grant Atkins, its Secretary, on the 4th day of June, 2001, and its President acknowledges that these Articles of Amendment are the act and deed of Eduverse.com and, under the penalties of perjury, that the matters and facts set forth herein with respect to authorization and approval are true in all material respects to the best of his knowledge, information and belief.

	EDUVERSE.COM

	By:	/s/ Grant Atkins
	Grant Atkins, President

	By:	/s/ Grant Atkins
	Grant Atkins, Secretary

Before me, _/s/ Stephanie Ebert____________, a Notary Public in and for the State of Washington, personally appeared Grant Atkins who acknowledged before me that he was the President of Eduverse.com, a Nevada corporation, on this day, and that he signed the foregoing Articles of Amendment as his free and voluntary act and dated for the uses and purposes therein set forth, and that the facts contained therein are true.

In witness whereof I have hereunto set my hand and seal this 4 day of June, 2001.

My commission expires 9 09 03		/s/ Stephanie Ebert
		Notary Public

Filed in the office of

Dean Heller,

SECRETARY OF STATE

July 9, 2002

Certificate of Amendment to Articles of Incorporation

For Nevada Profit Corporations

(Pursuant to NRS 78.380 – Before Issuance of Stock)

-Remit in Duplicate-

1.	Name of corporation:	Eduverse.com

2.	The articles have been amended as follows (provide article numbers, if available):

	Further Resolved that an amendment to the Articles of Incorporation of the
	Company to effectuate a change in name of the Company to “Genemax Corp.”
	be and hereby is approved, and that such amendment to the Articles of
	Incorporation be filed with the Nevada Secretary of State.

3. The undersigned declare that they constitute at least two-thirds of the incorporators (check) ___, or of the board of directors (check) xx.

4. The undersigned affirmatively declare that to the date of this certificate, no stock of the corporation has been issued.

5. Signatures:

/s/ Grant Atkins
Signature: Grant Atkins, President		Signature

IMPORTANT: Failure to include any of the above information and remit the proper fees may cause this filing to be rejected.

Filed in the office of

Ross Miller

Secretary of State

State of Nevada

Document Number 20070220121-87

Filing Date and Time

03/29/2007 3:40 PM

Certificate of Amendment to Articles of Incorporation

For Nevada Profit Corporation

(Pursuant to NRS 78.385 and 78.390 – After Issuance of Stock)

1.	Name of corporation:
GENEMAX CORP.

The articles have been amended as follows (provide article numbers, if available):

Article IV is hereby amended to read as follows:

“The corporation is authorized to have two classes of stock: (i) common and (ii) non-voting preferred. The total amount of authorized shares is 200,000,000 common and 5,000,000 preferred, each class of which shall have a par value of $0.001.”

The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the^*articles of incorporation have voted in favor of the amendment is: 75.5%.

4.	Effective date of filing (optional):

5.	Officer Signature (Required): X /s/ Denis Corin

^* If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the alternative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless of limitations or restrictions on the voting power thereof.

IMPORTANT: Failure to include any of the above information and submit the proper fees may cause this filing to be rejected.

Filed in the office of

Ross Miller

Secretary of State

State of Nevada

Document Number 00001403880-94

Filing Date and Time

06/21/2007 11:45 AM

ARTICLES OF MERGER

(Pursuant to Nevada Revised Statutes Chapter 92A)

(excluding 92A.200(4b))

1. Name and Jurisdiction of organization of each constituent entity (NRS 92A.200). If there are more than four merging entities, check box ¨ and attach an 8 1/2 x 11” blank sheet containing the required information for each additional entity.

TAPIMMUNE INC.
Name of merging entity
NEVADA	CORPORATION
Jurisdiction	Entity type*

Name of Merging entity

Jurisdiction	Entity type*

Name of Merging entity

Jurisdiction	Entity type*

Name of Merging entity

Jurisdiction	Entity type^*

and,
GENEMAX CORP.
Name of surviving entity

NEVADA	CORPORATION
Jurisdiction	Entity type*

2. Forwarding address where copies of process may be sent by the Secretary of State of Nevada (if a foreign entity is the survivor in the merger – NRS 92A.1 90):

Attn:

c/o:

3. (Choose one)

¨ The undersigned declares that a plan of merger has been adopted by each constituent entity (NRS 92A.208).

* Corporation, non-profit corporation, limited partnership, limited-liability company or business trust.

x The undersigned declares that a plan of merger has been adopted by the parent domestic entity (NRS 92A.180).

4. Owner’s approval (NRS 92A.200)(options a, b, or c must be used, as applicable, for each entity). (If there are more than four merging entities, check box ¨ and attach an 8 1/2” x 11” blank sheet containing the required information for each additional entity):

(a) Owner’s approval was not required from

TAPIMMUNE INC.

Name of merging entity, if applicable

and, or;

GENEMAX CORP.

Name of surviving entity, if applicable

(b) The plan was approved by the required consent of the owners of^*

Name of merging entity, if applicable

and, or;

Name of surviving entity, if applicable

The plan of merger has been approved by the directors of the corporation and by each public officer or other person whose approval of the plan of merger is required by the articles of incorporation of the domestic corporation.

^* Unless otherwise provided in the certificate of trust or governing Instrument of a business trust, a merger must be approved by all the trustees and beneficial owners of each business trust that is a constituent entity in the merger.

Name of merging entity, if applicable

and, or;

Name of surviving entity, if applicable

5. Amendments, if any, to the articles or certificate of the surviving entity. Provide article numbers, if available. (NRS 92A.200):^*

Article I of the articles of the surviving entity is hereby amended to read as follows:

“I. The name of the Corporation (hereinafter the Corporation) is TAPIMMUNE INC.”

6. Location of Plan of Merger (check a or b):

¨ (a) the entire plan of merger is attached;

or,

x (b) the entire plan of merger is on file at the registered office of the surviving corporation, limited-liability company or business trust, or at the records office address if a limited partnership, or other place of business of the surviving entity (NRS 92A.200).

7. Effective date (optional)^**: 6/28/07

8. Signatures – Must be signed by: An officer of each Nevada corporation; All general partners of each Nevada limited partnership; All general partners of each Nevada limited partnership; A manager of each Nevada limited liability company with managers or all the members if there are no managers; A trustee of each Nevada business trust (NRS 92A.230)^* (If there are more than four merging entities, check box ☐ and attach an 8 1/2” x 11” blank sheet containing the required information for each additional entity.):

^* Amended and restated articles may be attached as an exhibit or integrated into the articles of merger. Please entitle them “Restated” or “Amended and Restated,” accordingly. The form to accompany restated articles prescribed by the secretary of state must accompany the amended and/or restated articles. Pursuant to NRS 92A.180 (merger of subsidiary into parent – Nevada parent owning 90% or more of subsidiary), the articles of merger may not contain amendments to the constituent documents of the surviving entity except that the name of the surviving entity may be changed.

^** A merger takes effect upon filing the articles of merger or upon a later date as specified in the articles, which must not be more than 90 days after the articles are filed (NRS 92A.240).

^* The articles of merger must be signed by each foreign constituent entity in the manner provided by the law governing it (NRS 92A.230). Additional signature blocks may be added to this page or as an attachment, as needed.

IMPORTANT: Failure to include any of the above information and submit the proper fees may cause this filing to be rejected.

TAPIMMUNE INC.
Name of merging entity

X /s/ Denis Corin	President, Secretary & Treasurer
Signature	Title	Date

Name of merging entity

X
Signature	Title	Date

Name of merging entity

X
Signature	Title	Date

Name of merging entity


Signature	Title	Date

GENEMAX CORP.
Name of surviving entity

X /s/ Denis Corin	President & Chief Exec. Officer
Signature	Title	Date June 13, 2007

PLAN OF MERGER

THIS PLAN OF MERGER (the “Plan of Merger”), which has been adopted by the Board of Directors of GeneMax Corp., a Nevada corporation (the “Company”), as of the 13^th day of June, 2007, with respect to the merger of TapImmune, Inc. (“SubCo”), a Nevada corporation that is a wholly-owned subsidiary of the Company, with and into the Company, is executed on behalf of the Company as evidenced by the signature of the Company’s President and Chief Executive Officer as set forth at the end of this Plan of Merger.

PRELIMINARY STATEMENTS

The Board of Directors of the Company deems it desirable and in the best interests of its shareholders that SubCo be merged with and into the Company (the “Merger”) on the terms and conditions of this Plan of Merger.

The Board of Directors of the Company, by resolutions duly adopted, has approved and adopted this Plan of Merger as of the day first written above.

It is intended that the Merger be completed pursuant to the provisions of Section 92A.180 of the Nevada Revised Statutes: Chapter 92A, as amended, (the “Act”).

Pursuant to the provisions of Section 92A.180(1) of the Act, shareholder approval is not required by the shareholders of the Company or SubCo in order to effectuate the Merger.

STATEMENT OF TERMS

SECTION 1

THE MERGER

1.1 The Merger. SubCo will be merged with and into the Company in accordance with this Plan of Merger and the applicable provisions of the Act and the Articles of Merger substantially in the form of Exhibit A attached to this Plan of Merger (the “Articles of Merger”). Following the Merger, the Company will continue as the surviving corporation (the “Surviving Corporation”) and the separate existence of SubCo will cease, except insofar as it may be continued by the Act.

1.2 Effective Time of the Merger. The Merger will be effective at the time (the “Effective Time”) set forth in the Articles of Merger to be filed with the Secretary of State of the State of Nevada, which filing is to be completed as soon as practicable following the adoption of this Plan of Merger by the Board of Directors of the Company.

1.3 Effect of the Merger. The Merger will have the effects set forth in Section 92A.250 of the Act. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time all the property, rights, privileges, powers and franchises of SubCo and the Company will vest in Surviving Corporation without further act or deed, and all debts, liabilities and duties of SubCo and the Company will become the debts, liabilities and duties of the Surviving Corporation.

1.4 Articles of Incorporation: Bylaws.

(a) The articles of incorporation of the Company in effect immediately prior to the Effective Time will continue unchanged and will be the articles of incorporation of the Surviving Corporation until thereafter amended in accordance with the terms thereof and in accordance with applicable law, except that at the Effective Time, Article I of the articles of incorporation of the Surviving Corporation shall be amended to read: “The name of the Corporation (hereinafter the Corporation) is TAPIMMUNE INC.”

(b) The by-laws of the Company in effect immediately prior to the Effective Time will continue unchanged and will be the by-laws of the Surviving Corporation until thereafter amended in accordance with the terms thereof and in accordance with applicable law, except that any and all references to “GeneMax Corp.” shall be deemed to be references to “TapImmune Inc.”

1.5 Directors and Officers. The directors and officers of the Company immediately prior to the Effective Time will be the directors and officers of the Surviving Corporation after the Effective Time and shall hold office until their successors are duly elected, appointed or qualified or until their earlier death, resignation or removal in accordance with certificate of incorporation and bylaws of the Surviving Corporation.

1.6 Taking of Necessary Action. If after the Effective Time any further action is necessary to carry out the purposes of this Plan of Merger or to vest the Surviving Corporation with full title to all assets, rights, approvals, immunities and franchises of either SubCo or the Company, the officers and directors, or the former officers and directors, as the case may be, of SubCo, the Company and the Surviving Corporation will take all such necessary action.

SECTION 2

SUBCO AND COMPANY STOCK

2.1 Conversion of the SubCo Common Stock. The one (1) outstanding share of SubCo common stock, par value $0.001 per share (“SubCo Common Stock”) issued and outstanding immediately prior to the Effective Time will, by virtue of the Merger and without any action on the part of the holder thereof, be converted into one (1) share of common stock of the Company (“Company Common Stock”) on a post-reverse stock split basis (the Company is planning a reverse stock split on a two and one-half (2 ½) old shares for one (1) new share basis to occur at or around the Effective Time).

2.2 Company Common Stock. The terms and conditions of the Company’s Common Stock shall remain unchanged as a result of the Merger.

SECTION 3

MISCELLANEOUS PROVISIONS

3.1 Governing Law. This Plan of Merger will be governed by and construed in accordance with the laws of the State of Nevada.

3.2 Fax Exception. This Plan of Merger may be executed by delivery of an executed signature page by fax and such fax execution will be effective for all purposes.

3.3 Exhibit. The Exhibit A attached to this Plan of Merger if incorporated herein as an integral part of this Plan of Merger.

IN WITNESS WHEREOF, this Plan of Merger, having first been duly approved by the board of directors of the Company, is hereby executed on behalf of the Company.

GENEMAX CORP.

A Nevada Corporation

/s/ Denis Corin
Denis Corin, President and Chief Executive Officer

EXHIBIT A

ARTICLES OF MERGER

(Pursuant to Nevada Revised Statutes Chapter 92A)

(excluding 92A.200(4b))

TAPIMMUNE INC.
Name of merging entity
NEVADA	CORPORATION
Jurisdiction	Entity type*

Name of Merging entity

Jurisdiction	Entity type*

Name of Merging entity

Jurisdiction	Entity type*

Name of Merging entity

Jurisdiction	Entity type⁴

and, GENEMAX CORP.
Name of surviving entity

NEVADA	CORPORATION
Jurisdiction	Entity type*

2. Forwarding address where copies of process may be sent by the Secretary of State of Nevada (if a foreign entity is the survivor in the merger – NRS 92A.1 90):

Attn:

c/o:

3. (Choose one)

¨ The undersigned declares that a plan of merger has been adopted by each constituent entity (NRS 92A.208).

⁴ Corporation, non-profit corporation, limited partnership, limited-liability company or business trust.

x The undersigned declares that a plan of merger has been adopted by the parent domestic entity (NRS 92A.180).

	(a)	Owner’s approval was not required from

		TAPIMMUNE INC.
		Name of merging entity, if applicable

		Name of merging entity, if applicable

		Name of merging entity, if applicable

		Name of merging entity, if applicable

		and, or;

		GENEMAX CORP.
		Name of surviving entity, if applicable

	(b)	The plan was approved by the required consent of the owners of⁵

		Name of merging entity, if applicable

		Name of merging entity, if applicable

		Name of merging entity, if applicable

		Name of merging entity, if applicable

		and, or;

		Name of surviving entity, if applicable

	(c)	Approval of plan of merger for Nevada non-profit corporation (NRS 92A.150):

		The plan of merger has been approved by the directors of the corporation and by each public officer or other person whose approval of the plan of merger is required by the articles of incorporation of the domestic corporation.

⁵ Unless otherwise provided in the certificate of trust or governing Instrument of a business trust, a merger must be approved by all the trustees and beneficial owners of each business trust that is a constituent entity in the merger.

Name of merging entity, if applicable

and, or;

Name of surviving entity, if applicable

5. Amendments, if any, to the articles or certificate of the surviving entity. Provide article numbers, if available. (NRS 92A.200):⁶

Article I of the articles of the surviving entity is hereby amended to read as follows:

“I. The name of the Corporation (hereinafter the Corporation) is TAPIMMUNE INC.”

6. Location of Plan of Merger (check a or b):

¨ (a) the entire plan of merger is attached;

or,

7. Effective date (optional)^**: 6/28/07

⁶ Amended and restated articles may be attached as an exhibit or integrated into the articles of merger. Please entitle them “Restated” or “Amended and Restated,” accordingly. The form to accompany restated articles prescribed by the secretary of state must accompany the amended and/or restated articles. Pursuant to NRS 92A.180 (merger of subsidiary into parent – Nevada parent owning 90% or more of subsidiary), the articles of merger may not contain amendments to the constituent documents of the surviving entity except that the name of the surviving entity may be changed.

^** A merger takes effect upon filing the articles of merger or upon a later date as specified in the articles, which must not be more than 90 days after the articles are filed (NRS 92A.240).

IMPORTANT: Failure to include any of the above information and submit the proper fees may cause this filing to be rejected.

TAPIMMUNE INC. Name of merging entity

X	President, Secretary & Treasurer
Signature	Title	Date

Name of merging entity

X
Signature	Title	Date

Name of merging entity

X
Signature	Title	Date

Name of merging entity


Signature	Title	Date

GENEMAX CORP.
Name of surviving entity

X	President & Chief Exec. Officer
Signature	Title	Date

Filed in the office of Ross Miller Secretary of State State of Nevada

Document Number

20070429826-20

Filing Date and Time

06/21/2007 11:45 AM

Certificate of Change filed Pursuant to NRS 78.209

For Nevada Profit Corporations

Name of corporation:

GENEMAX CORP.

The board of directors have adopted a resolution pursuant to NRS 78.209 and have obtained any require approval of the stockholders.

The current number of authorized shares at the par value, if any, of each class or series, if any, of shares before the change:

200,000,000 authorized shares of common stock, par value $0.001 per share; and

5,000,000 authorized shares of preferred stock, par value $0.001 per share.

The number of authorized shares and the par value, if any, of each class or series, if any, of shares after the change:

80,000,000 authorized shares of common stock, par value $0.001 per share; and

5,000,000 authorized shares of preferred stock, par value $0.001 per share

The number of shares of each affected class or series, if any, to be issued after the change in exchange for each issued share of the same class or series:

23,122,682 shares of common stock shall be issued in exchange for 57,806,706 shares of common stock

The provisions, if any, for the issuance of fractional shares, or for the payment of money or the issuance of scrip to stockholders otherwise entitled to a fraction of a share and the percentage of outstanding shares effected thereby:

See Attachment A to this Certificate of Change

7.	Effective date of filing (optional):	6/28/07
		(must not be later than 90 days after the certificate if filed)

8.	Officer Signature:	X /s/ Denis Corin	President & CEO
		Signature

IMPORTANT: Failure to include any of the above information and submit the proper fees may cause this filing to be rejected.

Filed in the office of Ross Miller Secretary of State State of Nevada

Document Number

20090099715-12

Filing Date and Time

02/03/2009 4:34 PM

Certificate of Amendment to Articles of Incorporation

For Nevada Profit Corporations

(Pursuant to NRS 78.385 and 78.390 – After Issuance of Stock)

Name of corporation:

TAPIMMUNE INC.

The articles have been amended as follows: (provide article numbers, if available)

The number of authorized shares with a par value of $0.001 per share is 500,000,000 common shares and 5,000,000 preferred shares.

The vote by which the stockholders holding shares in the corporation entitling them to exercise a least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation^*have voted in favor of the amendment is: 50.33%.

4.	Effective date of filing: (optional)
		(must not be later than 90 days after the certificate if filed)

Signature: (required)

X /s/ Denis Corin
Signature of Officer

^* If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

Filed in the office of Ross Miller Secretary of State State of Nevada

Document Number

20090531049-23

Filing Date and Time

07/07/2009 10:45 AM

Certificate of Amendment to Articles of Incorporation

For Nevada Profit Corporations

(Pursuant to NRS 78.385 and 78.390 – After Issuance of Stock)

Name of corporation:

TapImmune Inc.

The articles have been amended as follows: (provide article numbers, if available)

The number of authorized shares with a par value of $0.001 per share is 50,000,000 common shares and 5,000,000 preferred shares.

4.	Effective date of filing: (optional)	7/10/09
		(must not be later than 90 days after the certificate if filed)

Signature: (required)

X /s/ Denis Corin
Signature of Officer Denis Corin, President & CEO

^* If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

Filed in the office of Ross Miller Secretary of State State of Nevada

Document Number

20090531051-66

Filing Date and Time

07/07/2009 10:45 AM

Certificate of Change filed Pursuant to NRS 78.209

For Nevada Profit Corporations

Name of corporation.

TapImmune Inc.

The board of directors have adopted a resolution pursuant to NRS 78.209 and have obtained any required approval of the stockholders.

The current number of authorized shares and the par value, if any, of each class or series, if any, of shares before the change.

500,000,000 common shares, par value $0.001, and 5,000,000 preferred shares, par value $0.001.

The number of authorized shares and the par value, if any, of each class or series, if any, of shares after the change:

50,000,000 common shares, par value $0.001, and 5,000,000 preferred shares, par value $0.001.

The number of shares of each affected class or series, if any, to be issued after the change in exchange for each issued share of the same class or series:

This certificate is to enact a reverse stock split whereby every 10 common shares currently outstanding shall be exchanged for one common share. The preferred shares shall not be affected by this certificate.

Any fractional common share that would exist as a result of the reverse stock split shall be rounded up to the nearest whole share.

7	Effective date of filing: (optional)	July 10, 2009
		(must not be later than 90 days after the certificate if filed)

Signature: (required)

X /s/ Denis Corin		Title: President & CEO
Signature of Officer

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

Filed in the office of Ross Miller Secretary of State State of Nevada

Document Number

20100108961-38

Filing Date and Time

02/22/2010 12:15 PM

Certificate of Amendment to Articles of Incorporation

For Nevada Profit Corporations

(Pursuant to NRS 78.385 and 78.390 – After Issuance of Stock)

Name of corporation:

TapImmune Inc.

The articles have been amended as follows: (provide article numbers, if available)

The number of authorized shares with a par value of $0.001 per share is 150,000,000 common shares and 5,000,000 preferred shares.

The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation^*have voted in favor of the amendment is: 55.6%.

4.	Effective date of filing: (optional)	2/22/10
		(must not be later than 90 days after the certificate if filed)

Signature: (required)

X /s/ Denis Corin
Signature of Officer

^* If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

Filed in the office of Ross Miller Secretary of State State of Nevada

Document Number

20140007739-73

Filing Date and Time

01/06/2014 1:55 PM

Certificate of Designation For

Nevada Profit Corporations

(Pursuant to NRS 78.1955)

Name of corporation:

TapImmune Inc.

By resolution of the board of directors pursuant to a provision in the articles of incorporation this certificate establishes the following regarding the voting powers, designations, preferences, limitations, restrictions and relative rights of the following class or series of stock.

Please see the attached Certificate of Designation for the Series A Convertible Preferred Stock.

3.	Effective date of filing: (optional)
		(must not be later than 90 days after the certificate is filed)

Signature: (required)

X /s/ Glynn Wilson
Signature of Officer

Filing Fee: $175.00

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

CERTIFICATE OF DESIGNATION

TapImmune Inc.

Pursuant to Section 78.1955 of the

Nevada Revised Statutes

_____________________________________

SERIES A CONVERTIBLE PREFERRED STOCK

On behalf of TapImmune Inc., a Nevada corporation (the “Corporation”), the undersigned hereby certifies that the following resolution has been duly adopted by the board of directors of the Corporation (the “Board”):

RESOLVED, that, pursuant to the authority granted to and vested in the Board by the provisions of the articles of incorporation of the Corporation (the “Articles of Incorporation”), there hereby is created, out of the five million (5,000,000) shares of preferred stock, par value $0.001 per share, of the Corporation authorized by Article III of the Articles of Incorporation (“Preferred Stock”), a series of Series A Convertible Preferred Stock, consisting of one million, two hundred and fifty thousand (1,250,000) shares, which series shall have the following powers, designations, preferences and relative participating, optional and other special rights, and the following qualifications, limitations and restrictions:

The specific powers, preferences, rights and limitations of the Series A Convertible Preferred Stock are as follows:

1. Designation; Rank. This series of Preferred Stock shall be designated and known as "Series A Convertible Preferred Stock." The number of shares constituting the Series A Convertible Preferred Stock shall be one million, two hundred and fifty thousand (1,250,000) shares. Except as otherwise provided herein, the Series A Convertible Preferred Stock shall, with respect to rights on liquidation, winding up and dissolution, rank pari passu to the common stock, par value $0.001 per share (the "Common Stock").

2. Dividends. The holders of shares of Series A Convertible Preferred Stock have no dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for that purpose.

3. Liquidation Preference.

(a) In the event of any dissolution, liquidation or winding up of the Corporation (a "Liquidation"), whether voluntary or involuntary, the Holders of Series A Convertible Preferred Stock shall be entitled to participate in any distribution out of the assets of the Corporation on a five (5) to one basis per share with the holders of the Common Stock.

(b) A sale of all or substantially all of the Corporation's assets or an acquisition of the Corporation by another entity by means of any transaction or series of related transactions (including, without limitation, a reorganization, consolidated or merger) that results in the transfer of fifty percent (50%) or more of the outstanding voting power of the Corporation (a "Change in Control Event"), shall not be deemed to be a Liquidation for purposes of this Designation.

4. Voting. The holders of Series A Convertible Preferred Stock shall have the right to cast one thousand (1,000) votes for each share held of record on all matters submitted to a vote of holders of the Corporation's common stock, including the election of directors, and all other matters as required by law. There is no right to cumulative voting in the election of directors. The holders of Series A Preferred Stock shall vote together with all other classes and series of common stock of the Corporation as a single class on all actions to be taken by the common stock holders of the Corporation except to the extent that voting as a separate class or series is required by law.

5. Conversion of Series A Convertible Preferred Stock.

(a) Automatic conversion. Upon the occurrence of a reverse stock split of the Corporation's common stock in which every 100 shares of the Corporation's common stock outstanding at the time that this certificate of designation was filed with the Secretary of State of Nevada is exchanged for one share of the Corporation's common stock, each share of Series A Convertible Preferred Stock shall automatically convert into five (5) shares of the Corporation's common stock (such number to be after the aforementioned 100:1 reverse stock split), subject to adjustment as provided in this Section.

(b) No Fractional Shares. No fractional shares of Common Stock or scrip shall be issued upon conversion of shares of Series A Convertible Preferred Stock. In lieu of any fractional share to which the Holder would otherwise be entitled, the Corporation shall issue a number of shares to such Holder rounded up to the nearest whole number of shares of Common Stock. No cash shall be paid to any Holder of Series A Convertible Preferred Stock by the Corporation upon conversion of Series A Preferred Convertible Stock by such Holder.

(c) Stock Dividends, Splits, Combinations and Reclassifications. If the Corporation shall (i) declare a dividend or other distribution payable in securities, (ii) split its outstanding shares of Common Stock into a larger number, (iii) combine its outstanding shares of Common Stock into a smaller number (other than the 100:1 reverse stock split referred to in Section 5(a)), or (iv) increase or decrease the number of shares of its capital stock in a reclassification of the Common Stock including any such reclassification in connection with a merger, consolidation or other business combination in which the Corporation is the continuing entity (any such corporate event, an "Event"), then in each instance the Conversion Rate shall be adjusted such that the number of shares issued upon conversion of one share of Series A Convertible Preferred Stock will equal the number of shares of Common Stock that would otherwise be issued but for such Event.

(d) Issue Taxes. The converting Holder shall pay any and all issue and other non-income taxes that may be payable in respect of any issue or delivery of shares of Common Stock on conversion of shares of Series A Convertible Preferred Stock.

IN WITNESS WHEREOF the undersigned has signed this Designation this December 24, 2013.

TapImmune Inc.

/s/ Glynn Wilson
Glynn Wilson
Chief Executive Officer and Director

Filed in the office of

Ross Miller

Secretary of State

State of Nevada

Document Number

20140117253-36

Filing Date and Time

02/18/2014 2:33 PM

Certificate of Change filed Pursuant to NRS 78.209

For Nevada Profit Corporations

Name of corporation:

TapImmune Inc.

The board of directors have adopted a resolution pursuant to NRS 78.209 and have obtained any required approval of the stockholders.

The current number of authorized shares and the par value, if any, of each class or series, if any, of shares before the change:

150,000,000 common shares, par value $0.001, and 5,000,000 preferred shares, par value $0.001 (of which 1,250,000 have been designated as Series A and 1,500,000 as Series B).

The number of authorized shares and the par value, if any, of each class or series, if any, of shares after the change:

150,000,000 common shares, par value $0.001, and 5,000,000 preferred shares, par value $0.001.

The number of shares of each affected class or series, if any, to be issued after the change in exchange for each issued share of the same class or series:

One share to be issued for each 100 shares of common stock outstanding.

Any fractional shares shall be rounded up to the nearest whole share.

7.	Effective date and time of filing (optional):	Date: Time:
		(must not be later than 90 days after the certificate is filed)

Signature: (required)

X /s/ Glynn Wilson
Signature of Officer		Title: President

IMPORTANT: Failure to include any of the above information and submit the proper fees may cause this filing to be rejected.

Filed in the office of Ross Miller Secretary of State State of Nevada

Document Number

20140118418-40

Filing Date and Time

02/18/2014 4:22 PM

Certificate of Designation For

Nevada Profit Corporations

(Pursuant to NRS 78.1955)

Name of corporation:

TapImmune Inc.

Please see the attached Certificate of Designation for the Series B Convertible Preferred Stock.

3.	Effective date of filing: (optional)
		(must not be later than 90 days after the certificate is filed)

Signature: (required)

X /s/ Glynn Wilson
Signature of Officer

Filing Fee: $175.00

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

CERTIFICATE OF DESIGNATION

TapImmune Inc.

Pursuant to Section 78.1955 of the

Nevada Revised Statutes

SERIES B CONVERTIBLE PREFERRED STOCK

The following resolution has been duly adopted by the board of directors of the Corporation (the "Board"):

RESOLVED, that, pursuant to the authority granted to and vested in the Board by the provisions of the articles of incorporation of the Corporation (the "Articles of Incorporation"), there hereby is created, out of the five million (5,000,000) shares of preferred stock, par value $0.001 per share, of the Corporation authorized by Article III of the Articles of Incorporation ("Preferred Stock"), a series of Series B Convertible Preferred Stock, consisting of one million, five hundred thousand (1,500,000) shares, which series shall have the following powers, designations, preferences and relative participating, optional and other special rights, and the following qualifications, limitations and restrictions:

The specific powers, preferences, rights and limitations of the Series B Convertible Preferred Stock are as follows:

1. Designation; Rank. This series of Preferred Stock shall be designated and known as "Series B Convertible Preferred Stock." The number of shares constituting the Series B Convertible Preferred Stock shall be one million, five hundred thousand (1,500,000) shares. Except as otherwise provided herein, the Series B Convertible Preferred Stock shall, with respect to rights on liquidation, winding up and dissolution, rank pari passu to (i) the common stock, par value $0.001 per share (the "Common Stock") and (ii) the Series A Convertible Preferred Stock, par value $0.001 per share.

2. Dividends. The holders of shares of Series B Convertible Preferred Stock have no dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for that purpose.

3. Liquidation Preference.

(a) In the event of any dissolution, liquidation or winding up of the Corporation (a "Liquidation"), whether voluntary or involuntary, the Holders of Series B Convertible Preferred Stock shall be entitled to participate in any distribution out of the assets of the Corporation on a seven (7) to one basis per share with the holders of the Common Stock and a one and four tenths (1.4) to one basis with the holders of the Series A Convertible Preferred Stock.

4. Voting. The holders of Series B Convertible Preferred Stock shall have the right to cast one thousand (1,000) votes for each share held of record on all matters submitted to a vote of holders of the Corporation's common stock, including the election of directors, and all other matters as required by law. This right is equal to that of the Series A Convertible Preferred Stock There is no right to cumulative voting in the election of directors. The holders of Series B Preferred Stock shall vote together with all other classes and series of common stock of the Corporation as a single class on all actions to be taken by the common stock holders of the Corporation except to the extent that voting as a separate class or series is required by law.

5. Conversion of Series B Convertible Preferred Stock.

(a) Automatic conversion. Upon the occurrence of a reverse stock split of the Corporation's common stock in which every 100 shares of the Corporation's common stock outstanding at the time that this certificate of designation was filed with the Secretary of State of Nevada is exchanged for one share of the Corporation's common stock, each share of Series B Convertible Preferred Stock shall automatically convert into seven (7) shares of the Corporation's common stock (such number to be after the aforementioned 100:1 reverse stock split), subject to adjustment as provided in this Section.

(b) No Fractional Shares. No fractional shares of Common Stock or scrip shall be issued upon conversion of shares of Series B Convertible Preferred Stock. In lieu of any fractional share to which the Holder would otherwise be entitled, the Corporation shall issue a number of shares to such Holder rounded up to the nearest whole number of shares of Common Stock. No cash shall be paid to any Holder of Series B Convertible Preferred Stock by the Corporation upon conversion of Series B Preferred Convertible Stock by such Holder.

(c) Stock Dividends, Splits, Combinations and Reclassifications. If the Corporation shall (i) declare a dividend or other distribution payable in securities, (ii) split its outstanding shares of Common Stock into a larger number, (iii) combine its outstanding shares of Common Stock into a smaller number (other than the 100:1 reverse stock split referred to in Section 5(a)), or (iv) increase or decrease the number of shares of its capital stock in a reclassification of the Common Stock including any such reclassification in connection with a merger, consolidation or other business combination in which the Corporation is the continuing entity (any such corporate event, an "Event"), then in each instance the Conversion Rate shall be adjusted such that the number of shares issued upon conversion of one share of Series B Convertible Preferred Stock will equal the number of shares of Common Stock that would otherwise be issued but for such Event.

Filed in the office of Ross Miller Secretary of State State of Nevada

Document Number

20140123643-86

Filing Date and Time

02/20/2014 1:03 PM

Certificate of Amendment to Articles of Incorporation

For Nevada Profit Corporations

(Pursuant to NRS 78.385 and 78.390 – After Issuance of Stock)

Name of corporation:

TapImmune Inc.

The articles have been amended as follows: (provide article numbers, if available)

The number of authorized shares is 500,000,000 shares of common stock and 5,000,000 shares of preferred stock (the terms of which are to be determined at the sole discretion of the Board of Directors), each class with a par value of $0.001

The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation^*have voted in favor of the amendment is: 278,685,000 of 428,685,000 (65%)

4.	Effective date and time of filing: (optional)	Date: Time:
		(must not be later than 90 days after the certificate if filed)

Signature: (required)

X /s/ Glynn Wilson
Signature of Officer

^* If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

Filed in the office of Ross Miller Secretary of State State of Nevada

Document Number

20160405751-11

Filing Date and Time

09/13/2016 2:00 PM

Certificate of Change filed Pursuant to NRS 78.209

For Nevada Profit Corporations

Name of corporation:

TapImmune Inc.

The board of directors have adopted a resolution pursuant to NRS 78.209 and have obtained any required approval of the stockholders.

The current number of authorized shares and the par value, if any, of each class or series, if any, of shares before the change:

500,000,000 authorized shares of Common Stock, par value $0.01 per share.

5,000,000 authorized shares of Preferred Stock, par value $0.001 per share.

The number of authorized shares and the par value, if any, of each class or series, if any, of shares after the change:

41,666,667 authorized shares of Common Stock, par value $0.001 per share.

5,000,000 authorized shares of Preferred Stock, par value $0.001 per share.

The number of shares of each affected class or series, if any, to be issued after the change in exchange for each issued share of the same class or series:

One (1) share of Common Stock will be issued in exchange for every twelve (12) shares of issued and outstanding Common Stock.

All fractional shares of Common Stock will be rounded up to the nearest whole share.

7.	Effective date and time of filing (optional)	Date: September 16, 2016 Time
		(must not be later than 90 days after the certificate is filed)

Signature: (required)

X /s/ Glynn Wilson		Chairman and Chief Executive Officer
Signature of Officer		Title

IMPORTANT: Failure to include any of the above information and submit with he proper fees may cause this filing to be rejected.

EX-31.1 3 v450946_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, Glynn Wilson, certify that:

(1)

I have reviewed this Report on Form 10-Q for the quarterly period ended September 30, 2016 of TapImmune Inc.;

(2)

Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

(3)

Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;

(4)

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting in the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this Report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5)

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 4, 2016

/s/ Glynn Wilson
By:	Glynn Wilson
Title:	Chief Executive Officer

EX-31.2 4 v450946_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, Michael J. Loiacono, certify that:

(1)

I have reviewed this Report on Form 10-Q for the quarterly period ended September 30, 2016 of TapImmune Inc.;

(2)

(3)

(4)

(a)

(b)

(c)

(d)

(5)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 4, 2016

/s/ Michael J. Loiacono
By:	Michael J. Loiacono
Title:	Chief Financial Officer and Chief Accounting Officer

EX-32.1 5 v450946_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL ACCOUNTING OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Glynn Wilson, the Chief Executive Officer of TapImmune Inc. (the “Company”) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Report on Form 10-Q of TapImmune Inc., for the quarterly period ended September 30, 2016, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of TapImmune Inc.

Date:	November 4, 2016

	/s/ Glynn Wilson
	Glynn Wilson Chief Executive Officer

EX-32.2 6 v450946_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL ACCOUNTING OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Michael J. Loiacono, the Chief Financial Officer and Chief Accounting Officer of TapImmune Inc. (the “Company”) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Report on Form 10-Q of TapImmune Inc., for the quarterly period ended September 30, 2016, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of TapImmune Inc.

Date:	November 4, 2016

	/s/ Michael J. Loiacono
	Michael J. Loiacono Chief Financial Officer and Chief Accounting Officer

GRAPHIC 7 pg18img1_10q.jpg GRAPHIC begin 644 pg18img1_10q.jpg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pg1img1_10q.jpg GRAPHIC begin 644 pg1img1_10q.jpg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tpiv-20160930.xml XBRL INSTANCE DOCUMENT 0001094038 2015-01-01 2015-09-30 0001094038 2015-01-01 2015-12-31 0001094038 2016-01-01 2016-09-30 0001094038 2015-07-01 2015-09-30 0001094038 2016-07-01 2016-09-30 0001094038 2016-08-01 2016-08-31 0001094038 2016-08-10 0001094038 2016-08-10 2016-08-10 0001094038 2016-09-01 2016-09-16 0001094038 2016-09-01 2016-09-30 0001094038 2016-09-30 0001094038 2016-11-02 0001094038 2015-12-31 0001094038 2014-12-31 0001094038 2015-09-30 0001094038 us-gaap:SeriesAPreferredStockMember 2016-09-30 0001094038 us-gaap:SeriesAPreferredStockMember 2015-12-31 0001094038 us-gaap:SeriesBPreferredStockMember 2016-09-30 0001094038 us-gaap:SeriesBPreferredStockMember 2015-12-31 0001094038 us-gaap:CommonStockMember 2015-12-31 0001094038 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001094038 us-gaap:RetainedEarningsMember 2015-12-31 0001094038 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001094038 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001094038 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0001094038 us-gaap:PrivatePlacementMember 2016-08-31 0001094038 us-gaap:CommonStockMember 2016-09-30 0001094038 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001094038 us-gaap:RetainedEarningsMember 2016-09-30 0001094038 tpiv:PromissoryNotesDueInTwoThousandTwelveMember 2016-09-30 0001094038 us-gaap:PrivatePlacementMember 2016-08-01 2016-08-31 0001094038 tpiv:PlacementAgentsMember us-gaap:PrivatePlacementMember 2016-08-31 0001094038 tpiv:PlacementAgentsMember us-gaap:PrivatePlacementMember 2016-08-01 2016-08-31 0001094038 tpiv:DebtConversionAgreementMember 2016-05-01 2016-05-31 0001094038 tpiv:ConsultingAgreementsMember 2016-01-01 2016-09-30 0001094038 tpiv:SharePurchaseWarrantsMember 2016-01-01 2016-09-30 0001094038 tpiv:SharePurchaseWarrantsMember 2015-01-01 2015-09-30 0001094038 us-gaap:FairValueInputsLevel3Member 2016-09-30 0001094038 us-gaap:FairValueHedgingMember 2016-09-30 0001094038 us-gaap:FairValueInputsLevel3Member 2015-12-31 0001094038 us-gaap:FairValueHedgingMember 2015-12-31 0001094038 tpiv:SharePurchaseWarrantsMember 2016-09-30 0001094038 tpiv:SharePurchaseWarrantsMember 2015-09-30 0001094038 us-gaap:CommercialPaperMember 2016-01-01 2016-09-30 0001094038 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001094038 us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-01 2016-09-30 0001094038 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001094038 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001094038 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001094038 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0001094038 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001094038 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001094038 us-gaap:ChiefExecutiveOfficerMember 2016-03-01 2016-03-31 0001094038 us-gaap:ChiefExecutiveOfficerMember us-gaap:GeneralAndAdministrativeExpenseMember 2016-03-01 2016-03-31 0001094038 us-gaap:ChiefOperatingOfficerMember 2016-07-01 2016-07-31 0001094038 us-gaap:ChiefOperatingOfficerMember us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-01 2016-07-31 0001094038 tpiv:AmendedWarrantsMember 2016-08-10 0001094038 tpiv:AmendedWarrantsMember 2016-08-10 2016-08-10 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:USD tpiv:Unit xbrli:pure 9586773 6576564 111652 68803 9698425 6645367 1678079 967358 492365 492365 29000 26493000 5000 30000 0 23000 2204444 28005723 10-Q false 2016-09-30 2016 Q3 TAPIMMUNE INC 0001094038 --12-31 Smaller Reporting Company TPIV 8379101 8396 5884 151724573 112142187 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BORDER-BOTTOM: black 0.5pt solid; MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase">Note 11: <font style="FONT-WEIGHT: normal">      </font> grant income</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the nine months ended September 30, 2016, the Company received approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">231,000</font> of grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV 200. The grant paid for the clinical supplies purchased by the Company.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> -144238988 -133508427 7493981 -21360356 9698425 6645367 0.001 0.001 5000000 5000000 0.001 0.001 0.001 0.001 1250000 1250000 1500000 1500000 0 0 0 0 0 0 0 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i><u>Share Purchase Warrants</u></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">A summary of the Company’s share purchase warrants as of September 30, 2016 and changes during the period is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number of<br/>  Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted Average<br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"> <div>Balance, December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,343,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,000,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,718,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"> <div>Balance, September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,059,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8.51</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.001 0.001 41666667 41666667 8395768 8395768 5882976 1109332 968759 3343248 2324432 1612305 769219 3557701 1579754 -2721637 -1737978 -6900949 -3904186 684000 30266000 5925000 -28485585 0 0 0 775 0 0 231200 0 -65325 -24697 -135640 -24697 -2102962 28503325 -878561 -32413693 -0.29 7.04 -0.14 -10.61 -0.29 4.23 -0.54 -10.61 7281000 4048750 6370000 3054297 7281000 6745416 6935000 3054297 5884 112142187 -133508427 5882976 3135196 653 3134543 0 0.001 6.00 653166 804070 0 804070 0 0 750 4499250 -4500000 750000 0 0 5352000 -5352000 15465000 0 15465000 0 6000000 1000 5999000 0 1000000 516651 0 516651 0 5074000 0 5074000 0 70315 10 70305 0 10191 1309108 99 1309009 0 99435 0 0 -878561 8396 151724573 -144238988 8395768 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BORDER-BOTTOM: black 0.5pt solid; MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase"><b>Note 9:       Promissory note, related party</b></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At December 31, 2015, the Company had an outstanding promissory note in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">23,000</font> owed to an officer of the Company. The promissory note bore no interest charges and had no fixed repayment terms. In September 2016, the note was paid in full.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> -5925000 28485585 1309109 261805 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BORDER-BOTTOM: black 0.5pt solid; MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase"><b>Note 8:      Promissory note</b></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At September 30, 2016, the Company had an outstanding promissory note in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000</font> as compared to two outstanding promissory notes totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,000</font> at December 31, 2015. The promissory note outstanding at September 30, 2016 bears <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% annual interest.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the nine months ended September 30, 2016, the Company paid a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> promissory note and $6,524 of accrued interest in final settlement.    </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 70315 24697 42849 55782 710720 204956 -4756266 -3492432 141944 6087016 0.1 0 0 0 0 -25000 0 6000000 7427998 516651 316508 7766475 9437504 3010209 5945072 23000 0 804070 137986 3135196 2464000 1 P5Y 800000 65317 4.80 P5Y 1 191000 0 0 24000 5352000 0 4500000 0 15465000 0 0 9313000 0 6133000 5074000 11745000 10191 70000 4.80 3100000 60000 414000 653166 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015, respectively:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three Months Ended September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine Months Ended September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>573,137</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>1,309,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>261,805</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>573,137</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>1,309,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>261,805</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;"> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">A summary of the Company’s stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Stock Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>per Share</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Contractual Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding as of December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>298,679</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>177,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>135,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Forfeited/Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,667)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>228.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding as of September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>432,013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>271,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercisable as of September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>262,395</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>174,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Total stock-based compensation cost related to unvested awards not yet recognized and the weighted average periods over which the awards are expected to be recognized as of September 30, 2016 are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Unrecognized stock-based compensation cost:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1,081,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Expected weighted average period compensation costs to be recognized (years):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 9587000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Grant Income</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company’s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable, and are not dependent on the Company’s ongoing future performance. The Company has adopted a policy of recognizing these payments as grant income when received.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Recent Accounting Pronouncement</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Accounting Standards Update (“ASU”), No. 2016-09 - In March 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-09, Compensation-Stock Compensation. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the specific changes associated with the update include all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) being recognized as income tax expense or benefit in the income statement. The tax effects of exercised or vested awards should be treated as discrete items in the reporting period in which they occur. An entity also should recognize excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. An entity can make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has evaluated the impact of ASU No. 2016-09 and has determined that the adoption of the impact of forfeitures, net of income taxes, will not have a material impact on the Company’s future financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 262395 135000 0 1667 9.25 6.00 0 228.00 7.25 8.00 P9Y9M P9Y 174000 P9Y3M 0 2663333 565000 0 0 33333 0 0 432000 39000 1081000 P1Y9M 5054000 211000 6000 4750000 5492000 5000000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the nine months ended 2016 and 201<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="64%"> <div>Share Purchase Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div> Weighted Average Inputs for the Period</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="64%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>For the Nine</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>For the Nine</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="64%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Months Ending</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Months Ending</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="64%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="64%"> <div>Date of valuation</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="64%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Contractual term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Volatility (annual)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>105</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>159</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Risk-free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Dividend yield (per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability  warrants:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="54%" colspan="14"> <div>As of September 30, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="54%" colspan="14"> <div>Fair Value Measurements</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Derivative liability - warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="54%" colspan="14"> <div>As of December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="54%" colspan="14"> <div>Fair Value Measurements</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Derivative liability - warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2016:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 82%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Derivative liability  warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Balance  December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Reclassification of derivative liabilities to equity at exercise date</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(5,074,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(15,465,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Change in fair value of warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(5,925,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Balance  September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> P1Y3M18D P4Y6M 1.05 1.59 0.01 0.01 0 0 29000 29000 29000 29000 29000 29000 1-for-12 26493000 26493000 26493000 26493000 26493000 26493000 26493000 5074000 15465000 -5925000 29000 3096665 750000 7.20 P5Y 4343000 1000000 1718000 2000 5059000 8.67 6.00 6.65 300 8.51 0 0 0 0 12 298679 432013 177000 271000 1.20 7.56 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine Months Ended September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Common stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>432,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>39,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Common stock warrants - equity treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,054,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>211,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Common stock warrants - liability treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,750,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Potentially dilutive securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>5,492,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 5882976 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM: black 1pt solid; WIDTH: 0.75in; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase">Note 4:</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase">SIGNIFICANT ACCOUNTING POLICIES</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 14, 2016 other than the one disclosed below relating to grant income:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Grant Income</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company’s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable, and are not dependent on the Company’s ongoing future performance. The Company has adopted a policy of recognizing these payments as grant income when received.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncement</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Accounting Standards Update (“ASU”), No. 2016-09 - In March 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-09, Compensation-Stock Compensation. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the specific changes associated with the update include all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) being recognized as income tax expense or benefit in the income statement. The tax effects of exercised or vested awards should be treated as discrete items in the reporting period in which they occur. An entity also should recognize excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. An entity can make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has evaluated the impact of ASU No. 2016-09 and has determined that the adoption of the impact of forfeitures, net of income taxes, will not have a material impact on the Company’s future financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The following table sets forth the computation of income (loss) per share:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>For the Three Months Ended<br/> September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>For the Nine Months Ended<br/> September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Net income (loss)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(2,102,962)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>28,503,325</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(878,561)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(32,413,693)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"> <div>Less: Non cash income from changes in fair value of derivative liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="9%"> <div>(2,856,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"> <div>Net income (loss) - diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(2,102,962)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>28,503,325</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(3,734,561)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(32,413,693)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Weighted average shares outstanding - basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>7,281,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,048,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>6,370,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3,054,297</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Common stock warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,663,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>565,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Common stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>33,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Weighted average shares outstanding - diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>7,281,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>6,745,416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>6,935,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>3,054,297</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Net income (loss) per share data:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(0.29)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>7.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(0.14)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(10.61)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(0.29)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4.23</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(0.54)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(10.61)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0 1828 0 0 0 0 -2856000 0 -2102962 28503325 -3734561 -32413693 556000 15500000 4500000 25000 P5Y 0.1 38000 0.5 200000 573137 13244 1309109 261805 0 573137 0 13244 0 1309109 0 261805 19018 146000 20833 103000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM: black 1pt solid; WIDTH: 0.75in; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase">Note 5:</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase">net income (loss) per share</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Basic income (loss) per common share is computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted income per common share is computed similar to basic income per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Income (loss) per-share amounts for all periods have been retroactively adjusted to reflect the Company’s <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1-for-12</font> reverse stock split, which was effective September 16, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table sets forth the computation of income (loss) per share:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>For the Three Months Ended<br/> September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>For the Nine Months Ended<br/> September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Net income (loss)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(2,102,962)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>28,503,325</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(878,561)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(32,413,693)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"> <div>Less: Non cash income from changes in fair value of derivative liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="9%"> <div>(2,856,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"> <div>Net income (loss) - diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(2,102,962)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>28,503,325</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(3,734,561)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(32,413,693)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Weighted average shares outstanding - basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>7,281,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,048,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>6,370,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3,054,297</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Common stock warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,663,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>565,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Common stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>33,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Weighted average shares outstanding - diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>7,281,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>6,745,416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>6,935,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>3,054,297</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Net income (loss) per share data:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(0.29)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>7.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(0.14)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(10.61)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(0.29)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4.23</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(0.54)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(10.61)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine Months Ended September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Common stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>432,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>39,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Common stock warrants - equity treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,054,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>211,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Common stock warrants - liability treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,750,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Potentially dilutive securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>5,492,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM: black 1pt solid; WIDTH: 0.75in; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Note 1:</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase">Nature of Operations</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">   </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM: black 1pt solid; WIDTH: 0.75in; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>NOTE 2:</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase">Basis of Presentation</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2016 or for any future interim period. The condensed consolidated balance sheet at December 31, 2015 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2015, and notes thereto included in the Company’s annual report on Form 10-K.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM: black 1pt solid; WIDTH: 0.75in; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Note 6:</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase">DERIVATIVE LIABILITY - WARRANTs</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the nine months ended 2016 and 201<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="64%"> <div>Share Purchase Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div> Weighted Average Inputs for the Period</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="64%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>For the Nine</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>For the Nine</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="64%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Months Ending</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Months Ending</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="64%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="64%"> <div>Date of valuation</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="64%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Contractual term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Volatility (annual)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>105</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>159</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Risk-free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Dividend yield (per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability  warrants:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="54%" colspan="14"> <div>As of September 30, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="54%" colspan="14"> <div>Fair Value Measurements</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Derivative liability - warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="54%" colspan="14"> <div>As of December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="54%" colspan="14"> <div>Fair Value Measurements</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Derivative liability - warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">There were no transfers between Level 1, 2 or 3 during the nine months ended September 30, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2016:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 82%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Derivative liability  warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Balance  December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>26,493,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Reclassification of derivative liabilities to equity at exercise date</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(5,074,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(15,465,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Change in fair value of warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(5,925,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Balance  September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>29,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Warrant Amendment Transaction</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On August 10, 2016, the Company and holders of an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,096,665</font> outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(the “Amended Warrants”)</font> in which they agreed to amend the terms of the outstanding series warrants to remove provisions that had previously precluded equity <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> classification treatment</font> on the Company’s balance sheets.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In consideration for such amendment and the exercise of the Series C Warrants and Series C-1 Warrants, the Company issued an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 750,000</font> additional shares of common stock to such warrant holders and new five-year warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of Company common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.20</font> per share. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The value of the shares and fair value of the warrants was treated as dividend on the statement of stockholders’ equity of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.5</font> million.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The fair value of the Amended Warrants was re-measured immediately prior to the date of amendment with changes in fair value recorded as a gain of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">556,000</font> in the statement of operations and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.5</font> million was reclassified to equity.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1000000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM: black 1pt solid; WIDTH: 0.75in; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Note 7:</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase">STOCK-BASED COMPENSATION</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015, respectively:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three Months Ended September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine Months Ended September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>573,137</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>1,309,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>261,805</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>573,137</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>1,309,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>261,805</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;"> <strong><i> </i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Stock Options</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the Company’s stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Stock Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>per Share</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Contractual Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding as of December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>298,679</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>177,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>135,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Forfeited/Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,667)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>228.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding as of September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>432,013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>271,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercisable as of September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>262,395</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>174,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div>    <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Total stock-based compensation cost related to unvested awards not yet recognized and the weighted average periods over which the awards are expected to be recognized as of September 30, 2016 are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Unrecognized stock-based compensation cost:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1,081,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Expected weighted average period compensation costs to be recognized (years):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM: black 1pt solid; WIDTH: 0.75in; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both"><font style="TEXT-TRANSFORM: uppercase"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Note 12:</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both"><font style="TEXT-TRANSFORM: uppercase">COMMITMENTS</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Employment Agreements</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In November 2015, the Company entered into an employment agreement with Dr. Glynn Wilson, the Company’s Chief Executive Officer, President and Chairman of the Company. As part of the agreement, Dr. Wilson was awarded <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 19,018</font> fully vested common shares in March 2016. The fair value of the common stock of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">146,000</font> was recognized as stock-based compensation in general and administrative expense.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In July, 2016, the Company entered into an employment agreement with Dr. John Bonfiglio relating to his appointment as the Company’s President and Chief Operating Officer. As part of the agreement, Dr. Bonfiglio was awarded <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,833</font> common shares, which will vest upon the earlier of (i) the listing of the Company’s common stock on a national securities exchange in the United States or (ii) the first anniversary of the employment agreement, so long as Dr. Bonfiglio is employed with the Company. The fair value of the common stock of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">103,000</font> was recognized as stock-based compensation in general and administrative expense.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In August 2016, the Company appointed Michael Loiacono as the Company’s Chief Financial Officer, Chief Accounting Officer, Secretary and Treasurer. In connection with Mr. Loiacono’s appointment he entered into an employment agreement with the Company. The employment agreement provides that Mr. Loiacono’s base salary will be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">200,000</font> per year and he is eligible for an annual performance bonus of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% of his base salary. The term of the employment agreement is for two years and will be automatically extended for an additional 12 months unless terminated by Mr. Loiacono or the Company.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM: black 1pt solid; WIDTH: 0.75in; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>NOTE 3:</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold"> <div><font style="TEXT-TRANSFORM: uppercase">LIQUIDITY AND FINANCIAL CONDITION</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of September 30, 2016, the Company had cash and cash equivalents of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,587,000</font>. Historically, the Company had net losses and negative cash flows from operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 6524 1000000 7.20 3096665 750000 4500000 P5Y <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BORDER-BOTTOM: black 0.5pt solid; MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase">Note 10: <font style="FONT-WEIGHT: normal">      </font> Capital Stock</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Reverse Stock Split</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Effective September 16, 2016, the Company effected a one for twelve reverse stock-split of our issued and outstanding common stock and has retroactively adjusted our common shares outstanding, options and warrants amounts outstanding. The Company has presented its share data for and as of all periods presented on this basis. The par value was not adjusted as a result of the one for twelve reverse stock split. All prior period share transactions included in the Company’s stock transactions and balances have been retroactively restated.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <strong>2016 Common Stock Transactions</strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i> </i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i><u>Private placements</u></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On August 10, 2016 and August 25, 2016, the Company completed private placements of units with certain accredited investors. The units consisted of (i) one share of the Company’s common stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share and (ii) one five-year warrant to purchase one share of Company common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.00</font>. The Company issued and sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 653,166</font> units at a purchase price per unit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.80</font> for an aggregate of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.1</font> million. The Company incurred approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.8</font> million in agency fees and legal costs.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 65,317</font> shares of Company common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.80</font> per share.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Pursuant to the registration rights agreements entered into in connection with the private placements, the Company is required to file a registration statement with the Securities and Exchange Commission registering for resale (a) the common stock issued in the private placement offering; (b) the shares of common stock issuable upon the exercise of the five-year warrants; and (c) the shares of common stock issuable upon the exercise of the warrants issued to the placement agent. The Company is required to file the registration statement within 120 days of the August 10, 2016 closing or by December 8, 2016. The Company is also required to ensure that the registration statement is declared effective within 90 calendar days after filing with the Securities and Exchange Commission, or by March 8, 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In accordance with the registration rights agreements, should the Company fail to meet the above criteria, the Company is subject to pay the investors liquidated damages. The liquidated damages shall be a cash sum payment calculated at a rate of ten percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%) per annum of the aggregate purchase price for the registrable securities or aggregate amount upon exercise of the placement agent warrants.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In accordance with applicable U.S. generally accepted accounting principles, a contingent obligation to make future payments must be recorded if the transfer of consideration under a registration payment arrangement is probable and can be reasonably estimated. The Company has determined that should it be required to pay liquidated damages to the investors of the private placements, the aggregate contingent liability it would be required to record would be approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">29,000</font> per month for each month it fails or is estimated to fail to meet the above criteria.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At the August 10, 2016 and August 26,2016 private placement closings, and on September 30, 2016, the Company concluded that it is not probable that it will be required to remit any payments to the investors for failing to obtain an effective registration statement or failing to maintain its effectiveness.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i> </i></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Warrant Amendment Transaction</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On August 10, 2016, the Company and holders of an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,096,665</font> outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements (the “Amended Warrants”) in which they agreed to amend the terms of the outstanding series warrants to remove provisions that had previously precluded equity classification treatment on the Company’s balance sheets.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In consideration for such amendment and the exercise of the Series C Warrants and Series C-1 Warrants, the Company issued an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 750,000</font> additional shares of common stock to such warrant holders and new five-year warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of Company common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.20</font> per share. The value of the shares and fair value of the warrants was treated as dividend on the statement of stockholders’ equity of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.5</font> million.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i><u>Share Purchase Warrants</u></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">A summary of the Company’s share purchase warrants as of September 30, 2016 and changes during the period is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number of<br/>  Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted Average<br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"> <div style="CLEAR:both;CLEAR: both"> Balance, December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,343,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div style="CLEAR:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(1,000,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div style="CLEAR:both;CLEAR: both">Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,718,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div style="CLEAR:both;CLEAR: both">Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(2,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"> <div style="CLEAR:both;CLEAR: both">Balance, September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,059,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8.51</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Consulting Arangements</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the nine months ended September 30, 2016, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60,000</font> common shares as part of consulting agreements. The fair value of the common stock of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">414,000</font> was recognized as stock-based compensation in general and administrative expense.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Debt Settlement</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In May 2016, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,191</font> common shares as part of debt conversion agreements from 2014. The fair value of the common stock of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70,000</font> was recognized as loss on debt settlement agreements in other income (expense).<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> In September 2016, the Company paid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27,000</font> for a promissory note from 2008 and related $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">38,000</font> of accrued interest. The $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65,000</font> payment was recognized as loss on debt settlement agreements in other income (expense). </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> EX-101.SCH 10 tpiv-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - NET INCOME (LOSS) PER SHARE link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - DERIVATIVE LIABILITY - WARRANTS link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - PROMISSORY NOTE link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - PROMISSORY NOTE, RELATED PARTY link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - CAPITAL STOCK link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - GRANT INCOME link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - COMMITMENTS link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - DERIVATIVE LIABILITY - WARRANTS (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - CAPITAL STOCK (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - NET INCOME (LOSS) PER SHARE - Computation of income (loss) per share (Details) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - NET INCOME (LOSS) PER SHARE - Potentially Dilutive Securities (Detail) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - NET INCOME (LOSS) PER SHARE - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - DERIVATIVE LIABILITY - WARRANTS - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Valuation Methodology (Detail) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - STOCK-BASED COMPENSATION - Components of Stock-based Compensation Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - STOCK-BASED COMPENSATION - Cost Related to Unvested Awards Not Yet Recognized and the Weighted Average Periods (Detail) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - PROMISSORY NOTE - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - PROMISSORY NOTE, RELATED PARTY - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - CAPITAL STOCK - Share Purchase Warrants (Detail) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - CAPITAL STOCK - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - GRANT INCOME - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - COMMITMENTS - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 11 tpiv-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 12 tpiv-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 13 tpiv-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series A Preferred Stock [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series B Preferred Stock [Member] Statement [Line Items] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current Assets Cash Cash Cash, beginning of period Cash, end of period Prepaid Expense, Current Prepaid expenses and deposits Assets Total Assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities, Current [Abstract] Current Liabilities Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Other Liabilities, Current Research agreement obligations Other current liabilities Derivative Liability, Current Derivative liability - warrants Derivative liability - warrants Notes Payable, Current Promissory note Outstanding promissory notes Notes Payable, Related Parties, Current Promissory note, related party Outstanding promissory notes Liabilities, Current Total Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity (Deficit) Preferred Stock, Value, Issued Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized Common Stock, Value, Issued Common stock, $0.001 par value, 41,666,667 shares authorized, 8,395,768 and 5,882,976 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total Stockholders’ Equity (Deficit) Beginning Balance, Amount Total stockholders' equity Ending Balance, Amount Liabilities and Equity Total Liabilities and Stockholders’ Equity (Deficit) Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock par value Preferred Stock, Shares Authorized Preferred stock shares authorized/designated Preferred Stock, Shares Issued Preferred stock issued Preferred Stock, Shares Outstanding Preferred stock outstanding Common Stock, Par or Stated Value Per Share Common stock shares par value Common stock par value Common Stock, Shares Authorized Common stock shares authorized Common Stock, Shares, Issued Common stock shares issued Common Stock, Shares, Outstanding Common stock shares outstanding Common stock outstanding Income Statement [Abstract] Costs and Expenses [Abstract] Operating Expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Income (Loss) Loss from Operations Nonoperating Income (Expense) [Abstract] Other Income (Expense) Derivative, Gain (Loss) on Derivative, Net Changes in fair value of derivative liabilities Foreign Currency Transaction Gain (Loss), before Tax Foreign exchange gain Revenue from Grants Grant income Gain (Loss) on Extinguishment of Debt Loss on debt settlement agreements Earnings Per Share, Basic Basic Net Income (Loss) per Share Basic Earnings Per Share, Diluted Diluted Net Income (Loss) per Share Diluted Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Common Shares Outstanding, Basic Weighted average shares outstanding - basic Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Common Shares Outstanding, diluted Weighted average shares outstanding - diluted Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid-In Capital [Member] Retained Earnings [Member] Accumulated Deficit [Member] Shares, Issued Beginning Balance, Share Ending Balance, Share Stock Issued During Period, Shares, New Issues Issuance of common stock in private placement (in shares) Units issued Stock Issued During Period, Value, New Issues Issuance of common stock in private placement Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Finders’ fee and legal costs relating to private placements offering costs Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued Fair value of shares issued as inducement on August 10, 2016 Deferred Compensation Arrangement with Individual, Shares Issued Fair value of shares issued as inducement on August 10, 2016 (in shares) Fair Value Of Series F And Series F-1 Warrants Issued Fair value of series F and F-1 warrants issued as inducement in August 2016 Fair value of Series F and Series F-1 warrants issued. Adjustments To Additional Paid In Capital Relating To Reclassification Of Fair Value Of Derivative Liabilities To Equity On Amendment Of Warrant Agreements Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements Adjustments to additional paid In capital relating to reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements. Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flow from operating activities Net Income (Loss) Attributable to Parent Net loss Net Income (Loss) Net loss Net income (loss) Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash from operating activities: Increase (Decrease) in Derivative Liabilities Changes in fair value of derivative liabilities Cash portion Of Loss on debt settlement agreements Loss on debt settlement agreements Amount of cash portion of loss on debt settlement agreements. Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense Prepaid expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flow from financing activities Proceeds from Issuance of Private Placement Private placements Payments of Stock Issuance Costs Finders’ fee and legal costs on private placements Proceeds from (Repayments of) Notes Payable Repayment of promissory note Repayments of Related Party Debt Repayment of promissory note - related party Cash, Period Increase (Decrease) Net increase in cash Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information Reclassification Of Accrued Liability Upon Issuance Of Common Shares Relating To Compensation Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson's compensation Reclassification of accrued liability upon issuance of common shares relating to compensation. Stock Issued Accounts payable settled in common stock Fair Value Of Issuance Of Series F And F-1 Warrants As Inducement Fair value of issuance of series F and F-1 warrants as inducement in August 2016 Fair value of issuance of series F and F-1 warrants as inducement in noncash investing or financing activities. Fair Value Of Shares Issued As Inducement Fair value of shares issued as inducement on August 10, 2016 Fair value of shares issued as inducement in noncash investing or financing activities. Reclassification Of Fair Value Of Derivative Liabilities To Equity On Amendment Of Warrant Agreements Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements in noncash investing or financing activities. Cash and Cash Equivalents [Abstract] Cash Equivalents, at Carrying Value Cash and cash equivalents Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Share Purchase Warrants [Member] Share Purchase Warrants [Member] Share Purchase Warrants [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Fair Value Assumptions, Exercise Price Exercise price Fair Value Assumptions, Expected Term Contractual term (years) Fair Value Assumptions, Expected Volatility Rate Volatility (annual) Fair Value Assumptions, Risk Free Interest Rate Risk-free rate Derivative, Fair Value, Net [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Fair Value Hedging [Member] Fair Value [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Derivative Liability, Fair Value, Gross Liability Derivative liability - warrants Derivative, Fair Value, Net Total Fair Value Disclosures [Abstract] Notes Payable [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Promissory Notes Due In Two Thousand Twelve [Member] Promissory Notes Due in 2012 [Member] Promissory Notes Due In Two Thousand Twelve [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Interest Rate, Stated Percentage Annual interest rate Related Party Transactions [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Equity [Abstract] Common Stock Capital Shares Reserved For Future Issuance [Table] Common Stock Capital Shares Reserved For Future Issuance [Table] Common Stock Capital Shares Reserved For Future Issuance [Table] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Consulting Agreements [Member] Consulting Agreements [Member] Consulting Agreements [Member] Sale of Stock [Axis] Sale of Stock [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Fair value of common stock Stock Issued During Period, Shares, Issued for Services Common shares issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Operations [Text Block] NATURE OF OPERATIONS Basis of Accounting [Text Block] BASIS OF PRESENTATION Text Block [Abstract] Liquidity And Financial Condition [Text Block] LIQUIDITY AND FINANCIAL CONDITION Liquidity and financial condition text block. Accounting Policies [Abstract] Significant Accounting Policies [Text Block] SIGNIFICANT ACCOUNTING POLICIES Grant Income [Policy Text Block] Grant Income Grant Income [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Recent accounting pronouncement Derivative Liability Warrants And Derivative Liability Conversion Option [Text Block] DERIVATIVE LIABILITY - WARRANTS Derivative Liability Warrants And Derivative Liability Conversion Option [Text Block] Valuation Methodology Valuation Methodology Valuation methodology. Financial Assets And Liabilities Measured At Fair Value On Recurring Basis Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on recurring basis. Measured At Fair Value Schedule of Changes in Level 3 Liabilities Measured at Fair Value Measured at fair value. Promissory Note [Text Block] PROMISSORY NOTE Promissory Note [Text Block] Promissory Note Related Party [Text Block] PROMISSORY NOTE, RELATED PARTY Promissory Note Related Party [Text Block] Capital Stock [Text Block] CAPITAL STOCK The entire disclosure for the capital stock. Grant Income [Text Block] GRANT INCOME Grant Income [Text Block] Document And Entity Information [Abstract] Document Information [Table] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Commitments and Contingencies Commitments and Contingencies Document Information [Line Items] Share Purchase Warrant [Text Block] Capital Stock The entire disclosure of share purchase warrants. Revenues [Abstract] Other Income Other income Class of Warrant or Right, Outstanding Number of Warrants, Beginning balance Number of Warrants, Ending balance Number Of Warrant Exercised Number of Warrants, Exercised Number of warrants exercised. Exercise Of Warrants Amount Exercise of warrants Amount Exercise of warrants amount. Exercise Of Warrants share Exercise of warrants share Exercise of warrants share. Adjustments To Additional Paid In Capital finders Fee On Warrants Exercised Finders’ fee on exercise of warrants Adjustments to additional paid in capital finders fee on warrants exercised. Income Statement Location [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Private Placement [Member] Private Placement [Member] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Adjustments to Additional Paid in Capital, Warrant Issued Reclassification of fair value of derivative liabilities at exercise date Stock Issued During Period, Value, Conversion of Convertible Securities Shares issued in debt settlement agreements Stock Issued During Period, Shares, Conversion of Convertible Securities Shares issued in debt settlement agreements, Shares Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Stock- based compensation, Amount Stock Issued During Period, Shares, Share-based Compensation, Gross Stock- based compensation, Share Share-based Compensation Stock based compensation Interest Paid Cash paid for interest Income Taxes Paid Cash paid for taxes Proceeds from Warrant Exercises Proceeds from exercise of warrants Payments For Finders Fee On Exercise Of Warrants Finders' fee on exercise of warrants Payments For Finders Fee On Exercise Of Warrants Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Class Of Warrant Or Right Expiration Period Class of warrant or right expiration period. Legal Fees Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of warrant or right, number of securities called by warrants or rights Supplemental schedule of non-cash activities [Abstract] Supplemental schedule of non-cash investing and financing activities: Noncash Or Part Noncash Transaction Fair Value Of Warrants Issued Fair value of issuance of warrants in January and March 2015 financing Noncash or part noncash transaction fair value of warrants issued. Number of common stocks included in unit offering Number of common stock included in unit offering. Noncash Or Part Noncash Transaction Issuance Of Additional Warrants Issuance of additional warrants in May 28, 2015 transaction Noncash Or Part Noncash Transaction Issuance Of Additional Warrants Noncash Or Part Noncash Transaction Reclassification Of Warrant Liabilities To Equity Reclassification of Derivative Warrant Liabilities to Equity at Exercise Date Noncash or part noncash transaction reclassification of warrant liabilities to equity Noncash Investing and Financing Items [Abstract] Non-cash investing and financing activities Number Of Equity Unit Issued Number of equity units issued. Equity Unit Issued Price Per Unit Equity units issued price per unit. Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchases Agreement Aggregate purchase price of shares agreed to purchase by accredited investors. Income Statement Location [Domain] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan Schedule of Share-based Compensation, Activity [Table Text Block] Schedule of Share-based Compensation, Activity Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block] Schedule of Unrecognized Compensation Cost, Nonvested Awards Schedule of Cash and Cash Equivalents [Table] Research and Development Expense [Member] General and Administrative Expense [Member] Cash and Cash Equivalents [Line Items] Allocated Share-based Compensation Expense Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Stock Options Outstanding, Begining Balance Stock Options Outstanding, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Stock Options, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Stock Options, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Stock Options, Forfeited/Cancelled Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Stock Options, Exercisable as of September 30, 2016 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price per Share Outstanding, Begining Balance Weighted Average Exercise Price per Share Outstanding, Ending Balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price per Share, Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise Price per Share, Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted Average Exercise Price per Share, Forfeited/Cancelled Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price per Share Exercisable as of September 30, 2016 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Exercisable as of September 30, 2016 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable as of September 30, 2016 Earnings Per Share [Abstract] Net income (loss) per share data: Earnings Per Share [Text Block] Earnings Per Share Applicable To Common Stockholders NET INCOME (LOSS) PER SHARE Computation Of Income Loss Per Share [Table Text Block] Computation Of Income Loss Per Share Computation Of Income Loss Per Share Net Loss Per Share [Table Text Block] Net Loss Per Share Net Loss Per Share NotesToFinancialStatements [Abstract] Notes To Financial Statements Dilutive Securities, Effect on Basic Earnings Per Share Less: noncash income from change in fair value of common stock warrants Less: Non cash income from changes in fair value of derivative liabilities Net Income (Loss) Attributable to Parent, Diluted Net income (loss) - diluted Common Stock Warrants Common stock warrants Common Stock Warrants Common Stock Options Common stock options Common Stock Options Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized stock-based compensation cost: Option Indexed to Issuer's Equity, Shares Common stock options Common stock options Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Expected weighted average period compensation costs to be recognized (years): Common Stock Warrants Equity Treatment Common stock warrants - equity treatment Common stock warrants - equity treatment Common stock warrants - equity treatment. Common Stock Warrants Liability Treatment Common stock warrants - liability treatment Common stock warrants - liability treatment Common stock warrants - liability treatment. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities Potentially dilutive securities Stockholders' Equity, Reverse Stock Split Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Balance - December 31, 2015 Balance - September 30, 2016 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Reclassification Of Derivative Liabilities To Equity Reclassification of derivative liabilities to equity at exercise date Reclassification of derivative liabilities to equity measured using unobservable inputs measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Fair Value Measurement With Unobservable Input Reconciliation Recurring Basis Derivative Liability Removed On Amendment To Warrant Agreements Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements Fair value of derivative liability removed on amendment to the warrant agreement measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Change in fair value of warrant liability Stock Issued During Period Shares, Upon Exercise Of Warrants The number of shares issued during the period upon exercise of warrants. Derivative, Gain on Derivative Number Of Warrant Issued Number of Warrants, Issued Number of warrants issued. Number Of Warrant Extinguished Or Expired Number of Warrants, Expired Number of warrants extinguished or expired. Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Ending Balance Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price. Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercise Price Weighted Average Exercise Price, Exercised Class of warrant or rights outstanding exercised weighted average exercise price. Class Of Warrant Or Rights Outstanding Issued Weighted Average Exercise Price Weighted Average Exercise Price, Issued Class of warrant or rights outstanding issued weighted average exercise price. Class Of Warrant Or Rights Outstanding Extinguished Or Expired Weighted Average Exercise Price Weighted Average Exercise Price, Expired Class of warrant or rights outstanding extinguished or expired weighted average exercise price. Debt Conversion Agreement [Member] Stockholders' Equity Note, Stock Split, Conversion Ratio Fair Value Assumptions, Expected Dividend Rate Dividend yield (per share) Fair Value Of Warrant Reclassification To Equity The fair value of warrants reclassified to equity. Dividends Repayments of Notes Payable Class of Warrant or Right, Warrant Terms Terms of warrants or rights outstanding. Payment Of Liquidated Damages, Percentages The amount of payment for liquidated damages based on percentage of purchase price.. Debt Instrument, Periodic Payment, Interest Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS Commitments And Contingencies [Table] Annual Performance Bonus On Base Salary, Percentage The percentage of bonus on Base salary. Salaries, Wages and Officers' Compensation Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Shares awarded Chief Executive Officer [Member] Chief Executive Officer, President and Chairman [Member] Chief Executive Officer, President and Chairman [Member] Commitments And Contingencies [Line Items] Chief Operating Officer [Member] Debt Instrument Repayments of Accured Interest The amount of interest paid on final repayment of debt instrument. Long-term Debt, Type [Axis] Amended Warrants [Member] Class Of Warrant Or Right Warrant Term This element represents the term of warrants. Fair Value Adjustment of Warrants Placement Agents [Member] Placement Agent [Member] Common Stock Capital Shares Reserved For Future Issuance [Line Items] Common Stock Capital Shares Reserved For Future Issuance [Line Items] Common Stock Capital Shares Reserved For Future Issuance [Line Items] Long-term Debt, Type [Domain] Commercial Paper [Member] EX-101.PRE 14 tpiv-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 15 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2

Document And Entity Information - shares
9 Months Ended

Sep. 30, 2016

Nov. 02, 2016

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2016

Document Fiscal Year Focus 2016

Document Fiscal Period Focus Q3

Entity Registrant Name TAPIMMUNE INC

Entity Central Index Key 0001094038

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Trading Symbol TPIV

Entity Common Stock, Shares Outstanding 8,379,101

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 16 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)

Sep. 30, 2016

Dec. 31, 2015

Current Assets

Cash $ 9,586,773 $ 6,576,564

Prepaid expenses and deposits 111,652 68,803

Total Assets 9,698,425 6,645,367

Current Liabilities

Accounts payable and accrued liabilities 1,678,079 967,358

Research agreement obligations 492,365 492,365

Derivative liability - warrants 29,000 26,493,000

Promissory note 5,000 30,000

Promissory note, related party 0 23,000

Total Liabilities 2,204,444 28,005,723

Commitments and Contingencies

Stockholders' Equity (Deficit)

Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized

Common stock, $0.001 par value, 41,666,667 shares authorized, 8,395,768 and 5,882,976 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 8,396 5,884

Additional paid-in capital 151,724,573 112,142,187

Accumulated deficit (144,238,988) (133,508,427)

Total Stockholders’ Equity (Deficit) 7,493,981 (21,360,356)

Total Liabilities and Stockholders’ Equity (Deficit) 9,698,425 6,645,367

Series A Preferred Stock [Member]

Stockholders' Equity (Deficit)

Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized 0 0

Series B Preferred Stock [Member]

Stockholders' Equity (Deficit)

Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized $ 0 $ 0

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13495-108611
+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Assets
-URI http://asc.fasb.org/extlink&oid=6509628

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Sep. 30, 2016

Dec. 31, 2015

Preferred stock par value $ 0.001 $ 0.001

Preferred stock shares authorized/designated 5,000,000 5,000,000

Common stock shares par value $ 0.001 $ 0.001

Common stock shares authorized 41,666,667 41,666,667

Common stock shares issued 8,395,768 5,882,976

Common stock shares outstanding 8,395,768 5,882,976

Series A Preferred Stock [Member]

Preferred stock par value $ 0.001 $ 0.001

Preferred stock shares authorized/designated 1,250,000 1,250,000

Preferred stock issued 0 0

Preferred stock outstanding 0 0

Series B Preferred Stock [Member]

Preferred stock par value $ 0.001 $ 0.001

Preferred stock shares authorized/designated 1,500,000 1,500,000

Preferred stock issued 0 0

Preferred stock outstanding 0 0

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Operating Expenses:

Research and development $ 1,109,332 $ 968,759 $ 3,343,248 $ 2,324,432

General and administrative 1,612,305 769,219 3,557,701 1,579,754

Loss from Operations (2,721,637) (1,737,978) (6,900,949) (3,904,186)

Other Income (Expense)

Changes in fair value of derivative liabilities 684,000 30,266,000 5,925,000 (28,485,585)

Foreign exchange gain 0 0 0 775

Grant income 0 0 231,200 0

Loss on debt settlement agreements (65,325) (24,697) (135,640) (24,697)

Other income 0 0 1,828 0

Net Income (Loss) $ (2,102,962) $ 28,503,325 $ (878,561) $ (32,413,693)

Basic Net Income (Loss) per Share $ (0.29) $ 7.04 $ (0.14) $ (10.61)

Diluted Net Income (Loss) per Share $ (0.29) $ 4.23 $ (0.54) $ (10.61)

Weighted Average Number of Common Shares Outstanding, Basic 7,281,000 4,048,750 6,370,000 3,054,297

Weighted Average Number of Common Shares Outstanding, diluted 7,281,000 6,745,416 6,935,000 3,054,297

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (a),(c),(d),(e)
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959
+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30700-110894

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30690-110894
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue and income classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.4)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_RevenueFromGrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 19 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - 9 months ended Sep. 30, 2016 - USD ($)

Total

Common Stock [Member]

Additional Paid-In Capital [Member]

Accumulated Deficit [Member]

Beginning Balance, Amount at Dec. 31, 2015 $ (21,360,356) $ 5,884 $ 112,142,187 $ (133,508,427)

Beginning Balance, Share at Dec. 31, 2015 5,882,976

Issuance of common stock in private placement (in shares) 653,166

Issuance of common stock in private placement 3,135,196 $ 653 3,134,543 0

Finders’ fee and legal costs relating to private placements (804,070) 0 (804,070) 0

Fair value of shares issued as inducement on August 10, 2016 0 $ 750 4,499,250 (4,500,000)

Fair value of shares issued as inducement on August 10, 2016 (in shares) 750,000

Fair value of series F and F-1 warrants issued as inducement in August 2016 0 $ 0 5,352,000 (5,352,000)

Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements 15,465,000 0 15,465,000 0

Exercise of warrants Amount 6,000,000 $ 1,000 5,999,000 0

Exercise of warrants share 1,000,000

Finders’ fee on exercise of warrants (516,651) $ 0 (516,651) 0

Reclassification of fair value of derivative liabilities at exercise date 5,074,000 0 5,074,000 0

Shares issued in debt settlement agreements 70,315 $ 10 70,305 0

Shares issued in debt settlement agreements, Shares 10,191

Stock- based compensation, Amount 1,309,108 $ 99 1,309,009 0

Stock- based compensation, Share 99,435

Net loss (878,561) $ 0 0 (878,561)

Ending Balance, Amount at Sep. 30, 2016 $ 7,493,981 $ 8,396 $ 151,724,573 $ (144,238,988)

Ending Balance, Share at Sep. 30, 2016 8,395,768

X

- Definition
Adjustments to additional paid in capital finders fee on warrants exercised.
+ References
No definition available.
+ Details

Name: tpiv_AdjustmentsToAdditionalPaidInCapitalFindersFeeOnWarrantsExercised

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Adjustments to additional paid In capital relating to reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements.
+ References
No definition available.
+ Details

Name: tpiv_AdjustmentsToAdditionalPaidInCapitalRelatingToReclassificationOfFairValueOfDerivativeLiabilitiesToEquityOnAmendmentOfWarrantAgreements

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Exercise of warrants amount.
+ References
No definition available.
+ Details

Name: tpiv_ExerciseOfWarrantsAmount

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Exercise of warrants share.
+ References
No definition available.
+ Details

Name: tpiv_ExerciseOfWarrantsShare

Namespace Prefix: tpiv_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of Series F and Series F-1 warrants issued.
+ References
No definition available.
+ Details

Name: tpiv_FairValueOfSeriesFAndSeriesF1WarrantsIssued

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28183637&loc=d3e4724-112606

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Warrant
-URI http://asc.fasb.org/extlink&oid=6528364
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The total fair value of shares issued during the period under a deferred compensation arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued pursuant to the terms of a deferred compensation arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Cash flow from operating activities

Net loss $ (878,561) $ (32,413,693)

Adjustments to reconcile net loss to net cash from operating activities:

Changes in fair value of derivative liabilities (5,925,000) 28,485,585

Loss on debt settlement agreements 70,315 24,697

Stock based compensation 1,309,109 261,805

Changes in operating assets and liabilities:

Prepaid expenses (42,849) (55,782)

Accounts payable and accrued liabilities 710,720 204,956

Net cash used in operating activities (4,756,266) (3,492,432)

Cash flow from financing activities

Private placements 3,135,196 2,464,000

Finders’ fee and legal costs on private placements (804,070) (137,986)

Repayment of promissory note (25,000) 0

Repayment of promissory note - related party (23,000) 0

Proceeds from exercise of warrants 6,000,000 7,427,998

Finders' fee on exercise of warrants (516,651) (316,508)

Net cash provided by financing activities 7,766,475 9,437,504

Net increase in cash 3,010,209 5,945,072

Cash, beginning of period 6,576,564 141,944

Cash, end of period 9,586,773 6,087,016

Supplemental disclosure of cash flow information

Cash paid for interest 0 0

Cash paid for taxes 0 0

Supplemental schedule of non-cash investing and financing activities:

Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson's compensation 191,000 0

Accounts payable settled in common stock 0 24,000

Fair value of issuance of series F and F-1 warrants as inducement in August 2016 5,352,000 0

Fair value of shares issued as inducement on August 10, 2016 4,500,000 0

Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements 15,465,000 0

Fair value of issuance of warrants in January and March 2015 financing 0 9,313,000

Issuance of additional warrants in May 28, 2015 transaction 0 6,133,000

Reclassification of Derivative Warrant Liabilities to Equity at Exercise Date $ 5,074,000 $ 11,745,000

X

- Definition
Amount of cash portion of loss on debt settlement agreements.
+ References
No definition available.
+ Details

Name: tpiv_CashPortionOfLossOnDebtSettlementAgreements

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of issuance of series F and F-1 warrants as inducement in noncash investing or financing activities.
+ References
No definition available.
+ Details

Name: tpiv_FairValueOfIssuanceOfSeriesFAndF1WarrantsAsInducement

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of shares issued as inducement in noncash investing or financing activities.
+ References
No definition available.
+ Details

Name: tpiv_FairValueOfSharesIssuedAsInducement

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Noncash or part noncash transaction fair value of warrants issued.
+ References
No definition available.
+ Details

Name: tpiv_NoncashOrPartNoncashTransactionFairValueOfWarrantsIssued

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Noncash Or Part Noncash Transaction Issuance Of Additional Warrants
+ References
No definition available.
+ Details

Name: tpiv_NoncashOrPartNoncashTransactionIssuanceOfAdditionalWarrants

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Noncash or part noncash transaction reclassification of warrant liabilities to equity
+ References
No definition available.
+ Details

Name: tpiv_NoncashOrPartNoncashTransactionReclassificationOfWarrantLiabilitiesToEquity

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Payments For Finders Fee On Exercise Of Warrants
+ References
No definition available.
+ Details

Name: tpiv_PaymentsForFindersFeeOnExerciseOfWarrants

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Reclassification of accrued liability upon issuance of common shares relating to compensation.
+ References
No definition available.
+ Details

Name: tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements in noncash investing or financing activities.
+ References
No definition available.
+ Details

Name: tpiv_ReclassificationOfFairValueOfDerivativeLiabilitiesToEquityOnAmendmentOfWarrantAgreements

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: tpiv_SupplementalScheduleOfNoncashActivitiesAbstract

Namespace Prefix: tpiv_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInDerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The fair value of stock issued in noncash financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586
+ Details

Name: us-gaap_StockIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2

NATURE OF OPERATIONS
9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

Note 1:

Nature of Operations



TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6003-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2A
-URI http://asc.fasb.org/extlink&oid=64851502&loc=SL51803626-108592
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2

BASIS OF PRESENTATION
9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

NOTE 2:

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results.

The results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2016 or for any future interim period. The condensed consolidated balance sheet at December 31, 2015 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2015, and notes thereto included in the Company’s annual report on Form 10-K.

X

- Definition
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2

LIQUIDITY AND FINANCIAL CONDITION
9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

LIQUIDITY AND FINANCIAL CONDITION

NOTE 3:

LIQUIDITY AND FINANCIAL CONDITION

The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings.

The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.

As of September 30, 2016, the Company had cash and cash equivalents of approximately $9,587,000. Historically, the Company had net losses and negative cash flows from operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

X

- Definition
Liquidity and financial condition text block.
+ References
No definition available.
+ Details

Name: tpiv_LiquidityAndFinancialConditionTextBlock

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2

SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

Note 4:

SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 14, 2016 other than the one disclosed below relating to grant income:

Grant Income

The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company’s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable, and are not dependent on the Company’s ongoing future performance. The Company has adopted a policy of recognizing these payments as grant income when received.

Recent Accounting Pronouncement

Accounting Standards Update (“ASU”), No. 2016-09 - In March 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-09, Compensation-Stock Compensation. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the specific changes associated with the update include all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) being recognized as income tax expense or benefit in the income statement. The tax effects of exercised or vested awards should be treated as discrete items in the reporting period in which they occur. An entity also should recognize excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. An entity can make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years.

The Company has evaluated the impact of ASU No. 2016-09 and has determined that the adoption of the impact of forfeitures, net of income taxes, will not have a material impact on the Company’s future financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18854-107790
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2

NET INCOME (LOSS) PER SHARE
9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

NET INCOME (LOSS) PER SHARE

Note 5:

net income (loss) per share

Basic income (loss) per common share is computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted income per common share is computed similar to basic income per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

Income (loss) per-share amounts for all periods have been retroactively adjusted to reflect the Company’s 1-for-12 reverse stock split, which was effective September 16, 2016.

The following table sets forth the computation of income (loss) per share:

For the Three Months Ended
September 30,

For the Nine Months Ended
September 30,

2016

2015

2016

2015

Net income (loss)

$

(2,102,962)

$

28,503,325

$

(878,561)

$

(32,413,693)

Less: Non cash income from changes in fair value of derivative liabilities

-

-

(2,856,000)

-

Net income (loss) - diluted

(2,102,962)

28,503,325

(3,734,561)

(32,413,693)

Weighted average shares outstanding - basic

7,281,000

4,048,750

6,370,000

3,054,297

Common stock warrants

-

2,663,333

565,000

-

Common stock options

-

33,333

-

-

Weighted average shares outstanding - diluted

7,281,000

6,745,416

6,935,000

3,054,297

Net income (loss) per share data:

Basic

$

(0.29)

$

7.04

$

(0.14)

$

(10.61)

Diluted

$

(0.29)

$

4.23

$

(0.54)

$

(10.61)

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

Nine Months Ended September 30,

2016

2015

Common stock options

432,000

39,000

Common stock warrants - equity treatment

5,054,000

211,000

Common stock warrants - liability treatment

6,000

4,750,000

Potentially dilutive securities

5,492,000

5,000,000

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2

DERIVATIVE LIABILITY - WARRANTS
9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

DERIVATIVE LIABILITY - WARRANTS

Note 6:

DERIVATIVE LIABILITY - WARRANTs

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the nine months ended 2016 and 2015 is as follows:

Share Purchase Warrants

Weighted Average Inputs for the Period

For the Nine

For the Nine

Months Ending

Months Ending

September 30,

September 30,

Date of valuation

2016

2015

Exercise price

$

1.20

$

7.56

Contractual term (years)

1.3

4.5

Volatility (annual)

105

%

159

%

Risk-free rate

1

%

1

%

Dividend yield (per share)

0

%

0

%

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

⋅

Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

⋅

Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and

⋅

Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:

As of September 30, 2016

Fair Value Measurements

Fair Value

Level 1

Level 2

Level 3

Total

Derivative liability - warrants

$

29,000

-

-

$

29,000

$

29,000

Total

$

29,000

-

-

$

29,000

$

29,000

As of December 31, 2015

Fair Value Measurements

Fair Value

Level 1

Level 2

Level 3

Total

Derivative liability - warrants

$

26,493,000

-

-

$

26,493,000

$

26,493,000

Total

$

26,493,000

-

-

$

26,493,000

$

26,493,000

There were no transfers between Level 1, 2 or 3 during the nine months ended September 30, 2016.

The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2016:

Derivative liability – warrants

Balance – December 31, 2015

$

26,493,000

Reclassification of derivative liabilities to equity at exercise date

(5,074,000)

Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements

(15,465,000)

Change in fair value of warrant liability

(5,925,000)

Balance – September 30, 2016

$

29,000

Warrant Amendment Transaction

On August 10, 2016, the Company and holders of an aggregate of 3,096,665 outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements (the “Amended Warrants”) in which they agreed to amend the terms of the outstanding series warrants to remove provisions that had previously precluded equity classification treatment on the Company’s balance sheets.

In consideration for such amendment and the exercise of the Series C Warrants and Series C-1 Warrants, the Company issued an aggregate of 750,000 additional shares of common stock to such warrant holders and new five-year warrants to purchase 1,000,000 shares of Company common stock at an exercise price of $7.20 per share. The value of the shares and fair value of the warrants was treated as dividend on the statement of stockholders’ equity of $4.5 million.

The fair value of the Amended Warrants was re-measured immediately prior to the date of amendment with changes in fair value recorded as a gain of $556,000 in the statement of operations and $15.5 million was reclassified to equity.

X

- Definition
Derivative Liability Warrants And Derivative Liability Conversion Option [Text Block]
+ References
No definition available.
+ Details

Name: tpiv_DerivativeLiabilityWarrantsAndDerivativeLiabilityConversionOptionTextBlock

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2

STOCK-BASED COMPENSATION
9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

Note 7:

STOCK-BASED COMPENSATION

The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015, respectively:

Three Months Ended September 30,

Nine Months Ended September 30,

2016

2015

2016

2015

Research and development

$

-

$

-

$

-

$

-

General and administrative

573,137

13,244

1,309,109

261,805

Total stock-based compensation

$

573,137

$

13,244

$

1,309,109

$

261,805

Stock Options

A summary of the Company’s stock option activity is as follows:

Weighted Average

Weighted Average

Exercise Price

Remaining

Aggregate

Stock Options

per Share

Contractual Life

Intrinsic Value

Outstanding as of December 31, 2015

298,679

$

9.25

9.75

$

177,000

Granted

135,000

6.00

Exercised

-

-

Forfeited/Cancelled

(1,667)

228.00

Outstanding as of September 30, 2016

432,013

$

7.25

9.25

$

271,000

Exercisable as of September 30, 2016

262,395

$

8.00

9.00

$

174,000


Total stock-based compensation cost related to unvested awards not yet recognized and the weighted average periods over which the awards are expected to be recognized as of September 30, 2016 are as follows:

Unrecognized stock-based compensation cost:

$

1,081,000

Expected weighted average period compensation costs to be recognized (years):

1.75

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65895303&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2

PROMISSORY NOTE
9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

PROMISSORY NOTE

Note 8:      Promissory note

At September 30, 2016, the Company had an outstanding promissory note in the amount of $5,000 as compared to two outstanding promissory notes totaling $30,000 at December 31, 2015. The promissory note outstanding at September 30, 2016 bears 10% annual interest.

During the nine months ended September 30, 2016, the Company paid a $25,000 promissory note and $6,524 of accrued interest in final settlement.

X

- Definition
Promissory Note [Text Block]
+ References
No definition available.
+ Details

Name: tpiv_PromissoryNoteTextBlock

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2

PROMISSORY NOTE, RELATED PARTY
9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

PROMISSORY NOTE, RELATED PARTY

Note 9:       Promissory note, related party

At December 31, 2015, the Company had an outstanding promissory note in the amount of $23,000 owed to an officer of the Company. The promissory note bore no interest charges and had no fixed repayment terms. In September 2016, the note was paid in full.

X

- Definition
Promissory Note Related Party [Text Block]
+ References
No definition available.
+ Details

Name: tpiv_PromissoryNoteRelatedPartyTextBlock

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2

CAPITAL STOCK
9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

CAPITAL STOCK

Note 10:        Capital Stock

Reverse Stock Split

Effective September 16, 2016, the Company effected a one for twelve reverse stock-split of our issued and outstanding common stock and has retroactively adjusted our common shares outstanding, options and warrants amounts outstanding. The Company has presented its share data for and as of all periods presented on this basis. The par value was not adjusted as a result of the one for twelve reverse stock split. All prior period share transactions included in the Company’s stock transactions and balances have been retroactively restated.

2016 Common Stock Transactions

Private placements

On August 10, 2016 and August 25, 2016, the Company completed private placements of units with certain accredited investors. The units consisted of (i) one share of the Company’s common stock, par value $0.001 per share and (ii) one five-year warrant to purchase one share of Company common stock for $6.00. The Company issued and sold an aggregate of 653,166 units at a purchase price per unit of $4.80 for an aggregate of approximately $3.1 million. The Company incurred approximately $0.8 million in agency fees and legal costs.

In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to 65,317 shares of Company common stock for $4.80 per share.

Pursuant to the registration rights agreements entered into in connection with the private placements, the Company is required to file a registration statement with the Securities and Exchange Commission registering for resale (a) the common stock issued in the private placement offering; (b) the shares of common stock issuable upon the exercise of the five-year warrants; and (c) the shares of common stock issuable upon the exercise of the warrants issued to the placement agent. The Company is required to file the registration statement within 120 days of the August 10, 2016 closing or by December 8, 2016. The Company is also required to ensure that the registration statement is declared effective within 90 calendar days after filing with the Securities and Exchange Commission, or by March 8, 2017.

In accordance with the registration rights agreements, should the Company fail to meet the above criteria, the Company is subject to pay the investors liquidated damages. The liquidated damages shall be a cash sum payment calculated at a rate of ten percent (10%) per annum of the aggregate purchase price for the registrable securities or aggregate amount upon exercise of the placement agent warrants.

In accordance with applicable U.S. generally accepted accounting principles, a contingent obligation to make future payments must be recorded if the transfer of consideration under a registration payment arrangement is probable and can be reasonably estimated. The Company has determined that should it be required to pay liquidated damages to the investors of the private placements, the aggregate contingent liability it would be required to record would be approximately $29,000 per month for each month it fails or is estimated to fail to meet the above criteria.

At the August 10, 2016 and August 26,2016 private placement closings, and on September 30, 2016, the Company concluded that it is not probable that it will be required to remit any payments to the investors for failing to obtain an effective registration statement or failing to maintain its effectiveness.

Warrant Amendment Transaction

On August 10, 2016, the Company and holders of an aggregate of 3,096,665 outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements (the “Amended Warrants”) in which they agreed to amend the terms of the outstanding series warrants to remove provisions that had previously precluded equity classification treatment on the Company’s balance sheets.

In consideration for such amendment and the exercise of the Series C Warrants and Series C-1 Warrants, the Company issued an aggregate of 750,000 additional shares of common stock to such warrant holders and new five-year warrants to purchase 1,000,000 shares of Company common stock at an exercise price of $7.20 per share. The value of the shares and fair value of the warrants was treated as dividend on the statement of stockholders’ equity of $4.5 million.

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of September 30, 2016 and changes during the period is presented below:

Number of
Warrants

Weighted Average
Exercise Price

Balance, December 31, 2015

4,343,000

$

8.67

Exercised

(1,000,000)

6.00

Issued

1,718,000

6.65

Expired

(2,000)

300

Balance, September 30, 2016

5,059,000

$

8.51

Consulting Arangements

During the nine months ended September 30, 2016, the Company issued 60,000 common shares as part of consulting agreements. The fair value of the common stock of approximately $414,000 was recognized as stock-based compensation in general and administrative expense.

Debt Settlement

In May 2016, the Company issued 10,191 common shares as part of debt conversion agreements from 2014. The fair value of the common stock of approximately $70,000 was recognized as loss on debt settlement agreements in other income (expense).

In September 2016, the Company paid $27,000 for a promissory note from 2008 and related $38,000 of accrued interest. The $65,000 payment was recognized as loss on debt settlement agreements in other income (expense).

X

- Definition
The entire disclosure for the capital stock.
+ References
No definition available.
+ Details

Name: tpiv_CapitalStockTextBlock

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2

GRANT INCOME
9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

GRANT INCOME

Note 11:        grant income

During the nine months ended September 30, 2016, the Company received approximately $231,000 of grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV 200. The grant paid for the clinical supplies purchased by the Company.

X

- Definition
Grant Income [Text Block]
+ References
No definition available.
+ Details

Name: tpiv_GrantIncomeTextBlock

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2

COMMITMENTS
9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS

Note 12:

COMMITMENTS

Employment Agreements

In November 2015, the Company entered into an employment agreement with Dr. Glynn Wilson, the Company’s Chief Executive Officer, President and Chairman of the Company. As part of the agreement, Dr. Wilson was awarded 19,018 fully vested common shares in March 2016. The fair value of the common stock of approximately $146,000 was recognized as stock-based compensation in general and administrative expense.

In July, 2016, the Company entered into an employment agreement with Dr. John Bonfiglio relating to his appointment as the Company’s President and Chief Operating Officer. As part of the agreement, Dr. Bonfiglio was awarded 20,833 common shares, which will vest upon the earlier of (i) the listing of the Company’s common stock on a national securities exchange in the United States or (ii) the first anniversary of the employment agreement, so long as Dr. Bonfiglio is employed with the Company. The fair value of the common stock of approximately $103,000 was recognized as stock-based compensation in general and administrative expense.

In August 2016, the Company appointed Michael Loiacono as the Company’s Chief Financial Officer, Chief Accounting Officer, Secretary and Treasurer. In connection with Mr. Loiacono’s appointment he entered into an employment agreement with the Company. The employment agreement provides that Mr. Loiacono’s base salary will be $200,000 per year and he is eligible for an annual performance bonus of up to 50% of his base salary. The term of the employment agreement is for two years and will be automatically extended for an additional 12 months unless terminated by Mr. Loiacono or the Company.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2

SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Grant Income

Grant Income

The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company’s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable, and are not dependent on the Company’s ongoing future performance. The Company has adopted a policy of recognizing these payments as grant income when received.

Recent accounting pronouncement

Recent Accounting Pronouncement

Accounting Standards Update (“ASU”), No. 2016-09 - In March 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-09, Compensation-Stock Compensation. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the specific changes associated with the update include all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) being recognized as income tax expense or benefit in the income statement. The tax effects of exercised or vested awards should be treated as discrete items in the reporting period in which they occur. An entity also should recognize excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. An entity can make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years.

The Company has evaluated the impact of ASU No. 2016-09 and has determined that the adoption of the impact of forfeitures, net of income taxes, will not have a material impact on the Company’s future financial statements.

X

- Definition
Grant Income [Policy Text Block]
+ References
No definition available.
+ Details

Name: tpiv_GrantIncomePolicyTextBlock

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2

NET INCOME (LOSS) PER SHARE (Tables)
9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Computation Of Income Loss Per Share

The following table sets forth the computation of income (loss) per share:

For the Three Months Ended
September 30,

For the Nine Months Ended
September 30,

2016

2015

2016

2015

Net income (loss)

$

(2,102,962)

$

28,503,325

$

(878,561)

$

(32,413,693)

Less: Non cash income from changes in fair value of derivative liabilities

-

-

(2,856,000)

-

Net income (loss) - diluted

(2,102,962)

28,503,325

(3,734,561)

(32,413,693)

Weighted average shares outstanding - basic

7,281,000

4,048,750

6,370,000

3,054,297

Common stock warrants

-

2,663,333

565,000

-

Common stock options

-

33,333

-

-

Weighted average shares outstanding - diluted

7,281,000

6,745,416

6,935,000

3,054,297

Net income (loss) per share data:

Basic

$

(0.29)

$

7.04

$

(0.14)

$

(10.61)

Diluted

$

(0.29)

$

4.23

$

(0.54)

$

(10.61)

Net Loss Per Share

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

Nine Months Ended September 30,

2016

2015

Common stock options

432,000

39,000

Common stock warrants - equity treatment

5,054,000

211,000

Common stock warrants - liability treatment

6,000

4,750,000

Potentially dilutive securities

5,492,000

5,000,000

X

- Definition
Computation Of Income Loss Per Share
+ References
No definition available.
+ Details

Name: tpiv_ComputationOfIncomeLossPerShareTableTextBlockTableTextBlock

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Net Loss Per Share
+ References
No definition available.
+ Details

Name: tpiv_NetLossPerShareTableTextBlockTableTextBlock

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2

DERIVATIVE LIABILITY - WARRANTS (Tables)
9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

Valuation Methodology

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the nine months ended 2016 and 2015 is as follows:

Share Purchase Warrants

Weighted Average Inputs for the Period

For the Nine

For the Nine

Months Ending

Months Ending

September 30,

September 30,

Date of valuation

2016

2015

Exercise price

$

1.20

$

7.56

Contractual term (years)

1.3

4.5

Volatility (annual)

105

%

159

%

Risk-free rate

1

%

1

%

Dividend yield (per share)

0

%

0

%

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:

As of September 30, 2016

Fair Value Measurements

Fair Value

Level 1

Level 2

Level 3

Total

Derivative liability - warrants

$

29,000

-

-

$

29,000

$

29,000

Total

$

29,000

-

-

$

29,000

$

29,000

As of December 31, 2015

Fair Value Measurements

Fair Value

Level 1

Level 2

Level 3

Total

Derivative liability - warrants

$

26,493,000

-

-

$

26,493,000

$

26,493,000

Total

$

26,493,000

-

-

$

26,493,000

$

26,493,000

Schedule of Changes in Level 3 Liabilities Measured at Fair Value

The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2016:

Derivative liability – warrants

Balance – December 31, 2015

$

26,493,000

Reclassification of derivative liabilities to equity at exercise date

(5,074,000)

Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements

(15,465,000)

Change in fair value of warrant liability

(5,925,000)

Balance – September 30, 2016

$

29,000

X

- Definition
Financial assets and liabilities measured at fair value on recurring basis.
+ References
No definition available.
+ Details

Name: tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Measured at fair value.
+ References
No definition available.
+ Details

Name: tpiv_MeasuredAtFairValue

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Valuation methodology.
+ References
No definition available.
+ Details

Name: tpiv_ValuationMethodology

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2

STOCK-BASED COMPENSATION (Tables)
9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan

The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015, respectively:

Three Months Ended September 30,

Nine Months Ended September 30,

2016

2015

2016

2015

Research and development

$

-

$

-

$

-

$

-

General and administrative

573,137

13,244

1,309,109

261,805

Total stock-based compensation

$

573,137

$

13,244

$

1,309,109

$

261,805

Schedule of Share-based Compensation, Activity

A summary of the Company’s stock option activity is as follows:

Weighted Average

Weighted Average

Exercise Price

Remaining

Aggregate

Stock Options

per Share

Contractual Life

Intrinsic Value

Outstanding as of December 31, 2015

298,679

$

9.25

9.75

$

177,000

Granted

135,000

6.00

Exercised

-

-

Forfeited/Cancelled

(1,667)

228.00

Outstanding as of September 30, 2016

432,013

$

7.25

9.25

$

271,000

Exercisable as of September 30, 2016

262,395

$

8.00

9.00

$

174,000

Schedule of Unrecognized Compensation Cost, Nonvested Awards

Total stock-based compensation cost related to unvested awards not yet recognized and the weighted average periods over which the awards are expected to be recognized as of September 30, 2016 are as follows:

Unrecognized stock-based compensation cost:

$

1,081,000

Expected weighted average period compensation costs to be recognized (years):

1.75

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the total compensation cost related to nonvested awards not yet recognized and the weighted-average period over which it is expected to be recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2

CAPITAL STOCK (Tables)
9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

Capital Stock

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of September 30, 2016 and changes during the period is presented below:

Number of
Warrants

Weighted Average
Exercise Price

Balance, December 31, 2015

4,343,000

$

8.67

Exercised

(1,000,000)

6.00

Issued

1,718,000

6.65

Expired

(2,000)

300

Balance, September 30, 2016

5,059,000

$

8.51

X

- Definition
The entire disclosure of share purchase warrants.
+ References
No definition available.
+ Details

Name: tpiv_SharePurchaseWarrantTextBlock

Namespace Prefix: tpiv_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2

LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail)

Sep. 30, 2016

USD ($)

Cash and Cash Equivalents [Line Items]

Cash and cash equivalents $ 9,587,000

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016
+ Details

Name: us-gaap_CashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 39 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2

NET INCOME (LOSS) PER SHARE - Computation of income (loss) per share (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Net income (loss) $ (2,102,962) $ 28,503,325 $ (878,561) $ (32,413,693)

Less: Non cash income from changes in fair value of derivative liabilities 0 0 (2,856,000) 0

Net income (loss) - diluted $ (2,102,962) $ 28,503,325 $ (3,734,561) $ (32,413,693)

Weighted average shares outstanding - basic 7,281,000 4,048,750 6,370,000 3,054,297

Common stock warrants 0 2,663,333 565,000 0

Common stock options 0 33,333 0 0

Weighted average shares outstanding - diluted 7,281,000 6,745,416 6,935,000 3,054,297

Net income (loss) per share data:

Basic $ (0.29) $ 7.04 $ (0.14) $ (10.61)

Diluted $ (0.29) $ 4.23 $ (0.54) $ (10.61)

X

- Definition
Common Stock Options
+ References
No definition available.
+ Details

Name: tpiv_CommonStockOptions

Namespace Prefix: tpiv_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Common Stock Warrants
+ References
No definition available.
+ Details

Name: tpiv_CommonStockWarrants

Namespace Prefix: tpiv_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_DilutiveSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256
+ Details

Name: us-gaap_NetIncomeLossAttributableToParentDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 40 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2

NET INCOME (LOSS) PER SHARE - Potentially Dilutive Securities (Detail) - shares
9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Common stock options 432,000 39,000

Common stock warrants - equity treatment 5,054,000 211,000

Common stock warrants - liability treatment 6,000 4,750,000

Potentially dilutive securities 5,492,000 5,000,000

X

- Definition
Common stock warrants - equity treatment.
+ References
No definition available.
+ Details

Name: tpiv_CommonStockWarrantsEquityTreatment

Namespace Prefix: tpiv_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Common stock warrants - liability treatment.
+ References
No definition available.
+ Details

Name: tpiv_CommonStockWarrantsLiabilityTreatment

Namespace Prefix: tpiv_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares that could be issued to net share settle a contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that may be required to be issued, disclose the fact that a potentially infinite number of shares could be issued to settle the contract.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 5
-Subparagraph (b)(2),(c)
-URI http://asc.fasb.org/extlink&oid=6445032&loc=d3e90205-114008
+ Details

Name: us-gaap_OptionIndexedToIssuersEquityShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 41 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2

NET INCOME (LOSS) PER SHARE - Additional Information (Detail)
1 Months Ended

Sep. 30, 2016

Stockholders' Equity, Reverse Stock Split 1-for-12

X

- Definition
Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2

DERIVATIVE LIABILITY - WARRANTS - Additional Information (Detail) - USD ($)
1 Months Ended

Aug. 10, 2016

Sep. 30, 2016

Dec. 31, 2015

Class of Warrant or Right, Outstanding 3,096,665 5,059,000 4,343,000

Stock Issued During Period Shares, Upon Exercise Of Warrants 750,000

Class Of Warrant Or Right Expiration Period 5 years

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 7.20

Derivative, Gain on Derivative $ 556,000

Fair Value Of Warrant Reclassification To Equity $ 15,500,000

Dividends $ 4,500,000

X

- Definition
Class of warrant or right expiration period.
+ References
No definition available.
+ Details

Name: tpiv_ClassOfWarrantOrRightExpirationPeriod

Namespace Prefix: tpiv_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The fair value of warrants reclassified to equity.
+ References
No definition available.
+ Details

Name: tpiv_FairValueOfWarrantReclassificationToEquity

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of shares issued during the period upon exercise of warrants.
+ References
No definition available.
+ Details

Name: tpiv_StockIssuedDuringPeriodSharesUponExerciseOfWarrants

Namespace Prefix: tpiv_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of increase in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (a),(c),(d),(e)
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959
+ Details

Name: us-gaap_DerivativeGainOnDerivative

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817
+ Details

Name: us-gaap_Dividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 43 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2

DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member] - $ / shares
9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]

Exercise price $ 1.20 $ 7.56

Contractual term (years) 1 year 3 months 18 days 4 years 6 months

Volatility (annual) 105.00% 159.00%

Risk-free rate 1.00% 1.00%

Dividend yield (per share) 0.00% 0.00%

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Agreed upon price for the exchange of the underlying asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Risk-free interest rate assumption used in valuing an instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=tpiv_SharePurchaseWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2

DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)

Sep. 30, 2016

Dec. 31, 2015

Derivatives, Fair Value [Line Items]

Derivative liability - warrants $ 29,000 $ 26,493,000

Total 29,000 26,493,000

Fair Value, Inputs, Level 3 [Member]

Derivatives, Fair Value [Line Items]

Derivative liability - warrants 29,000 26,493,000

Total 29,000 26,493,000

Fair Value [Member]

Derivatives, Fair Value [Line Items]

Derivative liability - warrants 29,000 26,493,000

Total $ 29,000 $ 26,493,000

X

- Definition
Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 4D
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=64830801&loc=SL51823488-111719

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=51825145&loc=SL20226000-175313
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value of the assets less the liabilities of a derivative or group of derivatives.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13495-108611
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativesFairValueLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2

DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)
9 Months Ended

Sep. 30, 2016

USD ($)

Balance - December 31, 2015 $ 26,493,000

Reclassification of derivative liabilities to equity at exercise date (5,074,000)

Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements (15,465,000)

Change in fair value of warrant liability (5,925,000)

Balance - September 30, 2016 $ 29,000

X

- Definition
Fair value of derivative liability removed on amendment to the warrant agreement measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
No definition available.
+ Details

Name: tpiv_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisDerivativeLiabilityRemovedOnAmendmentToWarrantAgreements

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Reclassification of derivative liabilities to equity measured using unobservable inputs measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
No definition available.
+ Details

Name: tpiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfDerivativeLiabilitiesToEquity

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 46 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2

STOCK-BASED COMPENSATION - Components of Stock-based Compensation Expense (Detail) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Allocated Share-based Compensation Expense $ 573,137 $ 13,244 $ 1,309,109 $ 261,805

Research and Development Expense [Member]

Allocated Share-based Compensation Expense 0 0 0 0

General and Administrative Expense [Member]

Allocated Share-based Compensation Expense $ 573,137 $ 13,244 $ 1,309,109 $ 261,805

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2

STOCK-BASED COMPENSATION - Stock Option Activity (Detail) - USD ($)
9 Months Ended 12 Months Ended

Sep. 30, 2016

Dec. 31, 2015

Stock Options Outstanding, Begining Balance 298,679

Stock Options, Granted 135,000

Stock Options, Exercised 0

Stock Options, Forfeited/Cancelled (1,667)

Stock Options Outstanding, Ending Balance 432,013 298,679

Stock Options, Exercisable as of September 30, 2016 262,395

Weighted Average Exercise Price per Share Outstanding, Begining Balance $ 9.25

Weighted Average Exercise Price per Share, Granted $ 6.00

Weighted Average Exercise Price per Share, Exercised 0

Weighted Average Exercise Price per Share, Forfeited/Cancelled 228.00

Weighted Average Exercise Price per Share Outstanding, Ending Balance 7.25

Weighted Average Exercise Price per Share Exercisable as of September 30, 2016 $ 8.00

Weighted Average Remaining Contractual Life, Outstanding 9 years 3 months 9 years 9 months

Weighted Average Remaining Contractual Life, Exercisable as of September 30, 2016 9 years

Aggregate Intrinsic Value Outstanding $ 271,000 $ 177,000

Aggregate Intrinsic Value, Exercisable as of September 30, 2016 $ 174,000

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 48 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2

STOCK-BASED COMPENSATION - Cost Related to Unvested Awards Not Yet Recognized and the Weighted Average Periods (Detail)
9 Months Ended

Sep. 30, 2016

USD ($)

Unrecognized stock-based compensation cost: $ 1,081,000

Expected weighted average period compensation costs to be recognized (years): 1 year 9 months

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 49 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2

PROMISSORY NOTE - Additional Information (Detail) - USD ($)
9 Months Ended

Sep. 30, 2016

Dec. 31, 2015

Debt Instrument [Line Items]

Outstanding promissory notes $ 5,000 $ 30,000

Repayments of Notes Payable 25,000

Debt Instrument Repayments of Accured Interest $ 6,524

Promissory Notes Due in 2012 [Member]

Debt Instrument [Line Items]

Annual interest rate 10.00%

X

- Definition
The amount of interest paid on final repayment of debt instrument.
+ References
No definition available.
+ Details

Name: tpiv_DebtInstrumentRepaymentsOfAccuredInterest

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=tpiv_PromissoryNotesDueInTwoThousandTwelveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2

PROMISSORY NOTE, RELATED PARTY - Additional Information (Detail) - USD ($)

Sep. 30, 2016

Dec. 31, 2015

Related Party Transaction [Line Items]

Outstanding promissory notes $ 0 $ 23,000

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2

CAPITAL STOCK - Share Purchase Warrants (Detail)
9 Months Ended

Sep. 30, 2016

$ / shares

shares

Number of Warrants, Beginning balance | shares 4,343,000

Number of Warrants, Exercised | shares (1,000,000)

Number of Warrants, Issued | shares 1,718,000

Number of Warrants, Expired | shares (2,000)

Number of Warrants, Ending balance | shares 5,059,000

Weighted Average Exercise Price, Beginning Balance | $ / shares $ 8.67

Weighted Average Exercise Price, Exercised | $ / shares 6.00

Weighted Average Exercise Price, Issued | $ / shares 6.65

Weighted Average Exercise Price, Expired | $ / shares 300

Weighted Average Exercise Price, Ending Balance | $ / shares $ 8.51

X

- Definition
Class of warrant or rights outstanding exercised weighted average exercise price.
+ References
No definition available.
+ Details

Name: tpiv_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePrice

Namespace Prefix: tpiv_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Class of warrant or rights outstanding extinguished or expired weighted average exercise price.
+ References
No definition available.
+ Details

Name: tpiv_ClassOfWarrantOrRightsOutstandingExtinguishedOrExpiredWeightedAverageExercisePrice

Namespace Prefix: tpiv_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Class of warrant or rights outstanding issued weighted average exercise price.
+ References
No definition available.
+ Details

Name: tpiv_ClassOfWarrantOrRightsOutstandingIssuedWeightedAverageExercisePrice

Namespace Prefix: tpiv_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price.
+ References
No definition available.
+ Details

Name: tpiv_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice

Namespace Prefix: tpiv_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants exercised.
+ References
No definition available.
+ Details

Name: tpiv_NumberOfWarrantExercised

Namespace Prefix: tpiv_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants extinguished or expired.
+ References
No definition available.
+ Details

Name: tpiv_NumberOfWarrantExtinguishedOrExpired

Namespace Prefix: tpiv_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants issued.
+ References
No definition available.
+ Details

Name: tpiv_NumberOfWarrantIssued

Namespace Prefix: tpiv_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 52 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2

CAPITAL STOCK - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended

Aug. 10, 2016

USD ($)

$ / shares

shares

Sep. 16, 2016

Aug. 31, 2016

USD ($)

$ / shares

$ / Unit

shares

May 31, 2016

USD ($)

shares

Sep. 30, 2016

USD ($)

$ / shares

shares

Sep. 30, 2015

USD ($)

Sep. 30, 2016

USD ($)

$ / shares

shares

Sep. 30, 2015

USD ($)

Dec. 31, 2015

USD ($)

$ / shares

shares

Common Stock Capital Shares Reserved For Future Issuance [Line Items]

Common Stock, Par or Stated Value Per Share | $ / shares $ 0.001 $ 0.001 $ 0.001

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 7.20

Class Of Warrant Or Right Expiration Period 5 years

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,000,000

Stockholders' Equity Note, Stock Split, Conversion Ratio 12

Class of Warrant or Right, Warrant Terms 5 years

Payment Of Liquidated Damages, Percentages 10.00%

Derivative Liability, Current | $ $ 29,000 $ 29,000 $ 26,493,000

Repayments of Notes Payable | $ 25,000

Gain (Loss) on Extinguishment of Debt | $ $ (65,325) $ (24,697) $ (135,640) $ (24,697)

Class of Warrant or Right, Outstanding 3,096,665 5,059,000 5,059,000 4,343,000

Commercial Paper [Member]

Common Stock Capital Shares Reserved For Future Issuance [Line Items]

Debt Instrument, Periodic Payment, Interest | $ $ 38,000

Amended Warrants [Member]

Common Stock Capital Shares Reserved For Future Issuance [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 7.20

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,000,000

Class Of Warrant Or Right Warrant Term 5 years

Class of Warrant or Right, Outstanding 3,096,665

Stock Issued During Period, Shares, New Issues 750,000

Fair Value Adjustment of Warrants | $ $ 4,500,000

Private Placement [Member]

Common Stock Capital Shares Reserved For Future Issuance [Line Items]

Common Stock, Par or Stated Value Per Share | $ / shares $ 0.001

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 6.00

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right 1

Class Of Warrant Or Right Expiration Period 5 years

Legal Fees | $ $ 800,000

Number of common stocks included in unit offering 1

Number Of Equity Unit Issued 653,166

Equity Unit Issued Price Per Unit | $ / Unit 4.80

Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchases Agreement | $ $ 3,100,000

Consulting Agreements [Member]

Common Stock Capital Shares Reserved For Future Issuance [Line Items]

Fair value of common stock | $ $ 414,000

Common shares issued 60,000

Debt Conversion Agreement [Member]

Common Stock Capital Shares Reserved For Future Issuance [Line Items]

Fair value of common stock | $ $ 70,000

Common shares issued 10,191

Placement Agent [Member] | Private Placement [Member]

Common Stock Capital Shares Reserved For Future Issuance [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 4.80

Class Of Warrant Or Right Expiration Period 5 years

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 65,317

X

- Definition
Aggregate purchase price of shares agreed to purchase by accredited investors.
+ References
No definition available.
+ Details

Name: tpiv_AggregatePurchasePriceOfSharesAgreedToPurchaseUnderStockPurchasesAgreement

Namespace Prefix: tpiv_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Class of warrant or right expiration period.
+ References
No definition available.
+ Details

Name: tpiv_ClassOfWarrantOrRightExpirationPeriod

Namespace Prefix: tpiv_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents the term of warrants.
+ References
No definition available.
+ Details

Name: tpiv_ClassOfWarrantOrRightWarrantTerm

Namespace Prefix: tpiv_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Terms of warrants or rights outstanding.
+ References
No definition available.
+ Details

Name: tpiv_ClassOfWarrantOrRightWarrantTerms

Namespace Prefix: tpiv_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
+ References
No definition available.
+ Details

Name: tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems

Namespace Prefix: tpiv_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity units issued price per unit.
+ References
No definition available.
+ Details

Name: tpiv_EquityUnitIssuedPricePerUnit

Namespace Prefix: tpiv_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common stock included in unit offering.
+ References
No definition available.
+ Details

Name: tpiv_NumberOfCommonStocksIncludedInUnitOffering

Namespace Prefix: tpiv_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of equity units issued.
+ References
No definition available.
+ Details

Name: tpiv_NumberOfEquityUnitIssued

Namespace Prefix: tpiv_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of payment for liquidated damages based on percentage of purchase price..
+ References
No definition available.
+ Details

Name: tpiv_PaymentOfLiquidatedDamagesPercentages

Namespace Prefix: tpiv_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of the required periodic payments applied to interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentPeriodicPaymentInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13495-108611
+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LegalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Stock Split
-URI http://asc.fasb.org/extlink&oid=6525746
+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=tpiv_AmendedWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=tpiv_ConsultingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=tpiv_DebtConversionAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=tpiv_PlacementAgentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2

GRANT INCOME - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Revenue from Grants $ 0 $ 0 $ 231,200 $ 0

X

- Definition
Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_RevenueFromGrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 54 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2

COMMITMENTS - Additional Information (Detail) - USD ($)
1 Months Ended 9 Months Ended

Aug. 31, 2016

Jul. 31, 2016

Mar. 31, 2016

Sep. 30, 2016

Sep. 30, 2015

Commitments And Contingencies [Line Items]

Annual Performance Bonus On Base Salary, Percentage 50.00%

Salaries, Wages and Officers' Compensation $ 200,000

Share-based Compensation $ 1,309,109 $ 261,805

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 135,000

Chief Executive Officer, President and Chairman [Member]

Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 19,018

Chief Executive Officer, President and Chairman [Member] | General and Administrative Expense [Member]

Commitments And Contingencies [Line Items]

Share-based Compensation $ 146,000

Chief Operating Officer [Member]

Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 20,833

Chief Operating Officer [Member] | General and Administrative Expense [Member]

Commitments And Contingencies [Line Items]

Share-based Compensation $ 103,000

X

- Definition
The percentage of bonus on Base salary.
+ References
No definition available.
+ Details

Name: tpiv_AnnualPerformanceBonusOnBaseSalaryPercentage

Namespace Prefix: tpiv_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: tpiv_CommitmentsAndContingenciesLineItems

Namespace Prefix: tpiv_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expenditures for salaries for officers and non-officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.
+ References
No definition available.
+ Details

Name: us-gaap_SalariesWagesAndOfficersCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_ChiefOperatingOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 58 184 1 false 19 0 false 5 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.tapimmune.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://www.tapimmune.com/role/CondensedConsolidatedStatementOfStockholdersEquityDeficit CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) Statements 5 false false R6.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 107 - Disclosure - NATURE OF OPERATIONS Sheet http://www.tapimmune.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 7 false false R8.htm 108 - Disclosure - BASIS OF PRESENTATION Sheet http://www.tapimmune.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 8 false false R9.htm 109 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION Sheet http://www.tapimmune.com/role/LiquidityAndFinancialCondition LIQUIDITY AND FINANCIAL CONDITION Notes 9 false false R10.htm 110 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.tapimmune.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 111 - Disclosure - NET INCOME (LOSS) PER SHARE Sheet http://www.tapimmune.com/role/NetIncomeLossPerShare NET INCOME (LOSS) PER SHARE Notes 11 false false R12.htm 112 - Disclosure - DERIVATIVE LIABILITY - WARRANTS Sheet http://www.tapimmune.com/role/DerivativeLiabilityWarrants DERIVATIVE LIABILITY - WARRANTS Notes 12 false false R13.htm 113 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.tapimmune.com/role/StockbasedCompensation STOCK-BASED COMPENSATION Notes 13 false false R14.htm 114 - Disclosure - PROMISSORY NOTE Sheet http://www.tapimmune.com/role/PromissoryNote PROMISSORY NOTE Notes 14 false false R15.htm 115 - Disclosure - PROMISSORY NOTE, RELATED PARTY Sheet http://www.tapimmune.com/role/PromissoryNoteRelatedParty PROMISSORY NOTE, RELATED PARTY Notes 15 false false R16.htm 116 - Disclosure - CAPITAL STOCK Sheet http://www.tapimmune.com/role/CapitalStock CAPITAL STOCK Notes 16 false false R17.htm 117 - Disclosure - GRANT INCOME Sheet http://www.tapimmune.com/role/GrantIncome GRANT INCOME Notes 17 false false R18.htm 118 - Disclosure - COMMITMENTS Sheet http://www.tapimmune.com/role/Commitments COMMITMENTS Notes 18 false false R19.htm 119 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.tapimmune.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 120 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables) Sheet http://www.tapimmune.com/role/NetIncomeLossPerShareTables NET INCOME (LOSS) PER SHARE (Tables) Tables http://www.tapimmune.com/role/NetIncomeLossPerShare 20 false false R21.htm 121 - Disclosure - DERIVATIVE LIABILITY - WARRANTS (Tables) Sheet http://www.tapimmune.com/role/DerivativeLiabilityWarrantsTables DERIVATIVE LIABILITY - WARRANTS (Tables) Tables http://www.tapimmune.com/role/DerivativeLiabilityWarrants 21 false false R22.htm 122 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.tapimmune.com/role/StockbasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.tapimmune.com/role/StockbasedCompensation 22 false false R23.htm 123 - Disclosure - CAPITAL STOCK (Tables) Sheet http://www.tapimmune.com/role/CapitalStockTables CAPITAL STOCK (Tables) Tables http://www.tapimmune.com/role/CapitalStock 23 false false R24.htm 124 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail) Sheet http://www.tapimmune.com/role/LiquidityAndFinancialConditionAdditionalInformationDetail LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail) Details 24 false false R25.htm 125 - Disclosure - NET INCOME (LOSS) PER SHARE - Computation of income (loss) per share (Details) Sheet http://www.tapimmune.com/role/NetIncomeLossPerShareComputationOfIncomeLossPerShareDetails NET INCOME (LOSS) PER SHARE - Computation of income (loss) per share (Details) Details http://www.tapimmune.com/role/NetIncomeLossPerShareTables 25 false false R26.htm 126 - Disclosure - NET INCOME (LOSS) PER SHARE - Potentially Dilutive Securities (Detail) Sheet http://www.tapimmune.com/role/NetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetail NET INCOME (LOSS) PER SHARE - Potentially Dilutive Securities (Detail) Details http://www.tapimmune.com/role/NetIncomeLossPerShareTables 26 false false R27.htm 127 - Disclosure - NET INCOME (LOSS) PER SHARE - Additional Information (Detail) Sheet http://www.tapimmune.com/role/NetIncomeLossPerShareAdditionalInformationDetail NET INCOME (LOSS) PER SHARE - Additional Information (Detail) Details http://www.tapimmune.com/role/NetIncomeLossPerShareTables 27 false false R28.htm 128 - Disclosure - DERIVATIVE LIABILITY - WARRANTS - Additional Information (Detail) Sheet http://www.tapimmune.com/role/DerivativeLiabilityWarrantsAdditionalInformationDetail DERIVATIVE LIABILITY - WARRANTS - Additional Information (Detail) Details 28 false false R29.htm 129 - Disclosure - DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Valuation Methodology (Detail) Sheet http://www.tapimmune.com/role/DerivativeLiabilityWarrantsConversionOptionValuationMethodologyDetail DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Valuation Methodology (Detail) Details 29 false false R30.htm 130 - Disclosure - DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) Sheet http://www.tapimmune.com/role/DerivativeLiabilityWarrantsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) Details 30 false false R31.htm 131 - Disclosure - DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail) Sheet http://www.tapimmune.com/role/DerivativeLiabilityWarrantsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail) Details 31 false false R32.htm 132 - Disclosure - STOCK-BASED COMPENSATION - Components of Stock-based Compensation Expense (Detail) Sheet http://www.tapimmune.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetail STOCK-BASED COMPENSATION - Components of Stock-based Compensation Expense (Detail) Details 32 false false R33.htm 133 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activity (Detail) Sheet http://www.tapimmune.com/role/StockbasedCompensationStockOptionActivityDetail STOCK-BASED COMPENSATION - Stock Option Activity (Detail) Details 33 false false R34.htm 134 - Disclosure - STOCK-BASED COMPENSATION - Cost Related to Unvested Awards Not Yet Recognized and the Weighted Average Periods (Detail) Sheet http://www.tapimmune.com/role/StockbasedCompensationCostRelatedToUnvestedAwardsNotYetRecognizedAndWeightedAveragePeriodsDetail STOCK-BASED COMPENSATION - Cost Related to Unvested Awards Not Yet Recognized and the Weighted Average Periods (Detail) Details 34 false false R35.htm 135 - Disclosure - PROMISSORY NOTE - Additional Information (Detail) Sheet http://www.tapimmune.com/role/PromissoryNoteAdditionalInformationDetail PROMISSORY NOTE - Additional Information (Detail) Details 35 false false R36.htm 136 - Disclosure - PROMISSORY NOTE, RELATED PARTY - Additional Information (Detail) Sheet http://www.tapimmune.com/role/PromissoryNoteRelatedPartyAdditionalInformationDetail PROMISSORY NOTE, RELATED PARTY - Additional Information (Detail) Details 36 false false R37.htm 137 - Disclosure - CAPITAL STOCK - Share Purchase Warrants (Detail) Sheet http://www.tapimmune.com/role/CapitalStockSharePurchaseWarrantsDetail CAPITAL STOCK - Share Purchase Warrants (Detail) Details 37 false false R38.htm 138 - Disclosure - CAPITAL STOCK - Additional Information (Detail) Sheet http://www.tapimmune.com/role/CapitalStockAdditionalInformationDetail CAPITAL STOCK - Additional Information (Detail) Details 38 false false R39.htm 139 - Disclosure - GRANT INCOME - Additional Information (Detail) Sheet http://www.tapimmune.com/role/GrantIncomeAdditionalInformationDetail GRANT INCOME - Additional Information (Detail) Details 39 false false R40.htm 140 - Disclosure - COMMITMENTS - Additional Information (Detail) Sheet http://www.tapimmune.com/role/CommitmentsAdditionalInformationDetail COMMITMENTS - Additional Information (Detail) Details 40 false false All Reports Book All Reports tpiv-20160930.xml tpiv-20160930.xsd tpiv-20160930_cal.xml tpiv-20160930_def.xml tpiv-20160930_lab.xml tpiv-20160930_pre.xml true true ZIP 61 0001144204-16-131724-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-16-131724-xbrl.zip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

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2016	Nov. 02, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Entity Registrant Name	TAPIMMUNE INC
Entity Central Index Key	0001094038
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	TPIV
Entity Common Stock, Shares Outstanding		8,379,101

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current Assets
Cash	$ 9,586,773	$ 6,576,564
Prepaid expenses and deposits	111,652	68,803
Total Assets	9,698,425	6,645,367
Current Liabilities
Accounts payable and accrued liabilities	1,678,079	967,358
Research agreement obligations	492,365	492,365
Derivative liability - warrants	29,000	26,493,000
Promissory note	5,000	30,000
Promissory note, related party	0	23,000
Total Liabilities	2,204,444	28,005,723
Commitments and Contingencies
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized
Common stock, $0.001 par value, 41,666,667 shares authorized, 8,395,768 and 5,882,976 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	8,396	5,884
Additional paid-in capital	151,724,573	112,142,187
Accumulated deficit	(144,238,988)	(133,508,427)
Total Stockholders’ Equity (Deficit)	7,493,981	(21,360,356)
Total Liabilities and Stockholders’ Equity (Deficit)	9,698,425	6,645,367
Series A Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized	0	0
Series B Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized	$ 0	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	5,000,000	5,000,000
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	41,666,667	41,666,667
Common stock shares issued	8,395,768	5,882,976
Common stock shares outstanding	8,395,768	5,882,976
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating Expenses:
Research and development	$ 1,109,332	$ 968,759	$ 3,343,248	$ 2,324,432
General and administrative	1,612,305	769,219	3,557,701	1,579,754
Loss from Operations	(2,721,637)	(1,737,978)	(6,900,949)	(3,904,186)
Other Income (Expense)
Changes in fair value of derivative liabilities	684,000	30,266,000	5,925,000	(28,485,585)
Foreign exchange gain	0	0	0	775
Grant income	0	0	231,200	0
Loss on debt settlement agreements	(65,325)	(24,697)	(135,640)	(24,697)
Other income	0	0	1,828	0
Net Income (Loss)	$ (2,102,962)	$ 28,503,325	$ (878,561)	$ (32,413,693)
Basic Net Income (Loss) per Share	$ (0.29)	$ 7.04	$ (0.14)	$ (10.61)
Diluted Net Income (Loss) per Share	$ (0.29)	$ 4.23	$ (0.54)	$ (10.61)
Weighted Average Number of Common Shares Outstanding, Basic	7,281,000	4,048,750	6,370,000	3,054,297
Weighted Average Number of Common Shares Outstanding, diluted	7,281,000	6,745,416	6,935,000	3,054,297

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - 9 months ended Sep. 30, 2016 - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance, Amount at Dec. 31, 2015	$ (21,360,356)	$ 5,884	$ 112,142,187	$ (133,508,427)
Beginning Balance, Share at Dec. 31, 2015		5,882,976
Issuance of common stock in private placement (in shares)		653,166
Issuance of common stock in private placement	3,135,196	$ 653	3,134,543	0
Finders’ fee and legal costs relating to private placements	(804,070)	0	(804,070)	0
Fair value of shares issued as inducement on August 10, 2016	0	$ 750	4,499,250	(4,500,000)
Fair value of shares issued as inducement on August 10, 2016 (in shares)		750,000
Fair value of series F and F-1 warrants issued as inducement in August 2016	0	$ 0	5,352,000	(5,352,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements	15,465,000	0	15,465,000	0
Exercise of warrants Amount	6,000,000	$ 1,000	5,999,000	0
Exercise of warrants share		1,000,000
Finders’ fee on exercise of warrants	(516,651)	$ 0	(516,651)	0
Reclassification of fair value of derivative liabilities at exercise date	5,074,000	0	5,074,000	0
Shares issued in debt settlement agreements	70,315	$ 10	70,305	0
Shares issued in debt settlement agreements, Shares		10,191
Stock- based compensation, Amount	1,309,108	$ 99	1,309,009	0
Stock- based compensation, Share		99,435
Net loss	(878,561)	$ 0	0	(878,561)
Ending Balance, Amount at Sep. 30, 2016	$ 7,493,981	$ 8,396	$ 151,724,573	$ (144,238,988)
Ending Balance, Share at Sep. 30, 2016		8,395,768

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flow from operating activities
Net loss	$ (878,561)	$ (32,413,693)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities	(5,925,000)	28,485,585
Loss on debt settlement agreements	70,315	24,697
Stock based compensation	1,309,109	261,805
Changes in operating assets and liabilities:
Prepaid expenses	(42,849)	(55,782)
Accounts payable and accrued liabilities	710,720	204,956
Net cash used in operating activities	(4,756,266)	(3,492,432)
Cash flow from financing activities
Private placements	3,135,196	2,464,000
Finders’ fee and legal costs on private placements	(804,070)	(137,986)
Repayment of promissory note	(25,000)	0
Repayment of promissory note - related party	(23,000)	0
Proceeds from exercise of warrants	6,000,000	7,427,998
Finders' fee on exercise of warrants	(516,651)	(316,508)
Net cash provided by financing activities	7,766,475	9,437,504
Net increase in cash	3,010,209	5,945,072
Cash, beginning of period	6,576,564	141,944
Cash, end of period	9,586,773	6,087,016
Supplemental disclosure of cash flow information
Cash paid for interest	0	0
Cash paid for taxes	0	0
Supplemental schedule of non-cash investing and financing activities:
Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson's compensation	191,000	0
Accounts payable settled in common stock	0	24,000
Fair value of issuance of series F and F-1 warrants as inducement in August 2016	5,352,000	0
Fair value of shares issued as inducement on August 10, 2016	4,500,000	0
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements	15,465,000	0
Fair value of issuance of warrants in January and March 2015 financing	0	9,313,000
Issuance of additional warrants in May 28, 2015 transaction	0	6,133,000
Reclassification of Derivative Warrant Liabilities to Equity at Exercise Date	$ 5,074,000	$ 11,745,000

LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail)	Sep. 30, 2016 USD ($)
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 9,587,000

NET INCOME (LOSS) PER SHARE - Additional Information (Detail)	1 Months Ended
	Sep. 30, 2016
Stockholders' Equity, Reverse Stock Split	1-for-12

DERIVATIVE LIABILITY - WARRANTS - Additional Information (Detail) - USD ($)		1 Months Ended
	Aug. 10, 2016	Sep. 30, 2016	Dec. 31, 2015
Class of Warrant or Right, Outstanding	3,096,665	5,059,000	4,343,000
Stock Issued During Period Shares, Upon Exercise Of Warrants	750,000
Class Of Warrant Or Right Expiration Period	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.20
Derivative, Gain on Derivative		$ 556,000
Fair Value Of Warrant Reclassification To Equity		$ 15,500,000
Dividends	$ 4,500,000

DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member] - $ / shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 1.20	$ 7.56
Contractual term (years)	1 year 3 months 18 days	4 years 6 months
Volatility (annual)	105.00%	159.00%
Risk-free rate	1.00%	1.00%
Dividend yield (per share)	0.00%	0.00%

DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	$ 29,000	$ 26,493,000
Total	29,000	26,493,000
Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	29,000	26,493,000
Total	29,000	26,493,000
Fair Value [Member]
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	29,000	26,493,000
Total	$ 29,000	$ 26,493,000

DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)	9 Months Ended
	Sep. 30, 2016 USD ($)
Balance - December 31, 2015	$ 26,493,000
Reclassification of derivative liabilities to equity at exercise date	(5,074,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements	(15,465,000)
Change in fair value of warrant liability	(5,925,000)
Balance - September 30, 2016	$ 29,000

STOCK-BASED COMPENSATION - Stock Option Activity (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Stock Options Outstanding, Begining Balance	298,679
Stock Options, Granted	135,000
Stock Options, Exercised	0
Stock Options, Forfeited/Cancelled	(1,667)
Stock Options Outstanding, Ending Balance	432,013	298,679
Stock Options, Exercisable as of September 30, 2016	262,395
Weighted Average Exercise Price per Share Outstanding, Begining Balance		$ 9.25
Weighted Average Exercise Price per Share, Granted	$ 6.00
Weighted Average Exercise Price per Share, Exercised	0
Weighted Average Exercise Price per Share, Forfeited/Cancelled	228.00
Weighted Average Exercise Price per Share Outstanding, Ending Balance	7.25
Weighted Average Exercise Price per Share Exercisable as of September 30, 2016	$ 8.00
Weighted Average Remaining Contractual Life, Outstanding	9 years 3 months	9 years 9 months
Weighted Average Remaining Contractual Life, Exercisable as of September 30, 2016	9 years
Aggregate Intrinsic Value Outstanding	$ 271,000	$ 177,000
Aggregate Intrinsic Value, Exercisable as of September 30, 2016	$ 174,000

STOCK-BASED COMPENSATION - Cost Related to Unvested Awards Not Yet Recognized and the Weighted Average Periods (Detail)	9 Months Ended
	Sep. 30, 2016 USD ($)
Unrecognized stock-based compensation cost:	$ 1,081,000
Expected weighted average period compensation costs to be recognized (years):	1 year 9 months

PROMISSORY NOTE - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Outstanding promissory notes	$ 5,000	$ 30,000
Repayments of Notes Payable	25,000
Debt Instrument Repayments of Accured Interest	$ 6,524
Promissory Notes Due in 2012 [Member]
Debt Instrument [Line Items]
Annual interest rate	10.00%

PROMISSORY NOTE, RELATED PARTY - Additional Information (Detail) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Outstanding promissory notes	$ 0	$ 23,000

CAPITAL STOCK - Share Purchase Warrants (Detail)	9 Months Ended
CAPITAL STOCK - Share Purchase Warrants (Detail)	Sep. 30, 2016 $ / shares shares
Number of Warrants, Beginning balance \| shares	4,343,000
Number of Warrants, Exercised \| shares	(1,000,000)
Number of Warrants, Issued \| shares	1,718,000
Number of Warrants, Expired \| shares	(2,000)
Number of Warrants, Ending balance \| shares	5,059,000
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 8.67
Weighted Average Exercise Price, Exercised \| $ / shares	6.00
Weighted Average Exercise Price, Issued \| $ / shares	6.65
Weighted Average Exercise Price, Expired \| $ / shares	300
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 8.51

CAPITAL STOCK - Additional Information (Detail)		1 Months Ended			3 Months Ended		9 Months Ended
CAPITAL STOCK - Additional Information (Detail)	Aug. 10, 2016 USD ($) $ / shares shares	Sep. 16, 2016	Aug. 31, 2016 USD ($) $ / shares $ / Unit shares	May 31, 2016 USD ($) shares	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($) $ / shares shares
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 0.001		$ 0.001		$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 7.20
Class Of Warrant Or Right Expiration Period	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000
Stockholders' Equity Note, Stock Split, Conversion Ratio		12
Class of Warrant or Right, Warrant Terms							5 years
Payment Of Liquidated Damages, Percentages							10.00%
Derivative Liability, Current \| $					$ 29,000		$ 29,000		$ 26,493,000
Repayments of Notes Payable \| $							25,000
Gain (Loss) on Extinguishment of Debt \| $					$ (65,325)	$ (24,697)	$ (135,640)	$ (24,697)
Class of Warrant or Right, Outstanding	3,096,665				5,059,000		5,059,000		4,343,000
Commercial Paper [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Debt Instrument, Periodic Payment, Interest \| $							$ 38,000
Amended Warrants [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 7.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000
Class Of Warrant Or Right Warrant Term	5 years
Class of Warrant or Right, Outstanding	3,096,665
Stock Issued During Period, Shares, New Issues	750,000
Fair Value Adjustment of Warrants \| $	$ 4,500,000
Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Common Stock, Par or Stated Value Per Share \| $ / shares			$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 6.00
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Class Of Warrant Or Right Expiration Period			5 years
Legal Fees \| $			$ 800,000
Number of common stocks included in unit offering			1
Number Of Equity Unit Issued			653,166
Equity Unit Issued Price Per Unit \| $ / Unit			4.80
Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchases Agreement \| $			$ 3,100,000
Consulting Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock \| $							$ 414,000
Common shares issued							60,000
Debt Conversion Agreement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock \| $				$ 70,000
Common shares issued				10,191
Placement Agent [Member] \| Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 4.80
Class Of Warrant Or Right Expiration Period			5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			65,317

COMMITMENTS - Additional Information (Detail) - USD ($)	1 Months Ended			9 Months Ended
COMMITMENTS - Additional Information (Detail) - USD ($)	Aug. 31, 2016	Jul. 31, 2016	Mar. 31, 2016	Sep. 30, 2016	Sep. 30, 2015
Commitments And Contingencies [Line Items]
Annual Performance Bonus On Base Salary, Percentage	50.00%
Salaries, Wages and Officers' Compensation	$ 200,000
Share-based Compensation				$ 1,309,109	$ 261,805
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				135,000
Chief Executive Officer, President and Chairman [Member]
Commitments And Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			19,018
Chief Executive Officer, President and Chairman [Member] \| General and Administrative Expense [Member]
Commitments And Contingencies [Line Items]
Share-based Compensation			$ 146,000
Chief Operating Officer [Member]
Commitments And Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		20,833
Chief Operating Officer [Member] \| General and Administrative Expense [Member]
Commitments And Contingencies [Line Items]
Share-based Compensation		$ 103,000